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ABSTRACT OF THE DISSERTATION
CAFFEINE INTAKE AND ITS ASSOCIATION WITH DISEASE PROGRESSION,
SLEEP QUALITY AND ANXIETY SYMPTOMS AND NUTRITIONAL
ALTERATIONS IN PEOPLE LIVING WITH HIV IN THE MIAMI ADULT STUDIES
ON HIV COHORT
by
Venkataraghavan Ramamoorthy
Florida International University, 2015
Miami, Florida
Professor Adriana Campa, Major Professor
Miami-Dade County has approximately 27,000 people living with HIV (PLWH),
and the highest HIV incidence in the nation. PLWH have reported several types of sleep
disturbances. Caffeine is an anorexic and lipolytic stimulant that may adversely affect
sleep patterns, dietary intakes and body composition. High caffeine consumption (>250
mg. per day or the equivalent of >4 cups of brewed coffee) may also affect general
functionality, adherence to antiretroviral treatment (ART) and HIV care. This study
assess the relationship of high caffeine intake with markers of disease progression, sleep
quality, insomnia, anxiety, nutritional intakes and body composition.
A convenience sample of 130 PLWH on stable ART were recruited from the
Miami Adult Studies on HIV (MASH) cohort, and followed for three months. After
consenting, questionnaires on Modified Caffeine Consumption (MCCQ), Pittsburg
Insomnia Rating Scale (PIRS), Pittsburg Sleep Quality Index (PSQI), Generalized
Anxiety Disorder-7 (GAD-7), socio-demographics, drug and medication use were
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completed. CD4 count, HIV viral load, anthropometries, and body composition measures
were obtained.
Mean age was 47.89±6.37 years, 60.8% were male and 75.4% were AfricanAmericans. Mean caffeine intake at baseline was 337.63 ± 304.97 mg/day (Range: 01498 mg/day) and did not change significantly at 3 months. In linear regression, high
caffeine consumption was associated with higher CD4 cell count (β=1.532, P=0.049),
lower HIV viral load (β=-1.067, P=0.048), higher global PIRS (β=1.776, P=0.046),
global PSQI (β=2.587, P=0.038), and GAD-7 scores (β=1.674, P=0.027), and with lower
fat mass (β=-0.994, P=0.042), energy intakes (β=-1.643, P=0.042) and fat consumption
(β=-1.902, P=0.044), adjusting for relevant socioeconomic and disease progression
variables. Over three months, these associations remained significant. The association of
high caffeine with lower BMI weakened when excluding users of other anorexic and
stimulant drugs such as cocaine and methamphetamine, suggesting that caffeine in
combination, but not alone, may worsen their action. In summary, high caffeine
consumption was associated with better measures of disease progression; but was also
detrimental on sleep quality, nutritional intakes, BMI and body composition and
associated with insomnia and anxiety. Large scale studies for longer time are needed to
elucidate the contribution of caffeine to the well-being of PLWH.
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CHAPTER I: INTRODUCTION AND SPECIFIC AIMS
General Introduction
Caffeine is one of the most widely consumed psycho-active substances
worldwide.1 Caffeine, a white, odorless, crystalline and bitter tasting substance was first
isolated form coffee beans in the year 1820.1 Over the years a huge body of literature has
accrued regarding the major sources and quantities consumed as well as the populations
consuming significant levels.2 Coffee constitutes the single largest source of caffeine and
contains more caffeine than all other available sources.2,3 Other significant sources
include tea leaves, cocoa pods, cola nuts, yerba mate, caffeinated drinks and many
prescription and over the counter medications.2 Many individual studies show that
athletes, students, young adults, teenagers, and military personnel are the major
populations consuming significant levels of caffeine.4-6 Some of the major methods of
caffeine consumption include brewed coffee, brewed tea, carbonated soft drinks, energy
drinks, energy shots, fruit drinks, fruit flavored beverages and watery beverages.2,3
Among children carbonated soft drink constitutes the largest source of caffeine
consumption; whereas brewed coffee constitutes the same among adults.4-6 It is difficult
to comprehensively summarize average consumption levels across different countries,
cultures and ethnicities given the diversities in sources and patterns of consumption. The
predicted average consumption across different coffee/tea consuming nations ranges
between 80 and 400 mg per person per day.7 A survey done by Faray et al.,3 estimated
that 87% of Americans consumed caffeine and average consumption approximated 193
mg per day per person and ranged between 166 mg and 336 mg per day. In addition to
caffeine there are many structurally and functionally similar xanthine-alkaloid

1

compounds in coffee and caffeinated products and major ones include theophylline and
theobromine.8 Tea is primarily rich in theophylline, and contains approximately 50 mg
of caffeine per 8 oz of black tea.8 Cola-acuminata extracts present in Coca-Cola and other
soft drinks contain variable amounts of caffeine (35 to 55 mg in 12 oz of soft drinks).8
Chocolate derived from cocoa pods and cocoa butter is primarily rich in theobromine, but
also contains trace amounts of caffeine.8 Based on standardized caffeine content of major
sources (135 mg per 8 oz of coffee, 50 mg per 8oz of black tea and 35-55 mg per 12oz of
soft drinks), it was estimated in 2014 that an average American consumes 135 mg of
caffeine from coffee, 30 mg of caffeine from tea and 50 mg of caffeine from soft drinks
per day.9 According to estimates in late eighties, 75% of total caffeine consumption
came from coffee, 15% from tea and 10% from caffeinated soft drinks. Chocolates,
medications and other caffeine containing products contributed very less to the average
consumption levels.9 Estimates in 2014 still show the same characteristics with coffee
being the highest source (66%), tea being the second highest (20%) and caffeinated soft
drinks the third highest source (11%), while all other sources contributed negligibly
towards the total consumption.9
Caffeine shows diuretic properties and stimulates respiratory, cardiovascular and
neuro-hormonal systems.10 In addition to its consumption as beverages, several
therapeutic interactions have been identified. This includes its effects on a variety of
medical conditions like narcolepsy, asthma, sleep apnea, migraine and cluster headaches,
Parkinsonism, ADHD, fetal asphyxia and major depression states.11-18 Other conditions
that affect the metabolism and elimination of caffeine include age, pregnancy,
concomitant medications and liver function levels.19 The half-life of the compound varies
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between 4-11 hours under normal physiological conditions.19 In acute liver failure states
caffeine can be significantly toxic as the half-life increases to as high as 90-100
hours.19,20 Caffeine is metabolized in the liver by the cytochrome P450 oxidase enzyme
systems into three major metabolites paraxanthine (80-85%), theobromine (10-15%) and
theophylline (0-5%).19 All these metabolites are dimethyl xanthines and have
independent actions similar to the parent compound caffeine and are further metabolized
through the same enzyme system in the liver and excreted through urine.19 Paraxanthine
has the same potency and nearly all the physiological actions of caffeine.21 In-spite of
caffeine being considered a therapeutic drug, regulatory agencies have not instituted any
restriction on the sale and purchase of caffeine: neither is caffeine consumption
considered any kind of recreational drug use.22 Initial efforts to include it in the list of
scheduled drugs are evident in studies done by Gilliland and Bullock, and Holtzman.23,24
Both the studies suggested that caffeine and associated xanthine alkaloids should be
considered as regulated substances because of their withdrawal, tolerance, dependence
and addictive potentials.23,24 The median lethal dose of caffeine was 192 milligrams per
kilogram body weight as estimated in rats.25 Based on estimates from animal studies the
median lethal dose for humans has been calculated to be about 150 to 200 milligrams per
kilogram of body weight or roughly 80 to 100 cups of coffee for an average adult, though
it would also depend upon the individual’s sensitivity and genetic factors affecting
caffeine metabolism26,27 or the presence of other medications and therapeutic drugs
affecting the same.28,29 Given these high lethal dose values caffeine consumption is
generally considered safe for all practical purposes.26
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The current study was a prospective observational study (follow-up study) of
associations between caffeine consumption and immunological and virologic markers of
disease progression (CD4 counts and HIV viral loads). This study also investigated for
associations between caffeine consumption and sleep derangements and anxiety
symptoms through sleep quality and anxiety questionnaires. Similarly, this study
investigated caffeine consumption and changes in nutrient intakes which included
carbohydrate intake, protein intake and fat intake. This study also investigated the effects
of caffeine on body composition measures like BMI, lean body mass (LBM), total fat
mass and other nutritional status indicators like hemoglobin, hematocrit and serum
albumin levels. Any adverse effect on these parameters should be considered as adverse
effects on HIV disease progression as the literature specifies.
Justification for the Study
Caffeine intake is very prevalent in this population of HIV infected individuals in
Miami (MASH cohort). Campa et al.,30 reported that 88.79% of the population sample
collected for the preliminary study ‘Zinc-supplementation and its effects on disease
progression in HIV infected patients’ recorded some levels of consumption. The mean
caffeine intake for this cohort was 115 mg per day.30 As discussed in the literature review
ahead, consumption of higher levels of caffeine leads to dependency and a variety of
unpleasant physical and mental conditions including nervousness, irritability,
restlessness, insomnia, headaches, and heart palpitations. These symptoms collectively
known as ‘caffeinism’31 was shown to have many adverse health effects in a number of
studies done in vulnerable populations.32-35
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There were significant negative associations between caffeine intake and sleep
quality scores as well as generalized anxiety levels.36,37 These effects were predicted to be
more pronounced in HIV+ patients with compromised health and immune status.36 Our
proposed study included PSQI and PIRS questionnaires for estimating sleep quality and
GAD-7 questionnaires for subjective symptoms of anxiety. Caffeine has been recognized
as a beneficial stimulant in low to moderate consumption levels (50 mg/day to 250
mg/day). Increased consumption beyond this limit, however, is associated with
heightened neuronal burn-outs and lack of adequate sleep.36,37 Our study retested these
hypotheses in a group of HIV positive participants who were already compromised in a
number of health and socio-economic parameters.
There are very few studies about the effects of caffeine consumption on nutrient
intake especially in HIV positive patients. Research shows that caffeine consumption has
both positive and negative health outcomes. The positive outcomes were observed mainly
in diabetic patients. Moderate caffeine intake showed benefits in patients with Type-2
diabetes and metabolic syndrome, as caffeine intake facilitates weight loss and reduction
of fat mass.38 Conversely, in people living with HIV, where wasting is a serious problem,
high caffeine intake could precipitate adverse health outcomes. In a study done by Kent
et al.39, it was observed that administration of fat lowering agent orlistat was associated
with higher viral loads compared to subjects not using this medication. Similarly another
study done by Shor-Prosner et.al.,40 on HIV positive participants from Miami showed
that body mass index (BMI) was inversely associated with progression to AIDS as well
as mortality; suggesting mild-to-moderate obesity having better immune function and
better survival rates in this cohort. Loss of fat mass as well as lean body mass, have
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always been reported to have detrimental effects on HIV disease progression. Both HIV41
and caffeine42 increase fat and protein catabolism and decrease appetite, and their
combined interactions have not been well studied. Based on these previous literatures,
our study investigated whether caffeine was associated with changes in body composition
measures, nutritional indicators and in nutrient consumption levels.
Significance of the Study
The study is particularly relevant for many reasons. This study aimed to
determine the effect of caffeine consumption on disease progression in HIV positive
patients. Though there are many studies on the effects of caffeine on healthy persons,
ergogenics, diabetes, pregnancy, liver failure and other medical conditions, to the best of
our knowledge, the literature on HIV positive participants is limited. The information
obtained through this study will be helpful for development of targeted interventions for
people living with HIV (PLWH). Future studies that estimate the effects of different
levels of consumption as well as standardized consumption limits in this population will
contribute to the development of adequate nutritional recommendations for caffeine in
PLWH.
This study also looked for the effects of caffeine on sleep quality, anxiety and
nutritional parameters. The majority of the participants enrolled in this study are
marginalized and disempowered. Their living conditions are plagued by food scarcity,
homelessness, drug abuse and criminalization. Because of these harsh living conditions
they are already susceptible to a variety of anxiety states and sleep disorders as well as
poor nutrient intakes.43-51 Caffeine consumption at high levels further contributes to these
conditions. Such effects will definitely increase the rate of disease progression in this
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population. Many studies have shown that adequate nutrition and sufficient sleep are
inseparable components of healthy living initiatives.52,53 Educating this marginalized
population about healthy living can never be accomplished without understanding their
caffeine consumption, its impact on sleep quality and nutrient consumption, as well as the
inter-relationships between these variables.
Specific Aims and Hypotheses
Specific aim 1: Examine the effect of caffeine on HIV disease progression
Rationale: Caffeine intake in higher than regular doses (>250 mg/day) has been
associated with decreased CD4 counts (adverse effect) as well as decreased viral loads
(beneficial effect). Our study looks for the net impact of caffeine over these opposing
effects on disease progression.
Hypothesis 1A: HIV+ adults with caffeine intake >250 mg/day have lower CD4 cell
counts compared with those who do not consume caffeine or do so in moderation (<250
mg/day) measured over 3 months.
Hypothesis 1B: HIV+ adults with caffeine intake >250 mg/day have higher viral loads
compared with those who do not consume caffeine or do so in moderation (<250 mg/day)
measured over 3 months.
Hypothesis 1C: Caffeine consumption as a continuous variable is associated with
decreased CD4 cell counts, CD4 counts<200 cells/μL and increased viral loads or lack of
viral load control, measured over 3 months.
Instruments/Tools/Observations: Caffeine Consumption questionnaires, CD4 cell count
and viral loads transcribed from medical records submitted by the participants.

7

Confounding Variables: Age, gender, income, race/ethnicity, grades, time from
diagnosis of HIV, drug use, alcohol consumption, smoking status, BMI, total body fat
percentage.
Specific Aim 2: Examine the effect of caffeine on sleep disorders in HIV
Rationale: Caffeine intake >250 mg/day is associated with poor quality of sleep and
increased episodes of insomnia.
Hypothesis 2A: HIV+ adults with caffeine intake >250 mg/day have decreased quality of
sleep measured by the PSQI scores, and increased periods of insomnia measured by the
PIRS over a period of 3-months.
Hypothesis 2B: Caffeine consumption as a continuous variable is associated with
decreased quality of sleep measured by the PSQI scores, and increased periods of
insomnia measured by the PIRS over a period of 3-months.
Instruments/Tools/Observations: Caffeine consumption questionnaires, Pittsburg Sleep
Quality (PSQI) questionnaire, Pittsburg Insomnia Rating Scale (PIRS) questionnaire.
Confounding Variables: Age, income, race/ethnicity, time from diagnosis of HIV, drug
use, alcohol consumption, smoking status, sleep medications and types of ART
medications.
Specific Aim 3: Examine the effect of Caffeine on Anxiety Symptoms
Rationale: Caffeine intake >250 mg/day has been associated with increased anxiety and
restlessness.
Specific Aim 3: Examine the effect of Caffeine on anxiety symptoms
Rationale: Caffeine intake >250 has been associated with increased anxiety and
restlessness.
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Hypothesis 3A: HIV+ adults with caffeine intake >250 mg/day have increased anxiety
symptoms measured by the GAD-7 scores over a period of 3-months.
Hypothesis 3B: Caffeine consumption as a continuous variable is associated with
increased anxiety symptoms measured by the GAD-7 scores over a period of 3-months.
Instruments/Tools/Observations: Caffeine consumption questionnaires, Generalized
Anxiety Disorder-7 (GAD-7) questionnaire.
Confounding Variables: Age, income, time from diagnosis of HIV, drug use, alcohol
consumption, smoking status and types of ART medications.
Specific Aim 4: Examine the effect of Caffeine on Body composition measures and
nutritional indicators such as hemoglobin, hematocrit and serum albumin levels
Rationale: Caffeine is associated with decreased caloric intakes as well as increased
energy expenditures thereby leading to nutritional deficiency states.
Hypothesis 4A: HIV+ adults with caffeine intake >250 mg/day have decreased lean body
mass and body fat mass estimated by Bio-impedance analysis (BIA) over a period of 3months.
Hypothesis 4B: HIV+ adults with caffeine intake >250 mg/day have decreased BMI
estimated by BIA over a period of 3-months.
Hypothesis 4C: HIV+ adults with caffeine intake >250 mg/day have lower than normal
hemoglobin measured over a period of 3-months.
Hypothesis 4D: HIV+ adults with caffeine intake >250 mg/day have lower than normal
hematocrit measured over a period of 3-months.
Hypothesis 4E: HIV+ adults with caffeine intake >250 mg/day have lower than normal
serum albumin levels, measured over a period of 3-months.
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Instruments/Tools/Observations: Caffeine consumption questionnaires, Bio-impedance
analysis (BIA), Hemoglobin levels, Hematocrit and serum albumin levels.
Confounding Variables: Age, gender, income, time from diagnosis of HIV, drug use,
alcohol consumption, smoking status and types of ART medications.
Specific Aim 5: Examine the effect of caffeine on caloric and nutrient intake and food
security status
Rationale: Caffeine is associated with decreased nutrient intakes and deficiency states.
Hypothesis 5A: HIV+ adults with caffeine intake >250 mg/day have decreased total
caloric intakes estimated by 24-hour dietary recall over a period of 3-months.
Hypothesis 5B: HIV+ adults with caffeine intake >250 mg/day have decreased caloric
intakes from proteins estimated by 24-hour dietary recall over a period of 3-months.
Hypothesis 5C: HIV+ adults with caffeine intake >250 mg/day have decreased caloric
intakes from carbohydrates estimated by 24-hour dietary recall over a period of 3months.
Hypothesis 5D: HIV+ adults with caffeine intake >250 mg/day have decreased caloric
intakes from fats estimated by 24-hour dietary recall over a period of 3-months.
Instruments/Tools/Observations: Caffeine consumption questionnaires, 24-hour dietary
recall, Nutribase-9 analysis reports of daily nutrient intake, food security questionnaire
(FSQ).
Confounding Variables: Age, gender, income, time from diagnosis of HIV, drug use,
alcohol consumption, smoking status and types of ART medications.
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Table 1: Summary of Hypotheses and Statistical Methods
Hypotheses
Hypothesis 1A :HIV+
adults with caffeine
intake >250 mg/d have
lower CD4 cell counts
compared with those
who do not consume
caffeine or do so in
moderation (<250
mg/day) measured over
a period of 3 months.
Hypothesis 1B: HIV+
adults with caffeine
intake >250 mg/d have
higher viral loads
compared with those
who do not consume
caffeine or do so in
moderation (<250
mg/day) measured over
a period of 3 months.

Dependent
Variables
CD4 count
square root

Independent
Variables
Total Caffeine
intake

Control Variables

Statistical Analysis

age, income, race
ethnicity, time from
diagnosis of HIV,
drug, tobacco and
alcohol use, BMI and
total body fat percent.

T-test and linear and logistic
regressions were used to
analyze baseline crosssectional data and Linear
Mixed Models were used for
over time changes in these
associations

Log 10 viral
load

Total Caffeine
intake

age, income, race
ethnicity, time from
diagnosis of HIV,
drug, tobacco and
alcohol use, BMI and
total body fat percent.

T-test and linear and logistic
regressions were used to
analyze baseline crosssectional data and Linear
Mixed Models were used for
over time changes in these
associations
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Table 1. Continued…
Hypotheses

Dependent
Variables
Hypothesis 1C:
CD4 count
Caffeine consumption as square root,
a continuous variable is Log 10 viral
associated with
load
decreased CD4 cell
counts, CD4 counts<200
cells/μL and increased
viral loads or lack of
viral load control,
measured over a period
of 3 months.
Hypothesis 2A: HIV+
PSQI
adults with caffeine
variables,
PIRS
intake >250 mg/d have
variables
decreased quality of
sleep measured by the
PSQI scores, and
increased periods of
insomnia measured by
the PIRS over a period
of 3-months.

Independent
Variables
Total Caffeine
intake

Control Variables

Statistical Analysis

age, income, race
ethnicity, time from
diagnosis of HIV,
drug, tobacco and
alcohol use, BMI and
total body fat percent.

Linear and logistic
regressions were used to
understand whether caffeine
consumption is associated
with changes in CD4 cell
counts and viral loads.
Linear Mixed Models were
used for overtime changes in
these relationships.

Total Caffeine
intake

age, income, race
ethnicity, time from
diagnosis of HIV,
drug, tobacco and
alcohol use, sleep
medications and
types of ART
medication.

T-test and linear and logistic
regressions were used to
analyze baseline crosssectional data and Linear
Mixed Models were used for
over time changes in these
associations.*
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Table 1. Continued…
Hypotheses

Dependent
Variables
Hypothesis 2B:
PSQI
Caffeine consumption as variables,
a continuous variable is PIRS
associated with
variables
decreased quality of
sleep measured by the
PSQI scores, and
increased periods of
insomnia measured by
the PIRS over a period
of 3-months.

Independent
Variables
Total Caffeine
intake

Hypothesis 3A: HIV+
GAD-7 scores
adults with caffeine
intake >250 mg/d have
increased anxiety
symptoms measured by
the GAD-7 scores over a
period of 3-months.

Total Caffeine
intake

Control Variables
age, income, race
ethnicity, time from
diagnosis of HIV,
drug, tobacco and
alcohol use, sleep
medications and
types of ART
medication.

Statistical Analysis

Linear and logistic
regressions were used to
understand whether caffeine
consumption is associated
with changes in quality of
sleep measured by PSQI
scores and severity of
insomnia measured by the
PIRS. Linear Mixed Models
were used for overtime
changes in these
relationships.
age, income, and time T-test and linear and logistic
from diagnosis of
regressions were used to
HIV, drug, tobacco
analyze baseline crossand alcohol use and
sectional data and Linear
different types of
Mixed Models were used for
ART medications
over time changes in these
associations.
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Table 1. Continued…
Hypotheses
Hypothesis 3B:
Caffeine consumption as
a continuous variable is
associated with
increased anxiety
symptoms measured by
the GAD-7 scores over a
period of 3-months.

Hypothesis 4A: HIV+
adults with caffeine
intake >250 mg/d have
decreased lean body
mass and body fat mass
estimated by Bioimpedance analysis
(BIA) over a period of
3-months.

Dependent
Variables
GAD-7 scores

Independent
Variables
Total Caffeine
intake

Control Variables

Statistical Analysis

age, income, and time
from diagnosis of
HIV, drug, tobacco
and alcohol use and
different types of
ART medications

Linear and logistic
regressions were used to
understand whether caffeine
consumption is associated
with changes in levels of
anxiety measured by GAD-7
scores. Linear Mixed Models
were used for overtime
changes in these
relationships.

Lean body
mass(LBM),
fat mass

Total Caffeine
intake

age, gender, income,
and time from
diagnosis of HIV,
drug, tobacco and
alcohol use and
different types of
ART medications

T-test and linear and logistic
regressions were used to
analyze baseline crosssectional data and Linear
Mixed Models were used for
over time changes in these
associations.
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Table 1. Continued…
Hypotheses

Dependent
Variables
Body mass
index (BMI)

Independent
Variables
Total Caffeine
intake

Control Variables

Statistical Analysis

age, gender, income,
and time from
diagnosis of HIV,
drug, tobacco and
alcohol use and
different types of
ART medications

T-test and linear and logistic
regressions were used to
analyze baseline crosssectional data and Linear
Mixed Models were used for
over time changes in these
associations.

Hypothesis 4C: HIV+
adults with caffeine
intake >250 mg/d have
lower than normal
hemoglobin measured
over a period of 3months.

Hemoglobin
levels

Total Caffeine
intake

age, gender, income,
and time from
diagnosis of HIV,
drug, tobacco and
alcohol use and
different types of
ART medications

T-test and linear and logistic
regressions were used to
analyze baseline crosssectional data and Linear
Mixed Models were used for
over time changes in these
associations.

Hypothesis 4D: HIV+
adults with caffeine
intake >250 mg/d have
lower than normal
hematocrit measured
over a period of 3months.

Hematocrit

Total Caffeine
intake

age, gender, income,
and time from
diagnosis of HIV,
drug, tobacco and
alcohol use and
different types of
ART medications

T-test and linear and logistic
regressions were used to
analyze baseline crosssectional data and Linear
Mixed Models were used for
over time changes in these
associations.

Hypothesis 4B: HIV+
adults with caffeine
intake >250 mg/d have
decreased BMI
estimated by BIA over a
period of 3-months.
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Table 1. Continued…
Hypotheses
Hypothesis 4E: HIV+
adults with caffeine
intake >250 mg/d have
lower than normal
serum albumin levels,
measured over a period
of 3-months.
Hypothesis 5A: HIV+
adults with caffeine
intake >250 mg/d have
decreased total caloric
intakes estimated by 24hour dietary recall over
a period of 3-months.
Hypothesis 5B: HIV+
adults with caffeine
intake >250 mg/d have
decreased caloric
intakes from proteins
estimated by 24-hour
dietary recall over a
period of 3-months.

Dependent
Variables
Serum
albumin
levels

Independent
Variables
Total Caffeine
intake

Control Variables

Statistical Analysis

age, gender, income,
and time from
diagnosis of HIV,
drug, tobacco and
alcohol use and
different types of
ART medications

T-test and linear and logistic
regressions were used to
analyze baseline crosssectional data and Linear
Mixed Models were used for
over time changes in these
associations.

Total caloric
intake

Total Caffeine
intake

Calories from
proteins

Total Caffeine
intake

age, gender, income,
and time from
diagnosis of HIV,
drug, tobacco and
alcohol use and
different types of
ART medications
age, gender, income,
and time from
diagnosis of HIV,
drug, tobacco and
alcohol use and
different types of
ART medications

T-test and linear and logistic
regressions were used to
analyze baseline crosssectional data and Linear
Mixed Models were used for
over time changes in these
associations.
T-test and linear and logistic
regressions were used to
analyze baseline crosssectional data and Linear
Mixed Models were used for
over time changes in these
associations.
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Table 1. Continued…
Hypotheses

Dependent
Variables
Calories from
carbohydrates

Hypothesis 5C: HIV+
adults with caffeine
intake >250 mg/d have
decreased caloric
intakes from
carbohydrates estimated
by 24-hour dietary recall
over a period of 3months.
Hypothesis 5D: HIV+
Calories from
adults with caffeine
fats
intake >250 mg/d have
decreased caloric
intakes from fats
estimated by 24-hour
dietary recall over a
period of 3-months.

Independent
Variables
Total Caffeine
intake

Control Variables

Statistical Analysis

age, gender, income,
and time from
diagnosis of HIV,
drug, tobacco and
alcohol use and
different types of
ART medications

T-test and linear and logistic
regressions were used to
analyze baseline crosssectional data and Linear
Mixed Models were used for
over time changes in these
associations.

Total Caffeine
intake

age, gender, income,
and time from
diagnosis of HIV,
drug, tobacco and
alcohol use and
different types of
ART medications

T-test and linear and logistic
regressions were used to
analyze baseline crosssectional data and Linear
Mixed Models were used for
over time changes in these
associations.
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CHAPTER II: LITERATURE REVIEW
There are many recent instances of adverse events due to caffeine abuse and a
number of television and newspaper reports suggest a pandemic of caffeine overuse in
United States in the current decade.1 There have also been many reports of energy drinks
related deaths and concerns about rising levels of caffeine consumption especially
amongst many vulnerable populations.1 In spite of such alarming rates of increased
adverse events due to caffeine, the extent to which these reports are scientific and
evidence-based has always been disputed and repeatedly challenged by the scientific
community.1 In lieu of these conflicting evidence, concerns over safety and permissible
levels of caffeine consumption needs to be addressed and researched amongst different
population groups. We need to understand the reasons for peaking levels of caffeine
consumption in many vulnerable populations, as well as the characteristics that place
these populations at higher risk. Many studies have linked caffeine intake to various
physical benefits, such as increased strength, endurance and stamina, making caffeinecontaining beverages a favorite amongst athletes and sports personnel.1-5 There are many
reports which show that caffeine is associated with mental faculties like increased
alertness, cognition and performance, thereby increasing its overuse potentials among
students and professionals.1-5 Many studies report the advantages of consuming caffeine
on increased duration and quality of work, increased working capacity at hours that
interfere with the biological rhythm, as well as increased work efficiency at the cost of
reducing the number of hours of sleep recommended per day.1-5 Vulnerable populations
according to numerous studies include students, business personnel, athletes, night shift
workers, population with chronic diseases, military personnel, geriatric population,
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frequent travelers as well as professionals in college and university settings.6 It is
particularly relevant that we research caffeine consumption as a phenomenon and
understand the effects in the general population before we focus on the effects in our
cohort of PLWH in Miami.
Daily Reported Caffeine use in United States
Secondary analyses of NHANES data collected between 2001 and 2010 showed
that the general levels and patterns of caffeine consumption have not significantly
changed over the last ten years.6-8 The average recorded consumption was 200 mg/day for
all the entire survey.6-8 All the age groups consumed highest amounts of caffeine through
coffee and average consumption through different beverages included, 135 mg/day form
coffee, 65 mg/day from energy drinks, 60 mg/day form tea and 35 mg/day from soda.6-8
Results also showed that highest caffeine consumptions (average caffeine intake recorded
beyond the 90th percentiles for the entire sample) were recorded in the age group of 50-59
years with average daily levels exceeding 500 mg/day, and in the 50-59 years group with
slightly less than 500 mg/day.6-8 There was also a statistically significant increase of 8
mg/day of caffeine from energy drinks during the past ten years (P<0.001).6-8 Another
large scale study done in US in the year 2011 with 37,604 participants showed similar
caffeine consumption characteristics to the ones reported by the NHANES data.9 The
largest caffeine source was coffee followed by energy drinks, tea and soda.9
Safe Levels of Caffeine Consumption
Over the last fifty years caffeine has been widely researched. Several studies have
been conducted by regulatory agencies for determining the safe levels of consumption as
well as levels producing side effects and adverse effects for different populations.10-15
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The U.S. Food and Drug Administration (USFDA) has different recommendations based
upon whether caffeine is consumed through naturally available sources like coffee, tea
and cocoa products or artificially added in caffeinated beverages and energy drinks.11,14
USFDA has classified natural sources as Generally Recognized as Safe (GRAS) category
while artificially added caffeine has been concluded to be safe, within the current average
levels of consumption (200 mg/day).11 Further research was recommended to confirm the
safety limits of artificially added caffeine.11 For both naturally occurring and artificially
added caffeine sources, FDA considers 400 mg/d to be generally safe and not associated
with any dangerous side effects.10,11 The World Health Organization (WHO) defines
caffeine overuse as daily consumption beyond 500 mg/d.12,13 Beyond this level caffeine
produces visible adverse effects collectively known as ‘caffeinism’. The World Health
Organization (WHO) has also cautioned that these adverse effects could be precipitated at
much lower doses depending on the physiological profiles of individuals as well as the
genetic makeup of the population.12,13 The International Classification of Diseases (ICD)
manual considers caffeine consumption beyond 250 mg/day to be associated with many
mental and behavioral disorders though it is inconclusive whether such effects would be
uniformly applicable in the general population.13 The Diagnostic and Statistical Manual
of Mental Disorders (DSM-5) considers consumption below 250 mg/day to be generally
safe and beyond this level to be associated with many adverse effects such as withdrawal,
addiction, irritability and craving.15 Thus we can conclude that consumption below 250
mg/day, irrespective of the sources is generally safe and devoid of adverse effects after
comparing and summarizing the recommendations of these individual regulatory bodies.
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Caffeine-Biological Actions-Adenosine Receptors (A1, A2a, A2b and A3)
Caffeine affects a number of physiological and biochemical processes.16 The
main action includes the blockade of a number of related adenosine receptor family
subtypes.16,17 Caffeine at plasma levels of 0.001-0.1 millimoles/ml produces significant
blockade of all adenosine receptor subtypes.16 Other biochemical effects include
inhibition of phosphodiesterases, blockade of GABA-A receptor subtypes, and release of
intracellular calcium.16 These actions are accomplished at higher plasma levels of 0.1-10
millimoles/ml.16 A number of other interactions including ion channel blockade and
enzyme inhibitions have also been reported.16 Four different adenosine receptor subsets
exist in mammals, which include A1, A2a, A2b and A3.17 When considered the order of
importance (in humans), in terms of relative concentrations and effects in the body, A2a
receptors stand the first, A1 the second and A2b the third.17 At A3 receptors caffeine is a
‘partial agonist’ with both agonist and antagonist like actions or in practical terms ‘no
significant effects’.17 Caffeine is primarily an antagonist at A1, A2a & A2b receptor
subtypes.17 To be antagonized, the receptors should be already acted upon by endogenous
adenosine. Caffeine has no CNS effects unless the receptors are already acted upon by
endogenously produced adenosine. Under normal physiological conditions, adenosine
acts on A1 and A2a receptors in both the Central Nervous System (CNS) and Peripheral
Nervous System (PNS) and produces inhibition of the neuronal circuitry.17 Adenosine
acts on A2b and A3 receptor during abnormal conditions like ischemia and necrosis, or
during increased firing states like convulsions and seizures.17 Blockade of A1 and A2b
receptor seem to be the most possible mechanism for pharmacological actions of caffeine
under normal resting physiological conditions.17 A number of drugs of abuse have the
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potentials to change the endogenously and constitutionally expressed levels of
adenosine.17 These endogenously expressed levels of adenosine show much ‘inter species
variability’ between different biological species and ‘intra-species variability’ between
different individuals.16 This is the likely mechanism for different levels of tolerance to the
effects of caffeine between different individuals, as well as different life forms.16 This
also accounts for the different set of responses when caffeine is co- administered with
other drugs of abuse.16 This is also responsible for different sets of biphasic responses
between animals and humans thereby delimiting the comparability between animal and
human studies.18 Caffeine also stabilizes these receptors to the normal circadian
fluctuating levels of adenosine expressed constitutionally thereby explaining the
phenomenon of reinforcement.18 In addition to inhibiting adenosine, caffeine also inhibits
phosphodiesterase enzymes and thereby increases the G-protein stimulation, increases
adenylyl cyclase enzyme activity and increases cyclic AMP levels in the cells.19 It has not
been possible to classify and isolate the effects of caffeine (e.g CNS stimulation, antidepressant, and somnolytic effects) specifically to its action on any of the individual
receptor subtypes. All these actions are accomplished through various levels of receptor
antagonism involving all the three receptors.19 Various ‘receptor sub-type specific
analogs’ of adenosine have been employed to study the individual receptor subtypes. But
these analogs have additional actions on many other receptor, which may or may not be
related to caffeine and adenosine, thus obscuring the results.19 Research has shown there
are many such dormant receptor subtypes that are not affected by endogenously produced
adenosine. These receptors are species specific and hence again, animal studies do not
produce comparable results.19 This is further complicated by the findings in many animal
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studies which show receptor ‘up-regulations’ and ‘down-regulations’ by caffeinated
products. In a study done on mice, chronic treatment with caffeine resulted in ‘upregulation’ of A1-adenosine receptors, serotonin receptors, GABA-A receptors,
muscarinic receptors, and δ-opoid receptors.20 Similarly it produced ‘down-regulation’ of
β-adrenergic receptors and ‘desensitization’ of nicotine receptors.20 Dopamine receptors
were not showing any such changes and hence the actions on dopaminergic receptors can
be considered unaffected by acuteness or chronicity of caffeine consumption, in both
humans and animals.21 These findings suggest that the biological effects of caffeine are
complex and variable (individual to individual variability), because of the differences in
the mechanism of action and variability in the types of receptors involved. Many studies
on acute and chronic caffeine use fail to yield adequate test-retest reliability due to these
variable levels of receptor-regulations.21
Caffeine and A1 Adenosine Receptors in the Central Nervous System (CNS)
A1 receptors are abundant in the cerebral cortex, cerebellar cortex, hippocampus,
substantia nigra, and thalamic nuclei.22 These receptors are located on synaptic clefts and
axo-dendritic buttons.22 When endogenous adenosine acts on these receptors it produces
substantial inhibition of the release of a number of neuro-transmitters. It is not well
known how these inhibitory actions are accomplished. Under normal physiological
conditions adenosine produces inhibition of only certain neuronal circuits while others
remain unaffected. These mechanisms too, are not fully understood. Caffeine has a dual
role when it comes to antagonism of adenosine at A1 receptors. It produces reversal of
the inhibition produced by Adenosine which is the most important and acute action. But
in the long term these receptors are also up-regulated by chronic caffeine use.23 Up-
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regulation occurs both by the process of desensitization to caffeine as well as increase in
the number of constitutionally synthesized receptors.23 Caffeine also increases the rate of
recycling of these receptors.23 Adenosine decreases the rate of firing of many CNS
neurons with nor-adrenergic, dopaminergic, cholinergic, and glutamatergic activity
through A1 receptor-mediated activation of fast potassium channels.24 Thus adenosine
produces hyper-polarization of the cells and thereby inhibition of neuronal circuitry.
Certain studies show that open chloride channels are also responsible for these actions.
This process is known as tonic inhibition of A1 receptors by adenosine.24 This tonic
inhibition is competitively antagonized by caffeine.24 A number of animal studies have
documented that caffeine increases the levels of acetylcholine in the cholinergic neurons
of meso-pons, hippocampus and amygdala and mesolimbic nuclei. 25 These are the
centers responsible for mood, aggression, locomotion, learning, memory and behavior.
This acetylcholine via stimulation of nicotinic receptors in Ascending Reticular
Activation System (ARAS) produces behavioral arousal. Actions of caffeine have also
been recorded in nigro-straital pathways, thus enhancing jitteriness and loss of fine motor
coordination skills.25 Caffeine also increases the levels of dopamine and glutamine in the
cortical neurons that innervate the thalamus and striatum.21 This is responsible for
locomotor stimulation and hyper-excitability states. An animal study done on mice
showed that both D1 and D2 receptors are involved in the locomotor stimulatory effects
of caffeine. Antagonists that blocked both D1 and D2 receptors inhibited the increased
locomotor stimulation induced by caffeine.21 Selective antagonists of D2 receptors
produced inhibition of rotational activity also induced by the same doses of caffeine.21
These processes are very complex and shows inter species and intra species variations.
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Irrespective of these complexities it is very convincing that caffeine produces a variety of
adverse effects through antagonism of Adenosine at A1 receptors. These biochemical
alterations can have serious effects in chronic disease states like HIV where brain cells
are constantly attacked and destroyed the virus.
Caffeine Effects on A2a and A2b Adenosine Receptors
A2a receptors are abundant in caudate nucleus, putamen, nucleus accumbens,
tuberculum olfactorium26 as well as the gabaminergic neurons of striatum.27 These nuclei
are mainly associated with D1 and D2 receptor mediated release of encephalins which are
natural endorphins that act as potent analgesics and mood elevators. D1 receptors are also
associated with release of other neurotransmitters like substance P and dynorphins which
have similar euphoric actions. Though both the dopaminergic receptors D1 and D2 are
positively modulated by caffeine, the effects of D1 predominate.28 These A2a receptors
stimulate Adenylyl cyclase, increase cyclic AMP levels, similar to A1 receptors. But
strikingly, D2 receptors decrease the levels of cyclic AMP. Caffeine antagonizes the
actions of endogenous adenosine at A2b receptors, thereby potentiating endogenous
dopaminergic effects on D2 receptors. This decreases the levels of cyclic AMP in the
neuronal cells. Thus caffeine acts as a depressant in some neuronal circuitry.29 These A2a
receptors are located on the dendritic spines and are virtually absent in the synaptic
buttons or clefts. 29 It is well established that inhibition of adenosine at A2a receptors by
caffeine, potentiate the inhibitory effects of GABA. 29 Caffeine blocks the striatal A2a
receptor activity tonically activated and controlled by adenosine. This would decrease the
effects of endogenous dopamine on D2 receptors. 29 This produces major changes in
circuitry associated with reward /arousal systems. Adenosine by its action on A1
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receptors produces some levels of physiological self-antagonism to its actions on A2a
receptors.29 These actions confuse the role played by caffeine both in acute and chronic
doses.29 Furthermore, this self-antagonism shows inters-species and intra-species
variations.29 Any findings from animal studies therefore need to be validated with human
studies and no acceptable levels of homogeneity and comparability exists. Caffeine
therefore has both effects; stimulating effects on certain neuronal circuitry and depressant
effects on others.30 Furthermore some nuclei like striato-pallidal and striato-nigral, are
inhibitory to the Globus pallidus and substantially higher concentrations of A2a receptors
are found to be active in these nuclei.31 Caffeine by blocking the constitutive inhibitory
effects of endogenous adenosine decreases the inhibitory effects on Globus pallidus and
thereby symptomatically ameliorates the progression of Parkinson’s disease.31 But this
effect is at the costs of increased activity in other neuronal circuits like those in cerebral
and cerebellar cortex which leads to increased burnout damages in these neurons. Thus,
we have an open question ‘Whether the beneficial effects of caffeine could be at the costs
of potential known or unknown side-effects?’
Biphasic Effects of Caffeine
Both human and animal studies have shown biphasic behavioral effects of
caffeine. Low to moderate doses elicited a stimulatory effect described by many as
desirable: high doses elicited undesirable effects like anxiety, nervousness, shakiness,
jitteriness and lack of concentration. 32 Very high doses have shown to induce
convulsions in animal models. The cluster of undesirable effects of high and very high
doses of caffeine is collectively known as ‘caffeinism’.32 Low doses of caffeine (<4
mg/kg body weight/day) stimulated a frenzy of motor activity in rodents. This is
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measured in terms of ‘open-field locomotion activity scores’ in normal mice and
‘rotational activity scores’ in mice with induced unilateral dopaminergic lesions. Low
doses elicited ‘conditioned place preference’ an indicator of desirable effects in mice.32
High doses on the contrary, elicited ‘place aversion’ an indicator of undesirable effects.32
High doses have also shown major depression like symptoms in these animals.32 Another
study suggested that high doses of caffeine produced profound suppression of motor
activity in knockout mice with absent A 2A -adenosine receptor.33 This shows that the
stimulatory effects are prominent until fullest saturation of these and other structurally
similar receptors and once these receptors are saturated depressive effects begin to
predominate. Mumford and Holtzman34 did an experiment in which the mice were trained
to identify drugs with similar effects as that of caffeine upon temporary withdrawal of
regularly administered doses of caffeine. The regularly administered doses were different
for different groups of mice and are referred to as ‘priming doses’. They were primed
initially either for low or high doses of caffeine and subsequently given choices of a
number of other test drugs. These experiments used extensive behavioral techniques in
order to derive exact cues from rodent behaviors. Mice that were primed with low doses
of caffeine chose dopaminergic drugs such as amphetamine and cocaine. Mice that were
primed for high doses of caffeine chose CNS depressants which included benzodiazepine
inverse agonists such as phencyclidine, pentylenetetrazole and papaverine. This study
reflects the biphasic response to caffeine, where the mice primed with low doses showed
euphoric effects and mice primed for high doses showed many complex effects, which
were behaviorally non-routine but definitely not euphoric and tended towards coping
mechanisms for depressive effects.34 These experiments cannot be generalized to human
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beings because humans show different sets of responses for both high and low doses of
caffeine. Furthermore, other xanthine alkaloids like theobromine have virtually no
responses in humans but are comparably active as caffeine in rodent populations.34 To
add to the limitations of this animal study, all sources of caffeine metabolize to three
xanthine alkaloid products in the human body and the metabolic products of caffeine
show many differences in types as well as levels between humans and animals.18 These
three xanthine alkaloid products are also naturally present in differing concentrations in
various caffeinated products.18 There are no unified cutoff points for high and low doses
of caffeine in human beings, as the effects may vary from individual to individual and in
the same individual from one time to another, depending on the intakes of other
substances and their regular intakes.18 Paraxanthine a biological metabolite of caffeine is
also as potent as caffeine in humans and this complicates the mechanisms further.18 Thus,
we see that caffeine produces biphasic responses in both humans and animal models,
although the exact signs and symptoms may be variable due to intra-species and interspecies biological dissimilarities. Most of these biphasic responses can elevate the levels
of stress in chronic disease states such as HIV infected patients, which can further
aggravate disease progression. These biphasic effects are also correlated with increased
consumption of alcohol due to delay in attaining the euphoric effects, and thereby
exacerbating the adverse effects of both alcohol and caffeine in combination.35
Caffeine-Adverse Effects Outweigh Apparent Beneficial Effects
A number of studies done during the early nineties have documented that
caffeine increases mental and physical alertness. These effects have been wrongly
interpreted as the beneficial effects of caffeine. The majority of them have been
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documented in situations of compromised alertness, like patients on benzodiazepines36
early morning shift workers37 night shift workers38 and persons on cold medications and
sleep loss39. Lieberman40 stated that some of these beneficial effects can increase
neuronal burnouts when administered under normal wakeful conditions. Caffeine in
single bolus dose infusion of 300 mg/day or higher, triggered acute anxiety states.41 This
heightened anxiety has been described by many healthy volunteers under normal
physiological conditions to increase their mental and physical capacities. A number of
healthy volunteers scored better in self-rated depression questionnaires when
administered 300 mg/d of caffeine per day.41 Caffeine reduces fatigue and produces
increased tension and nervousness, and human physiology perceives this as a pleasurable
experience.41 In a study done amongst apparently healthy volunteers, it was observed that
subjects who were administered 300 mg/d of caffeine showed increases jitteriness and
nervousness, and fine motor coordination scores were adversely affected.42 A number of
stress related physiological and neuro-hormonal changes have also been documented and
include increased levels of excitatory neuro-hormones like nor-epinephrine and
epinephrine, increased calcium mobilization into the cells, increased prostaglandin
antagonism and increased phosphodiesterase enzyme inhibition.43 Caffeine infusions
produced better performance in both simple reaction time and choice reaction time
scores; both indicators of increased stress and alertness.40 Caffeine facilitated
performance in jobs involving impulsive maneuverings, and reduced performance in
those involving complex cognitive skills.44 This finding is also supported by another
study in which caffeine in doses of 400 mg/day increased anxiety when paired up with a
stressful task requiring increased cerebral functions.45 Though many of these early studies
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record the beneficial versus adverse effects, they used fairly large doses of caffeine (>400
mg/day) in single administered doses and do not consider regular consumption levels of
caffeine. These studied are virtually inconclusive about the long term effects of regular
small to medium doses of caffeine on human behavior. Furthermore, these studies were
done on apparently healthy volunteers and the health related impacts could be many folds
higher in chronic disease states like HIV, and can be further adverse in those on Antiretroviral medications. Thus we can say that caffeine produces a number of adverse
effects masked by perceived beneficial effects.
Adverse Effects of Caffeine Withdrawal
Caffeine withdrawal as a topic has been widely researched and there exist
adequate evidences in literature on the addictive potentials and development of
dependence in regular users.46 Caffeine shows all the three criteria for labeling it as a
reinforcing drug, which includes dependence, tolerance and withdrawal.46 However the
reinforcing potentials of caffeine are much lesser that than other psychomotor stimulants
such as cocaine and amphetamines.46 Both the acute stimulating effects and undesirable
withdrawal effects contribute to the reinforcing potentials, but withdrawal effects
predominate in making it an additive substance.46 Many studies report the reinforcing or
addictive potentials but are inconclusive whether these are physiological or psychological
responses to decreasing serum caffeine levels. The most widely reported symptoms
include headache, body ache and mood changes.46 In a study done by Ratcliff-Crain et
al.,47 it was shown that caffeine deprivation leads to increased reporting of stress and
anxiety by regular caffeine consumers. This is further confirmed by another study done
by Schuh et al.,48 in which participants reported feelings of fatigue and decreased
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alertness on caffeine deprivation. Silverman et al.,49 reported that about 52% of
volunteers with low to moderate daily intakes of caffeine (mean=235 mg/day), reported
moderate to severe headaches, 11% reported increased depression, 8% reported increased
anxiety symptoms, 11% reported low vigor and 8% reported increased fatigue when their
regular doses were acutely substituted with placebo solutions. Some studies confirm that
even regular doses of caffeine (≤250 mg/day) produces tolerance as well as ill effects of
withdrawal due to habituation.42 This is very well confirmed by a double blind study
done by Goldstein et al.,42 in which both habitual and non-habitual caffeine consumers
were challenged with overnight caffeine deprivation. Habitual caffeine consumers
reported higher rates of caffeine withdrawal symptoms than non- habitual caffeine
consumers, which included decreased alertness, decreased feeling of content and
wellbeing, increased sleepiness, irritability and mild to moderate headaches.42
Consequent to the caffeine deprivation test, the participants were randomly divided into
three groups and each group received single dose pills of either 0 mg (placebo), 150 mg
or 300 mg of caffeine with approximately equal number of habitual and non-habitual
consumers in each of the three groups. This study showed that habitual caffeine
consumers showed significant reversal of the negative symptoms of caffeine withdrawal,
within minutes after administration of 150 or 300 mg of caffeine, but non-habitual
consumers did not show such responses. This study confirms the re-enforcing potentials
of caffeine.42 With regards to the beneficial effects such as increased cognitive acuity,
increased wakefulness and increased sense of well-being, both habitual and non-habitual
consumers showed no significant differences for both 150 mg and 300 mg doses; on the
contrary, the non-habitual consumers reported higher rates of negative symptoms such as
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nervousness, jitteriness and increased gastric acidity.42 Strikingly, non-habitual
consumers who were administered placebo pills (0 mg) also reported equivalent increase
in negative symptoms such as nervousness, jitteriness and increased gastric acidity,
indicating the role of placebo responses in these individuals.42 Habitual consumers who
received 0 mg of caffeine did not show significant reversal of negative symptoms
indicating the existence of physiological mechanisms for caffeine withdrawal and
reinforcements.42 This study very well documents the addictive potentials of caffeine.
This also shows that both physiological and psychological mechanisms are involved in
withdrawal reactions. A number of other possibilities should have been considered in
analyzing these responses, which include the preexisting differences in personalities,
possibilities of mood disorders in these volunteers, the number of hours of sleep, and the
number of hours of caffeine deprivation. These factors were not adequately considered in
the study and hence the conclusions are not entirely reliable. Another study done by
Bruce et al.,50 showed that negative symptoms of caffeine withdrawal like tiredness,
drowsiness, anger and depression successively increased and peaked in volunteers
deprived of caffeine for 24 hours, and beyond this time interval these effects started to
subside, and by the end of 7 days were completely resolved. Thus we can see that
caffeine withdrawal and dependence are associated with time elapsed since consumption
of habitual doses of caffeine.50 Furthermore it can be inferred that caffeine withdrawal
symptoms occur regularly in caffeine addicted individuals and force them to consume
regular or higher doses to overcome these symptoms.42 Caffeine withdrawal also
facilitates increasing doses in a vicious cycle. These increasing doses of caffeine would
lead to marginal weight loss even in normal subjects due to serially increasing levels of
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consumption.51 Such addictive and withdrawal effects can have increased adverse effects
on HIV positive patients who are already compromised in a variety of health related
parameters.
Caffeine is Associated with Changes in CD4 levels as well as Plasma Viral Loads
A study was done amongst HIV infected clinically stable (except for oral
Candidiasis in some participants) patients in order to quantify the variations in CD4 cell
counts that could be ascribed to laboratory and physiological factors. There was 15%
reduction in CD4 counts due to laboratory factors (alcohol, caffeine and tobacco) after
controlling for factors like age, gender, ART compliance, presence of opportunistic
infections and measurement errors.52 Though caffeine was considered one of the
laboratory factors in this study, it was clustered with many other factors like exercise,
tobacco and alcohol consumption.52 In addition, this study recruited a small sample size
of 30 participants and results are not generalizable.52 Another study was done amongst
clinically stable HIV positive individuals to establish the effects of caffeine consumption
on CD4 and CD8 cell counts after exercise (cycling for about 90 minutes). The
participants were asked to abstain from consumption of caffeine for 60 hours prior to the
experiment. Half of the subjects were administered 6 mg/kg/day of caffeine, while the
remaining subjects were administered placebo before the exercise. There was 54%
decrease in circulating CD4 cell counts and 55% decrease in circulating CD8 cell counts
post exercise in subjects administered caffeine when compared to placebo after
controlling for factors like fluid input levels, age, gender, BMI, lean body mass and fluid
output levels. 53 This study also reports that post exercise plasma catecholamine levels
were significantly higher in those administered caffeine when compared to placebo
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indicating increased stress levels in participants administered caffeine.53 This study also
reported that caffeine produced alterations in lymphocyte subset trafficking as well as
expression of CD69 molecules which are important intermediate steps in generating and
recruiting inflammatory cells.53 Through this process caffeine decreased production and
recruitment of inflammatory cells to the targeted areas of inflammation which included
decreased circulating CD4 and CD8 cells.53
In contrast to the findings that caffeine intake produces adverse effects on HIV
disease progression; an in-vitro tissue culture study showed that caffeine suppresses
replication of infectious HIV-1 strains in cultures of human peripheral mononuclear cells.
Caffeine in 100 millimoles/ml concentrations exerted these effects by inhibiting the
integration step of the HIV-1 viral replication cycle. This study also shows that other
methyl-xanthines like theophylline, theobromine, and paraxanthine, in 100 millimoles/ml
doses act through the same process to inhibit HIV-1 viral replication. They observed a 9fold reduction in HIV-1 p24 antigen values in samples treated with caffeine,
theobromine, paraxanthine or theophylline when compared to control solutions.54 These
analysis were controlled for confounding factors like solvents (Water vs 0.1% NaCl
solution) used for different xanthine compounds, rate of growth of human peripheral
mononuclear cells, differences in viral replications per unit time for different HIV-1
strains as well as the differences in reagents used for the experiment.54 Adjustments were
also made to account for variations in reverse transcriptase-polymerase chain reaction
procedures (RT-PCR), southern blotting assays for HIV gag sequences, as well as the
primer-probes SK38, SK39, and SK19.54 In another tissue culture study it was found that
caffeine in doses of 10 µgm/liter significantly inhibited retroviral transduction of dividing
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Human Neuronal Precursor (hNT-2) cells thereby blocking post integration repair of
HIV-1 viral strains. These effects have been postulated to a cellular target- ‘The Ataxia
Telangiectasia-Mutated And Rad3-Related (ATR) kinase’.55 Caffeine inhibits viral DNA
repair at the DNA damage-activated checkpoints.55 These results were adjusted for
different dosages of retinoic acid used for maturation of hNT-2 cells, different levels of
Nocodazole used for cell cycle arrest, differences in HIV-1vectors like vpr, vif, vpu, and
nef genes, as well as differences in western blot procedures for detecting levels of PCNA
(Proliferating Cell Nuclear Antigen) proteins and viral integrase.55
In summary, we can say that here are very few studies that document the direct
effect of caffeine on CD4 cells and viral load. The studies investigating viral loads are
tissue culture in-vitro studies. Furthermore, these effects are opposing one another in
terms of disease progression as caffeine inhibits viral replication as well as decreases the
number of CD4 cells. Therefore a question remains-whether caffeine is beneficial to HIV
infected individuals due to decreased viral replications or harmful due to depletions in
CD4 cell counts.
Caffeine Adversely Affects Sleep Quality and Precipitates Anxiety Disorders
In a study done amongst pre-AIDS seropositive men and women, it was observed
that increasing psychological distress scores were associated with increasing viral load
and lowering CD4 cells after controlling for age, medication use and HIV
symptomatology.56 In an animal study, it was observed that even mild acute stressors
produced increased plasma corticosterone levels and a significant decrease in the
numbers and percentages of all circulating lymphocytes, and these changes were rapidly
reversed upon removal of the stressors.57 Oral administration of 480 mg of caffeine
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provoked acute stress responses like panic attacks and heightened anxiety levels in a
sample of regular non HIV subjects with various forms of anxiety disorders, recruited in
a randomized double-blind experiment conducted on two occasions 7 days apart.58
General stress levels estimated by the number of anxiety symptoms and panic attacks,
were substantially higher in subjects administered 480 mg of caffeine when compared to
control solutions after adjusting for gender, age, educational level, marital status,
occupation, different sources of caffeine and previous psychiatric treatments if any. Four
hundred and eighty mg of caffeine on each of the two test dates precipitated panic attacks
in 60.7% all of the participants in experimental arm of the study while none of the
participants in control arm showed any such symptoms. This study concluded that higher
doses of caffeine precipitated anxiety and panic attacks even in regular non-HIV
volunteers with some levels of anxiety disorders.58 According to a review paper, caffeine
in higher than regular levels (>250 mg/day) worsened mental stress and precipitated acute
events in healthy subjects after controlling for many covariates such as sedative
medications, presence or absence of psychiatric symptoms, age, gender, lifestyle factors,
exercise and alternative therapies.59 In a case report, it was also observed that chronic
caffeine consumption in doses of 400 mg/day precipitated delusions and paranoia in a
schizophrenic patient undergoing treatment, with symptoms controlled through
medications. Lowering the doses of caffeine serially to end with the eventual cessation of
caffeine caused the delusions and paranoia to subside completely. This case study shows
the effects of caffeine in increasing neuronal excitability and stress, however the study
was very limited because the patient is a single isolated case with psychiatric
abnormalities.60 In a study that investigated the effects of day-long consumption of tea,
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coffee and water on cognitive and psychomotor performance, and of sleep quality at
night, it was observed that caffeine in doses of 35 to 150 mg/day, irrespective of sources,
significantly decreased the initial Critical Flicker Fusion Threshold (CFFT) which
signifies higher levels of neuronal excitability after controlling for age, BMI, exercise,
gender, body composition measures and lifestyle factors.61 This study also reports that the
caffeine in coffee produced significantly greater sleep disturbances than in tea, in the
form of altered sleep patterns after controlling for several cognitive and psychomotor
adverse effects for both the beverages and dose adjustments for different levels of
caffeine in both the beverages.61
In a cross-sectional survey conducted in 1514 men and 1528 women, men who
consumed more than 200 mg/d of caffeine had 50% higher interleukin 6 (IL-6), 30%
higher C-reactive protein (CRP), 28% higher tumor necrosis factor- (TNF- ) and 3%
higher white blood cell (WBC) counts . Women who consumed greater than 200 mg/d of
caffeine similarly showed 54% higher IL-6, 38% higher CRP, 28% higher TNF-
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4% higher WBC counts.62 These findings were significant even after controlling for
interactions between caffeine consumption and age, sex, smoking, body mass index,
physical activity, and other covariates. This study shows that caffeine consumption and
related physiological stress is associated with increased inflammatory states and thereby
wasteful immune functions.
HIV patients already report deteriorated sleep quality, increased periods of
insomnia and post morning sleepiness, cognitive impairments, and increased tiredness.6367

In a study done amongst HIV positive participants it was found that sleep quality

measured by the Pittsburgh Sleep Quality Index (PSQI) was significantly poorer after
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adjusting for underlying pathologies and medications(over-the-counter drugs, vitamins
and herbal products, and mood-altering substance).65 Another study was done to examine
the correlates of sleep quality in HIV-infected persons using the ‘Symptom Experience
Dimension’ of the revised ‘UCSF Symptom Management conceptual model’. According
to this study the variables significantly related to sleep quality included employment
status, trait anxiety, general well-being, length of time living with HIV disease,
depressive symptoms, state anxiety, severity of symptoms, daytime sleepiness, and
functional status of the participants.66 The length of time living with HIV disease was
significantly associated with poor sleep quality measured by the PSQI after controlling
for other covariates mentioned above.66 Another study done amongst 146 clinically
stable HIV positive participants showed that physical pain, stress and social support
variables were significantly associated with deteriorated sleep quality after controlling for
covariates like age, sex, marital status, compliance with ART, other medications,
concurrent drug use, alcohol and tobacco use as well as income.68 Similarly, a study
done amongst clinically stable HIV positive patients shows that that higher sleep quality
measured by the Pittsburgh Sleep Quality Index (PSQI) and Pittsburg Insomnia Rating
Scale (PIRS) was associated with better cognitive performance on tasks of attention,
frontal/executive function, and psychomotor/motor speed after controlling for the effects
of medications, alcohol consumption and drug abuse.67 However this study also reports
that more than 40% of the participants were chronically and severely sleep deprived.67 In
addition, another study done on injection drug users reported that general well-being
scores estimated by the HIV Assessment Tool (HAT) and the State-Trait Anxiety
Inventory(STAI), was significantly associated with sleep quality measured by Pittsburg
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sleep quality index (PSQI) after controlling for age, gender ethnicity, injection drug use,
employment status, income, sleep medications, day time dysfunction and alcohol
consumption.64
Side Effects of Caffeine in Non–sleep-deprived Volunteers
In a study done on non-sleep-deprived volunteers, caffeine was administered in
doses of 0, 100, 200, 400, and 600 mg and the biological effects were measured four
hours after this administered dose.69 This study found a dose dependent increase in
subjective symptoms of jitteriness, nervousness and shakiness with increasing dosages
after controlling for many co-factors like age, gender, number of hours of sleep and
physiological and psychological stressors. Even the lowest dose of 100 mg showed
statistically significant differences when compared to placebo for ratings in subjective
distress scores. There was also a statistically significant as well as dose dependent
increase in the ratings for “dislike effects” for caffeine doses of 400 mg and 600 mg after
controlling for the same co-factors mentioned earlier.69 Another study was done in a
group of non–sleep-deprived volunteers who were habitual smokers and drug users.70
This study looked for the side effects of 0 mg (placebo), 200, 400 and 800 mg doses of
caffeine on ratings of subjective distress scores. There was a dose dependent increase in
tension-anxiety ratings and this increase was statistically significant for all the doses of
caffeine when compared to placebo. In addition there was also a statistically significant
increase in scales associated dysphoric and somatic symptoms in participants
administered 800 mg doses when compared to placebo. There was also a significant
increase in ratings for drug induced euphoria in the participants administered 800 mg
doses. Although this study controlled for many covariates, such as stress, hours of sleep,
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age and physiological impairments, changes in subjective assessments could have been
affected by other drugs like nicotine and amphetamines which were prevalent in this
cohort. The study included only six subjects and a repeated–measures design was used.
There would have been many carryover effects affecting the results of the study. The
subjects were not restricted from smoking after caffeine consumption, and the subjective
symptoms could have been due to both nicotine and caffeine. Irrespective of the
limitations of these studies, we can infer that caffeine is associated with many subjective
sensations of anxiety, distress and discomfort which could affect sleep quality as well as
wellbeing even in non-sleep-deprived participants.69,70
Side Effects of Caffeine in Sleep-Deprived Volunteers
There are many recent studies that have mixed findings about the impact of
caffeine on performance and alertness in sleep-deprived volunteers. Sizeable amounts of
caffeine consumption are directed to overcoming the subjective effects of tiredness and
irritability due to insufficient sleep. In a study conducted amongst fifty healthy,
nonsmoking males between the ages of 18 and 32 years, caffeine was administered in
doses of 150, 300, or 600 mg after 48 hours of sleep deprivation.71 Mental alertness was
measured through Stanford Sleepiness Scale (SSS), and Visual Analog Scale (VAS).
Caffeine even in low doses of 150 mg/day produced reversal of sleep deprivation-induced
lack of alertness measured through SSS and VAS. In this study the highest doses of 600
mg/day produced complete reversal of sleepiness and the values of SSS and VAS were
close to fully rested physiological conditions with recommended number of hours of
sleep. Thus, this study reports the benefits of caffeine consumption in terms of increased
alertness during physiologically challenged condition such as sleep deprivation. However
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this study also suggests that these subjective feelings of increased alertness could be at
the cost of many health related parameters such as impaired immune functions, impaired
cognition and other indicators of healthy living.71 In the same study, it was also reported
that there was a dose dependent increase in frequency of sleepiness, anxiousness,
irritability, jitteriness, talkativeness, increased heart rate, headache, sweatiness, stomach
discomfort and other subjective symptoms.71 However, the doses at which these
subjective symptoms started to appear was not clearly mentioned in this study.71 In
another study to test the efficacy of modafinil versus caffeine on fifty sleep deprived
volunteers, it was found that 600 mg doses of caffeine produced increased subjective
symptoms of palpitations, irritability and nausea following 41 hours of forceful sleep
deprivation.6 In the same study it was also observed that 2 volunteers vomited
approximately after two hours of administration of 600 mg of caffeine.6 In the same
study, caffeine in doses beyond 100 mg was associated with increased blood pressure
tracings, though the increase was not significant. (Approximately 1mm Hg per 100 mg
increase in doses of caffeine).6 Thus we can summarize that, though many studies
discussed the adverse effects of caffeine in sleep deprived volunteers, none of them
reported any hospitalizations or other adverse events beyond subjective symptoms.
However, it should also be noted that the majority of these studies employed a convenient
sample of healthy volunteers, and that adverse events due to the administered doses of
caffeine were criteria for discontinuation of study participation. Furthermore these studies
did not look for the adverse effects of chronic levels of caffeine consumption.
In addition, caffeine intake affects sleep quality as demonstrated in a study done
amongst 88 HIV positive participants.72 In this study sleep quality was measured by the
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Revised Pittsburg Sleep Quality Index (R-PSQI). Mean caffeine intake of the entire
sample was 476 mg/day, which was 2.4 times the national US consumption average of
200 mg caffeine/day. This study showed that subjects having higher caffeine
consumption levels (>400 mg/day) showed decreased sleep quality index scores.72 Within
one month subjects who reduced their baseline caffeine consumption by 90% or higher,
showed significant improvements in sleep quality index scores after controlling for other
covariates like liver function tests, CD4 cell counts, viral loads, smoking, alcohol
consumption and recreational drug use. However this study had several limitations
because the average caffeine intake of the sample was very high, sample size was small,
and this study did not look for dose-based adverse effects of caffeine.
Thus, we see that caffeine consumption could be responsible for decreased sleep
quality, altered sleep patterns as well as increasing stress levels and anxiety symptoms.
All these factors could be responsible for accelerated disease progression in PLWH. Our
study aims at understanding whether such mechanisms would have existed in our
population of HIV positive participants from Miami-Dade County. We also aim at
estimating the share of caffeine in adverse effects on sleep quality and anxiety symptoms,
after controlling for covariates such as age, gender, drug abuse, alcohol consumption,
tobacco use and types of ART, as well as explore the effects of moderate (<250 mg/day)
and high (>250 mg/day) doses of caffeine on these outcome variables.
Caffeine Intake is Associated with Significant Nutritional Alterations
A long-term follow-up study from 1980 to 1998, that recruited 1333 males and
4085 females having type -2 diabetes, showed that there was a strong association between
increased caffeine consumption (> 4 cups/day which is approximately >240 mg
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caffeine/day) and weight loss (approximately 5.5 kg/ year) and this weight loss produced
significant reduction in risk factors for diabetic complications after controlling for age,
weight status, insulin administration, anti-diabetic drugs, physical activity and lifestyle
factors.73 Further analysis also revealed that there was decreased risk for diabetes in those
who lost weight, and that there was a positive dose–response relationship between
caffeine intake and weight loss when caffeine was considered as a continuous variable.73
In a systematic review of twenty studies on the protective effects of caffeine in diabetes,
twelve studies reported that the protective effects were due to weight loss induced by
caffeine.74 This review also mentions an estimated 100kcal/day increased energy
expenditure due to habitual consumption of 6 cups of coffee (400 mg caffeine/d).74 This
review states that caffeine is the primary, and possibly the sole, ingredient responsible for
the negative energy balance observed in several studies.74 Eight studies of these twenty
studies also reported a dose-response relationship between caffeine intake and weight
loss.74 Caffeine intake is also associated with decreased feeding in animal models. In a
vertebrate study on Wistar rats, it was observed that rats administered 1gm/liter caffeine
solutions in their drinking water for forty days showed significant aversions to palatable
rat foods, when compared to the rats administered 0.3g/liter caffeine solutions or plain
water control solutions after controlling for baseline weights and feeding behaviors.75
This study also showed that such effects were more profound in the female rats, when
compared male rats, after controlling for the differences in catecholamine levels, baseline
weights, and baseline calorie consumption levels, in all groups of animals.75 In another
study done in young healthy women, caffeine was responsible for increasing basal energy
expenditures (BEE), even in the presence of genetic abnormalities predisposing to
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decreased BEE. The Arg allele in the beta-3 adrenergic receptor gene (beta-3-AR) is a
marker for obesity-related traits, and mutations in this gene make an individual
susceptible to decreased BEE.76 In a group of women showing beta-3-AR Trp64Arg
abnormalities, and consequently decreased basal energy expenditures, an average early
morning dose of caffeine (4 mg/kg body weight/day) produced significant increase in
energy expenditures, measured through indirect open-circuit calorimetric studies at four
intervals during the day, after controlling for age; physical activity; height; blood
pressure; dietary intakes of fat, proteins, carbohydrates, cholesterol, fiber; BMI; and
lifestyle factors.76 This study showed that caffeine, independent of genetic predispositions
to gain weight, increased resting energy expenditure leading to significant weight loss.
However, the study was limited because it included a convenient sample of healthy
young women with an average age of 21±1 years, and men and subjects from other age
groups are not included.76
Jones et al.77 showed that increased fat mass was associated with lower rates of
disease progression, and fat loss produced faster progression to CD4 counts less than 200
cells/μl.77 The HIV Epidemiology Research (HER) Initiative enrolled 871 HIV positive
women for an observational study of three years. Cross sectional analysis, survival
analysis and longitudinal analysis were done on the data obtained from this cohort. All
five study outcomes, (which included CD4 cell count and viral load; time to ﬁrst
occurrence of CD4 cell count ≤200 cells/mm3; ﬁrst occurrence of CD4 cell count ≤100
cells/mm3; ﬁrst occurrence of other Infection/malignancy; and HIV-related death), were
significantly delayed in women who were in the obese group (BMI≥35 kg/m2) after
controlling for ART status, BMI changes, baseline CD4 cell counts, attrition due to death
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and progression to AIDS, age and lifestyle factors.77 This study established the need to
prevent weight loss; especially loss of fat mass in HIV positive patients.
Deficiencies of several essential micronutrients in HIV-infection have been
reported to accentuate disease progression and mortality risks.78 Several altered metabolic
pathways are responsible for such nutrient depletions in these patients. One such pathway
is chronic anti-oxidant depletion, including a drastic depletion of cysteine from the
glutathione pool, and a progressive decline in serum selenium levels.79 There is
significant correlation between caffeine intake and depletion of antioxidants, although
this relationship is controversial, with some studies reporting an anti-oxidant effect80
while others reporting a pro-oxidant effect for caffeine itself.81 In a laboratory study done
with chemical equivalents of naturally produced biological oxidative species, it was
observed through Electron Spin Resonance (ESR) trapping that caffeine, in
concentrations of 1 mmols/L, acted as an antioxidant with efficient free radical
scavenging rates of 5.9 x 109 M-1 sec-1, which is comparable to the scores of other
naturally occurring antioxidants such as vitamin C, vitamin E, Selenium, and Zinc.80
However this study is a measure of reductive behavior of the chemical named 1,3,7trimethylxanthine (caffeine) and may or may not correlate with the biological effects of
caffeine.80 Such disclaimers about the antioxidant capacities of caffeine and other
xanthine alkaloids in living animals and humans, in spite of laboratory evidences for
antioxidant effects, was also reported in recent study done by Tsoi et al.,82 where he
recommends better technologies such as Oxygen Radical Absorbance Capacity (ORAC)
and Cellular Antioxidant Activity Assay (CAAA), for comparing biological versus
laboratory antioxidant capacities of caffeine and other xanthine compounds. Caffeine
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consumption in higher than normal doses (>250 mg/day) has also been reported to lower
the plasma levels of antioxidant trace elements such as zinc and selenium after
controlling for dietary intakes, age, physical activity, smoking, alcohol use and drug
use.26 This relationship also shows a dose-response, with lower caffeine consumption
associated with decreased depletion of antioxidant elements.26 Thus, the net effect of
caffeine on total antioxidant status has not been elucidated, and remains questionable.
In summary, we see that caffeine can accentuate weight loss which may be useful
for diabetic patients as shown in several studies, but extremely detrimental to PLWH. It
also produces nutritional changes such as lower serum selenium levels and decreased
plasma zinc levels. However, the effects on total antioxidant capacity in PLWH are
controversial and need further research.
Caffeine Intake and its Effects on Fluid-Electrolyte Balance and Blood Pressure
Caffeine and other methyl -xanthene compounds have significant diuretic
properties. Consumers are often cautioned to avoid these beverages when their fluidelectrolyte balance is jeopardized due to various medical conditions. Acute ingestion of
caffeine in doses of 250-300 mg (equivalent to 2-3 cups of coffee or 5-8 cups of tea) is
associated with short-term stimulation of urine output. But these effects are observed
only in subjects deprived of caffeine for few days before the study. There is profound
tolerance to these effects in regular and frequent coffee drinkers. As such there is no
concrete relationship between caffeine intake in regular doses (≤ 250 mg/d) and fluid
losses in excess of the volume ingested under normal physiological conditions.83 But this
is not the same for stressful or non-physiological states. Recreation enthusiasts and
athletes are often advised to decrease the consumption of coffee or caffeine containing
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carbonated drinks to avoid dehydration, electrolyte imbalance, and potential
complications.84 A number of contrary evidences also exist. One study supports that
caffeine intake is associated with only 0.03% higher diuretic capacity than plain water
itself and hence it is advisable to administer caffeinated beverages to athletes.85 Thus
there is no general consensus as to whether caffeine produces or does not produce
dehydration and electrolyte imbalance. Furthermore tolerance to caffeine reduces the
likelihood of any serious fluid electrolyte imbalance.84 Abstaining from caffeine has a
protective effect on hypertension. Caffeine, even in moderate doses (250 mg/day)
produces small elevation in blood pressure (8-10 mm hg). Many other substances present
in brewed coffee like poly-phenols and soluble fibers may reverse the adverse effects of
pure caffeine.86 Coffee and caffeine containing beverages produce similar increases in
Muscle Sympathetic Activity (MSA) Scores and blood-pressure in non-habitual coffee
drinkers; but in habitual coffee drinkers there is no comparable increase in blood pressure
even when there is MSA activation.84 This could be attributed to the homeostatic
mechanisms of the cardio-vascular system. This can also be attributed to ingredients
other than caffeine, such as poly-phenols and chlorogenic acids and hunic acid, but the
mechanism still remains unclear.84 In a study done amongst hypertensive patients, it was
observed that caffeine through ‘acute presser response’ significantly increased both
systolic and diastolic blood pressure levels.87 This study concludes with a word of caution
for hypertensive patients to restrict their caffeine consumption. It also states that the
hemodynamic effects of chronic caffeine consumption should be studied through
prospective longitudinal studies. This report also proposes the inhibition of
phosphodiesterases as the probable mechanism for these responses.87 Thus, we see that
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caffeine definitely has some role in altering the fluid-electrolyte balance and systemic
blood pressure tracings, though not clinically significant to produce visible adverse
effects. Partly, this phenomenon is due to the increased tolerance of the body to the
diuretic effects of caffeine. Some other constituents of coffee, other than caffeine, can
also be suspected, but the mechanism remains unclear. But it is definite that caffeine can
have adverse effects in HIV infected patients, because of their already jeopardized fluidelectrolyte balance, which is secondary to nutritional inadequacies and intermittent
diarrheal episodes.
Caffeine is Associated with Smoking, Alcohol Consumption and Drug Abuse
A British study consisting of 376 young adults suggested that estimated daily
caffeine consumption increased with age, and was associated with increased smoking and
greater alcohol consumption.88 This study, however, does not show any correlation
between caffeine consumption and drug abuse.88 Other studies have also shown that
caffeine intake is higher in smokers than in nonsmokers. A secondary analysis of data
from adults who participated in the Second National Health and Nutrition Examination
Survey showed that subjects who ingested caffeine from tea had lower alcohol
consumption.89 In comparison to this, the subjects who ingested caffeine from coffee and
caffeinated beverages were more likely to be heavy alcohol consumers and chain
smokers.89 There was also a positive correlation between income and caffeine intake;
caffeine intake and alcohol consumption, and caffeine intake and smoking.89 Smokers
were much more likely to drink caffeinated coffee, and a significant dose-response
relationship between caffeine intake and smoking was observed.89 These studies also
show a definite linear relationship between caffeine intake and alcohol consumption.89
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The relationship between caffeinated beverages, alcohol consumption and smoking, was
also researched in a group of chronic alcoholics from Israel. There was a significant
linear relationship between caffeine intake and alcohol consumption & smoking.90 In
addition, the subgroup of subjects with a family history of alcoholism revealed significant
correlations between alcohol and caffeine consumption, between alcohol intake and
smoking, as well as caffeine use and smoking.90 The subjects without a family history of
alcoholism also showed similar linear relationships between alcohol and caffeine use, but
no relationship between caffeine intake and smoking.90 A review article on the
relationships between caffeine, alcohol and drugs of abuse concluded that many studies
show positive correlations between caffeine consumption, alcohol intake and drugs of
abuse such as cocaine, amphetamines and marijuana.91 In a Sardinian study, conducted
amongst patients with bipolar disorders, it was observed that smoking, alcohol
consumption and illicit drug abuse synergistically increased the levels of stress in
subjects consuming high amounts of caffeine, and the collective effects of these factors
increased suicidal tendencies.92 A study assessing the combined biological influence of
coffee, smoking, and alcohol showed that caffeine consumption from coffee showed
inverse correlations with biological markers of heavy drinking, after controlling for
baseline alcohol consumption levels, the number of cigarettes smoked per day, as well as
number of years of smoking.93 This study shows that in addition to adverse health effects,
these addictive substances also show associations with nutritional deficiencies such as
vitamin B12 depletion and anemic states.93 Alcohol intake can be indirectly measured
through a number of markers. γ-Glutamyltransferase is one such widely used marker.
Coffee intake was significantly (P< 0.01) and negatively related to γ-Glutamyltransferase
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activity. This study contradicts other studies presented earlier in this section, and shows
that caffeine consumption reduces alcohol intake.94 Caffeine also influences the actions
of other dependence producing drugs such cocaine and amphetamines.95 An animal study
conducted in rats showed that there are significant interactions between caffeine and
cocaine on many behavioral paradigms related to drug abuse.95 Caffeine was responsible
for reinstating cocaine consumption behavior in rats that were forced to abstain from
cocaine after initial priming. In this study, rats were administered either normal saline,
cocaine in different doses (5.0, 10.0, or 20.0 mg/kg) through foods and caffeine in
different doses (5.0, 10.0, 20.0, 40.0 mg/kg) through injections. There was a dosedependent increase in cocaine consumption behaviors with increasing doses of injected
caffeine.95 This study confirms that caffeine can modulate the drug seeking tendencies
and provoke drug reinstating response to dopaminergic drugs such as cocaine and
amphetamines.95 Caffeine affects the dopaminergic reward circuitry, and hence, it is
responsible for altering the addictive potentials of many dopaminergic drugs.95 In another
study conducted on cocaine addicted individuals, it was found that caffeine consumption
was significantly higher in cocaine dependent individuals when compared to matched
controls.96 The same study also found that habitual caffeine consumption was associated
with lower cocaine use within the cocaine dependent group, and that caffeine deprivation
tends to increase the abuse of cocaine in these individuals.96 In summary, we can say that
caffeine intake shows significant associations with alcohol, tobacco and drug use levels,
patterns and behaviors. There could be many behavioral, physiological and genetic
mechanisms responsible for these observations. Through these mechanisms, caffeine
consumption can have a number of adverse effects in these HIV-infected subjects, among
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whom drug use, alcohol and smoking are frequent. Drug abuse, along with alcohol
consumption and smoking, can quickly and synergistically deteriorate their health status
and contribute to HIV disease progression. Because of these interactions, we have
decided to control for tobacco, drug and alcohol use in all our analysis related to the
adverse effects of caffeine on several health related parameters.
Caffeine and its Metabolites and Their Collective Role in Metabolic Alterations
Cardiovascular diseases and diabetes are a major health problem in HIV infected
patients. A large number of these diseases can be traced back to their roots in metabolic
syndrome. A longitudinal study done by Balk et al.,97 examined the relationship between
caffeine consumption and the components of the metabolic syndrome. This study used
the data from “Amsterdam Growth and Health Longitudinal Study (AGAHLS)” for
analyzing these associations. All the earlier studies on the benefits of caffeine in
metabolic syndrome are challenged by this study, as the study shows no significant
improvements in any of the parameters used to assess the severity of metabolic
syndrome.97 This study questions the very benefits of caffeine in metabolic syndrome,
and rather discusses the adverse effects. All the analyses were adjusted for other
confounding variables such as physical activity, energy intake, alcohol consumption,
smoking behavior etc., thus, eliminating many confounders clouding the validity of these
observations.97 Coffee is a complex mixture of cholrogenic acid, cafestol, kahweol,
diterpines and caffeine. 98 These other components significantly alter the serum levels of
both healthy and non-healthy lipids. These components are implicated in increasing
several risk factors associated with cardiovascular health such as blood pressure and
plasma homocysteine levels.98 High consumption of unfiltered coffee such as French
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press and boiled house brew have been reported to increase the levels of LDL and VLDL
fractions of serum lipid profile.99 People with hypertensive disorders, children,
adolescents, and the elderly are at the highest risks for these adverse effects. There is
compelling evidence to decrease caffeine consumption in pregnant women and women of
reproductive age groups. Caffeine is also associated with several cases of spontaneous
abortions, sudden fetal death syndromes and impaired fetal growth.100 A recent study has
established the existence of genetic polymorphisms in the process of metabolism and
actions of caffeine.101 Thus, caffeine may be beneficial to certain sets of genetically
privileged individuals. But in individuals with genetic weakness, caffeine could
exacerbate the adverse effects. Diterpines present in caffeine have been strongly
associated with adverse cardiac events.102 Caffeine is also associated with increased
levels of fibrinogen and C-reactive proteins, both individually potent and significant risk
factors for a number complications such as stroke, myocardial infarction, diabetes, renal
disorders, and thrombo-embolic sequels.103 Habitual caffeine consumption is also
associated with accelerating the adverse effects of mental stress on vascular inflammatory
response as evidenced by a dietary study done amongst eighty-five healthy non-smoking
men with various levels of caffeine consumption.104 This study found that caffeine was
positively associated with baseline systolic blood pressure, increased heart rate and
increased inflammatory markers such as C-reactive protein (CRP) and Von Willebrand
factor antigen (vWF), after controlling for age, body mass index and consumption of tea,
red wine, fruit, vegetables, oily fish and dietary supplements.104 These adverse effects
could be more pronounced in HIV positive subjects who experience dyslipidemias due to
ART medications. Such adverse effects could also affect their general health status.
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Inference
In summary, evidence to date indicates that caffeine intake is associated with
depletion of circulating CD4 cells. It is also associated with weight loss and wasting. It is
implicated for altered sleep patterns , decreased intervals of sleep, decreased sleep quality
scores, decreased perceptional wellbeing scores, increased neuronal excitability and
increased plasma levels of inflammatory markers such as interleukein-6, C-reactive
proteins and tumor necrosis factor-α . All these factors can have a bearing in hastening
disease progression in HIV infected patients. Moderate caffeine intake produces small
elevations in blood pressure. Caffeine also produces minor non-significant electrolyte
imbalances in healthy subjects. This, however, can have accentuated effects in HIV
infected patients, because of their already jeopardized fluid-electrolyte balance secondary
to nutritional inadequacies and intermittent diarrheal episodes. Caffeine intake is
associated with increased smoking, greater alcohol consumption and increased
recreational drug abuse. Drugs along with alcohol consumption and smoking can
synergistically deteriorate the health status of HIV-positive patients. Chronic caffeine
consumption may have irreversible effects on palatability and food consumption. There
exists strong evidences for caffeine producing significant weight loss. There is significant
correlation between caffeine intake and depletion of antioxidants. It reduces the plasma
levels of anti-oxidant trace elements like selenium and zinc. Such weight changes, loss of
appetite and antioxidant depletion can have adverse effects on the health status of these
HIV infected patients. Caffeine produces many metabolic alterations like increased levels
of LDL and VLDL fractions of serum lipid profile, increased plasma homocysteine
levels, increased fibrinogen and C-reactive protein, all signifying increased stressful
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states and chronic inflammation. These markers of chronic inflammation are already
aggravated in HIV infected patients due to the disease as well as the medications.
Caffeine can accentuate these adverse effects. It is associated with altered dopaminergic
neurotransmission and consequent heightened neuronal excitability and potential loss of
brain cells due to neuronal burnouts. Caffeine also precipitates fluid and electrolyte
imbalances. Our proposed study aims at elucidating the net combined effects of these
adverse reactions of caffeine consumption on HIV disease progression in PLWH.
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CHAPTER III: METHODOLOGY
Preliminary Study
A preliminary study was conducted to understand the relationship between
caffeine consumption and CD4 cell counts and viral loads in 231 HIV positive
participants.1 This study was a secondary analysis of data collected by the parent study
“Zinc-supplementation and HIV disease progression in HIV infected adults in Miami”
also known as the Zinc study.1,2 For this study, HIV positive adults were recruited
between March, 2002 and December, 2005 from several outreach sites in Miami-Dade
County. The procedures included an informed consent, medical history, physical
examination, blood collection for various disease related parameters; several standardized
and validated questionnaires and standardized 24-hr dietary recalls using NUTRIBASE-7
diet-analysis program. Participants were eligible, if HIV infection was documented, had
low plasma zinc levels (<0.75 μg/ml), were ≥18 years, and did not have history of
endocrine or psychiatric disorders; women were excluded if pregnant or had intention to
become pregnant. Participants with plasma zinc levels ≤0.35 μg/ml at any time during the
study were excluded for scientific and ethical reasons. HIV-viral load, complete blood
counts and chemistries were monitored at baseline and every 6 months and any abnormal
value communicated to the primary care physician. The study protocol was approved by
the Florida International University (FIU) Internal Review Board.

For this analysis only

the baseline measures were used for 231 HIV+ adults. About 78% were AfricanAmerican, 62% received ART and 73.2% were men. The mean age was 42.7±7.0 years.
The mean caffeine intake was 115 mg/day and about 10% recorded zero mg caffeine
intakes in the past month. There was a positive correlation between caffeine intake and
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viral load (r=0.3, p<0.008) in patients who were not on ART (N=87), but no relationship
was found in those on ART (N=144). This association also showed a dose response
relationship which strengthened after controlling for several associated variables like age,
drug use, smoking and alcohol consumption (β=739, p=0.004). This study served as a
preliminary data to calculate sample size and for the current observational study on the
effects of caffeine consumption on potential risk factors for HIV disease progression.
Figure 1: Regression Analysis Scatter Plot with Line of Fit for Caffeine Intake and HIV
Viral Load

Table 1: Caffeine Intake and Viral Load using Mixed Models
Variable
Coefficients
β=739
P=0.004
Viral Load*
*Controlled for age, drug use, smoking and alcohol consumption
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Overview of the Current Study
The current study was a prospective observational study (follow-up study) of data
collected over a period of three months. It also included secondary analysis of relevant
variables collected from the Miami Adult Studies on HIV (MASH) cohort which
included a total of 803 HIV positive and 78 uninfected participants followed from 2002
to 2014, for two NIH sponsored grant studies, co-infection study and alcohol study,
described elsewhere in this chapter. It included a baseline visit and a follow-up visit at
three months. This study collected data from February to June of 2014. One hundred and
thirty HIV+ adults (sample size calculations given in page 28) were recruited from the
participants who were already enrolled in the MASH cohort. This study was approved by
the Florida International University Institutional Review Board. The initial screening
included detailed explanation of the current study as well as obtaining informed voluntary
written consent for participation. To obtain a study sample of 130 patients (65 consuming
≤ 250 mg/day and 65 consuming > 250 mg/day of caffeine) a total of 150 patients were
screened. Outreach personnel from the parent grants collaborated in scheduling of
appointments and establishing contacts with the participants. All data collected during the
baseline and 3-month visits were used for data analysis and inferences.
Parent Studies
At the time of recruitment from MASH, there were two active NIH sponsored
studies for which we had already screened more than 800 HIV positive participants.
These two studies were ‘HIV and HIV/HCV co-infection, Disease Progression, Oxidative
Stress and Antioxidants’ also known as Co-infection study and ‘Alcohol &
Antiretrovirals in HIV infection, Oxidative Stress and Liver Disease’ also known as
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Alcohol study. Co-infection study looked for the adverse effects of HCV co-infection on
oxidative stress and plasma levels of antioxidant micronutrients as well as the net effects
of these variables on HIV disease progression. The “Alcohol study” similarly examined
the effects of alcohol consumption on oxidative stress, mitochondrial DNA damage and
hepatocellular injury as well as the combined effects on HIV disease progression. The
majority of the participants in both the studies were receiving antiretroviral therapy
(ART). They were interviewed every three months at Borinquen Health Center, and at the
semiannual and annual visits blood and urine were collected for laboratory values. Both
the studies had stringent eligibility criteria, meticulous recruitment and retention
protocols and safety and confidentiality procedures.
Inclusion Criteria for Co-Infection Study
1)

HIV/HCV co-infected or HIV mono-infected participants with HBV infection
ruled out and documented in the medical chart. HIV mono-infected participants
will have qualitative HCV-RNA analysis by PCR to rule out HCV infection also
documented in the medical chart

2)

Identified from the Borinquen Healthcare Center

3)

HIV/HCV co-infected patients determined with biopsy or another accepted noninvasive method of staging to be either F0-F5 fibrosis grading or its equivalence

4)

Age 40-60 years

5)

BMI >18, but < 40 kg/m2

6)

Compliant, as determined by regular visits to the clinic and adherence to
treatment

7)

Free of significant active psychiatric conditions
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8)

Free of co-morbid diseases (uncontrolled diabetes, symptomatic cardiovascular
disease)

9)

Willingness to provide consent for a second biopsy if clinically indicated

10)

Signature on a consent form

11)

Willingness to participate in a study for 4 years (monthly contact with the clinic
for follow-up, assessment visits at baseline and every 3 months thereafter for 48
months)

12)

English speaking

Exclusion Criteria for Co-Infection Study
1)

HBV infection

2)

BMI <18, or > 40 kg/m2

3)

Chronic inflammatory diseases

4)

Age<40, or >60 years

5)

Elevated liver enzymes > than grade 2 according to ATCG criteria, in HIV monoinfected participants

6)

Ishak score F6 or end stage liver disease defined by clinical criteria of hepatic
encephalopathy, esophageal varices, ascites, or hepatocellular carcinoma

7)

Receiving HCV treatment

8)

Pregnancy or the intent to become pregnant. Although the proposed study is
observational, CD4 cell count increases in pregnancy, and pregnant women need
to be referred to the obstetrics clinics where they are given micronutrient
supplementation, which may confound the micronutrient and the oxidative stress
findings
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Inclusion Criteria for Alcohol Study
1)

HIV status documented in the medical chart

2)

HIV-positive adults identified from the Borinquen clinics where the participants
are followed medically and we will have access to their medical charts with
written permission of the participant

3)

ART naïve or treatment experienced

4)

For Groups 1 and 2, CD4 cell count <350, initiating ART and achieving
undetectable HIV viral load within 6 months, just prior to baseline. The ART will
be a tenofovir based regimen

5)

For Groups 3 and 4 (CD4 cell count > 450, and viral load < 50,000), not yet
eligible for ART

6)

For Group 5 (85 HIV-negative participants) participants will have a documented
seronegative test in the last year

7)

Willing to respond to questionnaires on alcohol use pattern, frequency and type of
beverages consumed

8)

Age 18 – 60 years old

9)

BMI >18, but < 40 kg/m2 to control for malnutrition or obesity

10)

Compliant, as determined by regular visits to the clinic and adherence to
treatment

11)

Controlled co-morbid diseases (diabetes, symptomatic cardiovascular disease,
hyperlipidemia, and metabolic syndrome). Free of HBV and HCV (as confirmed
by test results)

12)

Free of heavy tobacco smoking (defined as >20 cigarettes/day)
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13)

Signature on a consent form

14)

Willingness to participate in a study for 2 years (monthly contact with the clinic
for follow-up, assessment visits at baseline and every 3 months thereafter)

Exclusion Criteria for Alcohol Study
1)

HBV and HCV infected as confirmed by testing or medical records

2)

BMI <18, or > 40 kg/m2

3)

Chronic inflammatory diseases

4)

Pregnancy or the intent to become pregnant. Although the proposed study is
observational, CD4 cell count increases in pregnancy. Pregnant women will be
referred to the obstetrics clinics

Additional Inclusion Criteria for The Current Study
1)

Enrolled in the MASH cohort

2)

History of ART

3)

Willing to participate in a study that is at least 3 months duration

Additional exclusion criteria for the current study
1)

Any major cardiovascular abnormalities or implanted pacemakers

2)

Any morbid medical conditions such as uncontrolled hypertension, anemia, malabsorption syndromes or AIDS defining opportunistic infections during the course
of the study

Characteristics of the MASH Cohort
For the two NIH grant sponsored studies, co-infection study and alcohol study, a
total of 803 HIV positive and 78 uninfected participants were followed from 2002 to
2014, for a period of twelve years. This constituted the Miami Adult Studies on HIV
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(MASH) cohort and included a specimen repository and database for a number of
clinical, laboratory, socio-demographic, substance abuse and behavioral data collected at
regular intervals during the studies. The mean age of the cohort was 45.13 ± 7.9 years. Of
these participants, 74.73% were African American, 6.8% were non-Hispanic White,
19.92% were Hispanic, and 1.55% belonged to other races. Males constituted 68.95% of
all participants. The mean family income for the entire cohort was 439 ± 638.4 $ per
month. The average time from diagnosis of HIV was 12.2 ± 8.7 years. About 33.62%
reported adequate control over disease progression represented by undetectable HIV viral
loads, while 23.4% reported inadequate control over disease progression represented by
CD4 counts less than 200 cells per microliter. About 54.41% of the cohort reported some
form of recreational drug use. The mean CD4 cell count for the entire cohort was 470.81
± 444.81 cells per microliter. The mean log 10 HIV viral load was 3.23 ± 1.33 copies of
HIV viral RNA.
Human Subjects and Institutional Review Board (IRB)
This study was approved by the Institutional Review Board at Florida
International University. According to the eligibility criteria of the parent studies, all the
participants recruited for the current study were under standard medical care prior to the
recruitment, as well as during the entire period of the study. All the data collected were
entered into a de-identified database where visits were linked only by a coded ID. All the
software used for data storage and retrieval procedures were password protected to ensure
safety and confidentiality.
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Recruitment of Study Subjects
All the study participants were recruited from the MASH cohort followed at the
FIU-Borinquen Research Clinic. Participants were a consecutive convenience sample of
130 people (65 consuming ≤ 250 mg/day and 65 consuming > 250 mg/day of caffeine)
living with HIV (PLWH). We recruited participants from both genders and major racial
and ethnic characteristics. To ensure compliance with the current study, the participants
were provided incentives such as reimbursement for their time and effort, nutritional
education and counseling.
Initial Screening and Enrollment
During the screening, participants were explained the details of the study and the
eligibility criteria; if they were eligible and willing to participate, they were enrolled in
the study. The participants were also assured confidentiality of the data obtained from
them, as well as voluntary withdrawal from the study without any penalization. The
consent forms are currently maintained at FIU in a locked cabinet only accessible to
investigators for audit purposes.
Pilot Testing of the Questionnaires, Logistics and Instruments
Though all the questionnaires and instruments used in the current study were
already validated in original studies and publications, we additionally pilot tested all
questionnaires and instruments in a subset of 15 participants to assess the understanding
of the questions by the participants. We evaluated the wording, understandability and
schematic and grammatical layout of the administered questionnaires, and develop an
efficient clinic logistic to administer them. No changes to the questionnaires and logistics
were made throughout the duration of the study.
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Baseline and 3-month Visits
All eligible participants were screened and enrolled into the study and the baseline
visits were scheduled at their earliest convenience, including the dates when the
participants were screened for the current study. The baseline visits included the Caffeine
Consumption Questionnaire (CCQ), Pittsburg Insomnia Rating Scale (PIRS)
questionnaire, Pittsburg Sleep Quality Index (PSQI) questionnaire and Generalized
Anxiety Disorder-7(GAD-7) questionnaire. Participants were interviewed at the threemonth visits with the same set of questionnaires and assessments. At the end of the study
we followed all the study termination procedures enlisted in the Good Clinical Practice
protocol. We also ensured that the data collected did not include any personal identifiers
and were transported safely to a secure storage location within the premises of Florida
International University ensuring their confidentiality.
Compliance
Compliance with the assigned schedule of visits and eligibility requirements was
closely monitored. A variety of factors such as non-compliance to ART medications,
inappropriate nutritional practices, self-supplementations, self-medications and types and
frequency of substance abuse were assessed every three months in the MASH cohort. We
tried to overcome potential barriers to compliance through meticulous efforts such as
calling and reminding the participants a month and a week before the scheduled visit,
reimbursing costs for their time spent with us, reducing wait time through organized
appointments, and provisions for free parking through collaborations with the
administration at Borinquen Health Care Center. We also tried to achieve higher
compliance by assuring that the participants were interviewed by the same staff on every
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successive visit, and by trying to contact the participants for rescheduling on the same
day, third day, a week, a month and two months after no show for the scheduled visits.
During the visits, we established rapport before asking uncomfortable questions such as
the reasons for their missing appointments, failure to follow study requirements, as well
as other factors affecting compliance, so as to understand and take necessary steps to
maximize compliance for the study. For those participants who did not show up for the 3month visit, we also searched the incarceration records and vital statistics. In-spite of
these efforts to ensure compliance with follow-up visits, when we had missing values, we
imputed them during the analysis of data.
Safety Monitoring
The majority of the safety-monitoring procedures were already in place in the
MASH cohort when we collected data for the current study. Viral loads and CD4 counts
were scrupulously monitored for signs of disease progression beyond healthy levels.
Though there were no adverse events recorded during the current study, as this was not
an intervention study, all protocols were in place for prompt intervention and resolution
of adverse events. In case of adverse events severe enough to warrant prompt medical
attention, we also had provisions for referrals to the nearby hospitals and emergency
services. The MASH cohort was already monitored for signs of medical illness or
nutritional deficiencies during follow-up visits of the parent studies.
Outcomes and Assessments
The primary outcomes of the study were changes in the markers of HIV disease
progression which included changes in CD4 counts and viral loads. The outcomes
collected during the current study included variables gathered from Caffeine
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Consumption Questionnaire (CCQ), Pittsburg Insomnia Rating Scale (PIRS)
questionnaire, Pittsburg Sleep Quality Index (PSQI) questionnaire and Generalized
Anxiety Disorder-7(GAD-7) questionnaire. Several variables such as age, gender,
race/ethnicity, education, income, smoking, alcohol consumption, drug use, ART
medications, CD4 counts, plasma viral load, 24-hour dietary intakes, body mass index
(BMI), lean body mass (LBM), total fat mass, hemoglobin, hematocrit, serum albumin
levels, and food security questionnaire (FSQ) scores were collected as part of the MASH
cohort requirements and were used for secondary analysis in the current study. The
following table provides a brief description of variables collected during the study as well
as variables transcribed from the MASH cohort.
Table 2: Outcomes and Assessments Collected During the Current Study
Assessments
Caffeine Consumption Questionnaire (CCQ)

Visits
Baseline 3-month



Pittsburg Insomnia Rating Scale (PIRS) questionnaire





Pittsburg Sleep Quality Index (PSQI) questionnaire





Generalized Anxiety Disorder-7(GAD-7) questionnaire





Caffeine Consumption Questionnaire (Appendix-1): We used the Modified Caffeine
Consumption Questionnaire (MCCQ) developed by Preston et al in the year 1998.3 This
questionnaire is easy to understand, compact, organized and reported adequate
compliance, validity and reliability.3 This questionnaire was field tested and validated in
many large scale studies and adequately reflected average daily caffeine consumption
levels.4 It includes a total of 21 sources of caffeine classified in to three groups,
‘beverages’, ‘over the counter medications’ and ‘prescription medications’. This
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questionnaire also included ‘total caffeine consumption per day’ by adding these
individual sources. Caffeine consumption was analyzed both as a continuous variable and
a categorical variable. Caffeine categories included low (≤250 mg/day) and high (>250
mg/day) based on previous studies5 and recommendations by regulatory bodies like
World Health Organization (WHO) 6,7, International Classification of Diseases (ICD)
manual13 and The Diagnostic and Statistical Manual of Mental Disorders (DSM-V).8
The Pittsburg Insomnia Rating Scale (PIRS): The PIRS (Appendix-1) is a 66-item
self-report questionnaire that measures the subjective levels of insomnia experienced over
the past seven days.9 This questionnaire consists of four components: Distress Score;
Sleep Parameter Score; Quality of Life Sore; and Total Insomnia Score. The ‘Distress
Score’ equals the total of first 46 questions each rated on a 0-3 scale and higher scores
indicate increased levels of subjective distress symptoms experienced by the participants.
Similarly, the ‘Sleep Parameter Score’ totals questions 47 to 56 each rated on a 0-3 scale
and higher scores signify poor sleep quality. The ‘Quality of Life Score’ adds questions
57 to 65 and higher scores signify poor quality of life. The ‘The Global PIRS Score’
sums all the 65 questions and higher scores represent increased subjective reports of
insomnia. The original study of the questionnaire also recommends scores 0-50 as ‘No
Insomnia’, scores 51-100 as ‘Moderate Insomnia’ and scores greater than 100 as ‘Severe
Insomnia’.9 The questionnaire also contains an ‘Overall Sleep Quality’ estimator with
scores from 0% to 100%, and serves as a simplified summary of overall sleep. In
opposition to the other components and the global score, increasing scores in ‘Overall
Sleep Quality’ signify lower levels of insomnia. The PIRS questionnaire showed
excellent internal consistency, test-retest reliability and discriminative validity in a mixed
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sample of 456 normal adult participants between 18 and 85 years in the original study.
The original study also reported a Cronbach's alpha coefficient of 0.88 indicating high
internal consistency and an intra-class correlation of 0.89 indicating good test-retest
reliability.9 The original study also reported a sensitivity of 83.4% and a specificity of
88.6% for the questionnaire.9 In the present study the global PIRS scores were analyzed
as both continuous and categorical variables. The global PIRS score categories included:
≤50 (No Insomnia), 51-100 (Moderate Insomnia), and >100(Severe Insomnia) as
recommended in the original study.9
The Pittsburg Sleep Quality Index Questionnaire (PSQI):The PSQI (Appendix-1) is a
19-item self-report questionnaire that measures self-reported quality of sleep over the
past 30 days.10 This questionnaire includes seven individual components: Sleep Duration;
Sleep Disturbance; Sleep Latency; Days Dysfunction due to Sleepiness; Sleep Efficiency;
Overall Sleep Quality; and Need Meds to Sleep. Each component is rated on a 0–3 scale
with higher scores signifying worsening outcomes. ‘Sleep Duration’ is calculated using
question 4 and represents the total number hours slept per day. ‘Sleep Disturbance’ is
calculated by summarizing individual scores in questions 5b to 5j and represents various
factors like bad dreams, pain, breathing problems etc. that have impaired the quality of
sleep. ‘Sleep Latency’ represents the total time spent awake on bed trying to sleep each
day and is calculated using the questions 2 and 5 with necessary re-coding. ‘Days
Dysfunction due to Sleepiness’ is calculated from questions 8 and 9 and represents daily
problems related to sleep, such as having trouble staying awake or having enough
enthusiasm to get things done. ‘Sleep Efficiency’ is calculated from questions 1 and 3
and represents the ratio of actual number of hours of sleep, given the number of hours
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spent in bed. ‘Overall Sleep Quality’ is calculated from question 6 and represents general
sleep quality over the past month. ‘Need Meds to Sleep’ is calculated from question 7
and represents use of sleep medications over the past month. These seven component
scores are added to obtain a global PSQI score which ranges from 0 to 21 and higher
scores represent worsening sleep quality. According to the original study a global PSQI
score of 5 or greater represents poor sleep quality.10 However other studies recommend
scores 0-5 as good sleep quality, 6-10 as poor sleep quality and greater than 10 as worst
sleep quality.11,12 This questionnaire had good internal consistency, test-retest reliability,
and discriminative validity in the original study with a sample of 168 participants aged 19
to 83 years.10 The original study also reported a Cronbach's alpha coefficient of 0.83
indicating high internal consistency and an intra-class correlation of 0.85 indicating good
test-retest reliability.10,13 The original study also reported a sensitivity of 89.6% and a
specificity of 86.5% for the questionnaire.10,13 In the current study the global PSQI scores
were analyzed as both continuous and categorical variables. The global PSQI score
categories included: ≤5 (Good Sleep Quality), 6-10 (Poor Sleep Quality), and >10 (Worst
Sleep Quality).23,24
The Generalized Anxiety Disorder-7 (GAD-7) Questionnaire: The GAD-7
(Appendix-1) is a 7-item self-reported questionnaire for screening and evaluating the
severity of generalized anxiety symptoms over the past two weeks.14 Although primarily
developed for measuring generalized anxiety disorder, studies have also reported good
sensitivity and specificity for many other anxiety and panic disorders.15 There are seven
questions about anxiety symptoms each rated on a 0-3 scale representing the options ‘not
at all’, ‘several days’ , ‘more than half the days’ , and ‘nearly every day’. The total scores
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range from 0 to 21 and higher scores represent greater anxiety levels. GAD-7 had shown
good internal consistency, test-retest reliability, and discriminative validity in the original
study of 2470 participants aged 19 to 95 years.14 The original study of this questionnaire
reported a Cronbach's alpha coefficient of 0.92 indicating very high internal consistency
and an intra-class correlation of 0.83 indicating good test-retest reliability.14 The original
study also reported a sensitivity of 89% and a specificity of 82% for the questionnaire.14
In the current study the GAD-7 scores were analyzed as both continuous and categorical
variables. The GAD-7 score categories included: ≤5 (Minimal Anxiety), 6-10 (Mild
Anxiety), 11-15 (Moderate Anxiety) and >15 (Severe Anxiety) as recommended in the
original study.14
Table 3: Assessments Variables Collected by the MASH Cohort
Assessments
Demographic and Socioeconomic information

Visits
Baseline 3-month

×

24-hour dietary recall





Bio-impedance analysis (BIA)





CD4 cell count





Viral loads





Alcohol, tobacco, and illicit drugs





Food Security Questionnaire (FSQ)





Hemoglobin





Hematocrit





Serum Albumin levels





Demographic and socioeconomic information: The parent studies collected
demographic and socioeconomic information for all participants. Information used for the
present study included age, gender, race/ethnicity, education and income levels. A
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number of health and lifestyle related factors like tobacco use, alcohol consumption, drug
use and types of antiretroviral (ART) medications were also transcribed from the MASH
cohort data.
24-hour dietary recall: All research personnel in the parent studies were trained to
obtain 24-hour dietary recalls which were used to estimate dietary and nutrient
consumption by the participants. During each visit participants were queried about foods
and beverages consumed on the day prior to the visit. All details including cooking
methods, amount consumed, additional ingredients and seasonings and food brands were
recorded to ensure the comprehensiveness of the obtained information. We also used
props like food models and measuring cups to ensure accuracy of the amounts and
volumes recalled as well as providing cues for better recall of consumed foods. We used
Nutribase Professional Software Version 9 (Cybersoft Inc, 2011), into which all the
collected information were entered to obtain estimation of several nutrients consumed by
the participants.
Bio-impedance analysis (BIA): In the parent studies after screening the participants,
height was recorded immediately using a stadiometer, calibrated according to the
instruction manual. Height was recorded to the nearest 0.5 inch after removing shoes,
socks and other footwear. Height was recorded only once to ensure that it was uniform
and there were no minor variations during every successive visit. Weight was measured
every visit to the nearest 0.1 lbs. using a standard weighing machine which was calibrated
and maintained throughout the study and the participants were requested to remove, their
watches, shoes, mobile phones or other heavy materials possessed by them. The data so
obtained along with age were entered into the bio-impedance machine (Biodynamics-
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450)16 to obtain several body composition measures such as, body cell mass, extracellular
mass, lean body mass (LBM), fat mass, body mass index (BMI) and intracellular and
extracellular fluid levels. In addition we also obtained the waist-to-hip ratio using a nonstretchable tape to measure the waist and hip circumference at the narrowest levels of the
waist and widest levels of the hip.
CD4 counts and viral load: The BHCC provides a variety of comprehensive health
services for HIV/AIDS patients which include quarterly check-up visits, laboratory
services, nutritional counseling and emergency services. Based on requests from their
primary health care physicians or their HIV/ STD consultant at BHCC, CD4 counts, viral
loads and other clinical variables are measured every six months for all HIV infected
patients. The parent grant collected and documented these reports after appropriate
medical release forms signed by the participants. The parent grants also paid a
compensation of $15 every six month to motivate participants towards timely submission
of medical records and lab reports which included CD4 counts and viral load. We took
meticulous efforts to ensure that lab reports submitted by the participants were timely and
done within the interval between two six monthly follow-up visits in the parent study.
The CD4 counts and viral loads were analyzed as both continuous and categorical
variables. In analyses where CD4 counts and viral load were used as continuous variables
they were transformed into CD4 square root and log 10 viral load to ensure normal
distribution and better model fit criteria. In analysis where CD4 counts and viral loads
were used as categorical variables both the variables were divided into three groups of
adequate control on disease progression (CD4 count >500 and viral load < 75 copies of
HIV RNA); moderate control over disease progression (CD4 count between 200-499 and
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viral load between 76-9999 copies of HIV RNA); and inadequate control over disease
progression (CD4 count <200 and viral load >10,000 copies of HIV RNA), based on
immunological and viroloigc stratification of HIV disease progression by the World
Health Organization (WHO).17,18
Alcohol, tobacco, and illicit drugs: A trained interviewer administered alcohol, tobacco,
and drug abuse questionnaires. The alcohol use questionnaires include information on
frequency and type of alcohol use over time collected by the Lifetime Alcohol History
(LAH),19 and history of alcohol binging and prolonged heavy exposure utilizing the
validated and standardized Alcohol Use Disorders Identification Test (AUDIT).19
Hemoglobin, hematocrit and serum albumin: Two chemistry panels and complete
blood counts (CBC) from visits that tallied closest to the baseline and 3-month visit of the
current study were transcribed form the laboratory reports of blood samples collected
from the MASH cohort for the two parent studies. We obtained nutritional indicators like
hemoglobin; hematocrit and serum albumin form these lab reports.
Data Collection for the Study
To reduce observer bias, we used standardized procedures with uniform protocols.
All equipment, questionnaires and instruments were calibrated according to the
instructions in user’s manual and the requirements of the MASH cohort. We also assured
that these procedures were done prior to the commencement of the study to reduce wait
time, as well as the time taken to administer the questionnaires and assessments. Each
visit lasted approximately 30 minutes and was primarily devoted towards answering and
filling out the forms and questionnaires. Participant responses were recorded and
maintained in the paper based research charts for each study visit. Every chart included a
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checklist of activities and the questionnaires were arranged according to the specific aims
of the current study. The consent forms were maintained separately to ensure better levels
of confidentiality as well as availability for audit purposes. All the research charts were
quality assured at least twice during the course of the study to avoid missing data and
non-rectifiable errors.
Sample Size Calculation
G-Power is a common software used for power analysis in social and behavioral
research.20 G-Power 3 has incorporated several improvements over previous versions and
is adapted to run on several interfaces like Windows XP, Windows Vista, and Mac OS X
10.4. This software covers many different statistical tests of the t, F and χ2 categories.20
G-Power 3 provides improved effect size calculations and graphic options, supports both
distribution-based and design-based input models. This software comes handy in several
types of power analysis with adjustments according to the study designs and sample size
limitations.20 Hypothesis 1A was used for calculating the sample size for the study. The
input parameters for the sample size calculations included a two tailed t-tests to
determine difference between two independent means or two group means. The effect
size was set at 0.5. Cohen et al.,21 has described three effect sizes: 0.3 for strong
associations, 0.5 for moderate associations, and 0.8 for strong associations. Considering
the associations between caffeine and CD4 cells to be moderate as evident in the
preliminary study, we had decided 0.5 as the effect size. We set the probability of alpha
error at 0.05 and statistical power levels at 0.80 i.e. 80 percentage. We obtained an actual
power of 0.801 for a total sample size of 128 participants for the study. We rounded this
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figure to 130 participants (65 consuming ≤ 250 mg/day and 65 consuming > 250 mg/day
of caffeine) for the study.
Statistical Methods Used in the Study
SPSS-21 for windows was used for analyzing the relationship between caffeine
intake and outcome variables in the study. Standard statistical methods were used to
calculate the rates, describe the demographic characteristics and show basic summary
statistics. Caffeine intake was analyzed as a as a categorical variable by splitting into two
groups of <250 mg (low intake) and >250 mg (high intake) based on the studies that
classify the dosage based adverse effects of caffeine.4-8,22 T-tests and chi-square tests
were used for significant differences between the two caffeine groups with respect to all
the outcome variables in the study. Multinomial logistic regressions were used to
estimate the associations between different levels of caffeine consumption and several
categorical outcome variables. Linear Mixed Models were used for over time changes in
these associations. Caffeine intake was also considered as a continuous variable for
several analyses. Correlation analyses were used to find significant associations between
caffeine intake and several continuous outcome variables. Correlation matrices helped to
understand the existence of these associations. Linear regressions were used to analyze
baseline cross-sectional data and report the strength and predictability of the associations
between caffeine intake and continuous outcome variables. Linear Mixed Models were
used for overtime changes in these associations. The results were considered significant
for p <0.05
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Quality Control
We took several steps to ensure that data collected during the study were accurate
and free from errors. All the procedures were done according to the ‘Good Clinical
Practice’ protocols for quality control. We meticulously strived to ensure that there was
no breach of protocol and we had adequate procedures to resolve them and take effective
measures if we found any such occurrences. The Doctoral Candidate, Dr. Ramamoorthy’s
responsibilities included monitoring every visit along with immediate perusal of all the
data collected in charts as well as data entered into the software programs. He was also
assisted by other staff members in quality assurance procedures. The PI, Dr. Marianna
Baum, PhD, and the committee members were constantly consulted to discuss logistic
issues as well as sufficient supply of binders, folders, forms, questionnaire, copies and
other supplies. The gathered data were regularly monitored through standardized
procedures to ensure validity as well as reliability. All activities done during each week
were discussed in weekly meetings to get feedback on the progress of the project as well
as technical issues. A weekly review of performance, protocol compliance, and
recommendations was done by the major professor, Dr. Adriana Campa, PhD, during the
entire period of data collection and data entry. The security and confidentiality of data
were ascertained through scrupulous and meticulous coding procedures. An elaborate
system of patient identification numbers and study identification numbers were already in
place for the parent study and were used for the current project. The data form charts
were entered into databases by trained personnel with sufficient experience in data entry
and retrieval procedures. All the working steps were intermittently scrutinized to ensure
adequate quality control. The confidentiality and security of the data was further
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strengthened by assigning appropriate password protections and accessibility codes for all
the software used in the current study. All the instruments, logistics as well as the
questionnaires were pilot tested to ensure the continuation of established standards of the
parent study. To the best of our knowledge we took adequate steps to ensure the validity
as well as reliability of the data collected during the current study as well as secondary
analysis variables from the parent studies.
Proposed Benefits of the Study
This prospective study would serve as the basis for further large clinical trials for
understanding the effects of caffeine consumption on disease progression levels. Several
other factors that could not be covered in this study can be progressively determined,
measured and analyzed. These researches can further help in instituting studies on
standardized dietary recommendations on the consumption of coffee and other caffeine
containing beverages in HIV infected patients. This can alleviate the already immunocompromised states in these patients, contribute to immune recuperation and bring
significant changes in their general wellbeing.
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CHAPTER IV: CAFFEINE INTAKE AND ITS ASSOCIATION WITH DISEASE
PROGRESSION IN MIAMI ADULT STUDIES ON HIV (MASH) COHORT – AN
OBSERVATIONAL STUDY
ABSTRACT
Introduction: In the year 2013, Miami-Dade County reported about 26,760 people living
with HIV (PLWH). Though there are many studies on adverse health effects of alcohol,
recreational drugs and tobacco use in this population, similar studies about caffeine
consumption are few. In this study we investigated for the effects of caffeine on
immunological and virologic markers of disease progression.
Methods: A convenience sample of 130 consecutive, clinically stable HIV-positive
participants on ART, (65 consuming ≤ 250 mg/day and 65 consuming > 250 mg/day of
caffeine) were recruited from the Miami Adult Studies on HIV (MASH) cohort. This
prospective study included a baseline and a follow-up visit after 3 months. After
obtaining written consent, the Modified Caffeine Consumption Questionnaire (MCCQ),
CD4 cell count, HIV viral load, demographics, anthropometries, Body Mass Index
(BMI), bio impedance measures, substance abuse and types of ART were obtained. Data
were sequentially entered in secure databases and analyzed using SPSS-21 for windows.
T-tests and chi-square tests were used to describe demographics and health and lifestyle
characteristics of the participants. Linear regressions were used to analyze baseline data
for relationships between caffeine consumption and parameters of HIV disease
progression. Linear Mixed Models were used to understand the effect of caffeine
consumption on these parameters over time.
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Results: The mean age of the cohort was 47.89 ± 6.37 years, 60.8% were male and
75.4% were African-Americans. All participants were on ART during both the visits.
Mean caffeine intake at baseline was 161.26 ± 194.95 mg/day (3-8 cups of coffee)
(Range: 0 mg-1498 mg/day) and did not change significantly at the 3-month follow-up
visit. Linear regression analysis showed significant associations between higher caffeine
consumption and higher CD4 cell count (β=1.532, P=0.049) and lower HIV viral load
(β=-1.067, P=0.048), after adjusting for age, gender, education, income, and time from
diagnosis of HIV, drug use, smoking status, alcohol use and different types of ART
medications. Linear mixed model analysis showed that higher caffeine consumption was
associated with higher CD4 cell count (β=1.720, P=0.042) and lower HIV viral load (β= 1.389, P=0.033), in a dose-response manner, after adjusting for the same covariates.
Conclusion: Higher caffeine consumption was associated with higher CD4 cell counts
and lower HIV viral loads indicating beneficial effects on HIV disease progression.
Future studies examining bio-chemical effects of caffeine on CD4 cell counts and viral
replication are needed to shed light on the mechanisms of these potential beneficial
effects.
Keywords: Caffeine, HIV infection, CD4 cell count, HIVviral load.
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INTRODUCTION
HIV/AIDS is a leading cause of morbidity and mortality worldwide.1 According
to CDC estimates in 2013, about 1.2 million people were living with HIV/AIDS in
United States.2 In Miami-Dade County, there were 26,760 people living with HIV/AIDS
(PLWH), in the same year.3 In the year 2013, it was also estimated that one in 99 MiamiDade resident was living with HIV infection which included one in 36 African American,
one in 123 White, and one in 163 Hispanic.4 HIV/AIDS has also successively been in the
list of ten leading causes of death among African Americans in Florida.5 This
epidemiological evidence shows that Miami-Dade County and the State of Florida suffer
increased burden of the disease compared to the national average.
Antiretroviral therapy (ART) has significantly improved survival rates and
decreased morbidity and mortality in PLWH and constitutes the single most effective
strategy to prevent HIV-1 transmission rates.6 Combination ART has decreased the
numbers of patient entering health-care centers from 75,486 in the year 2000 to 24,780 in
the year 2010.15 The estimated cumulative survival benefits of combination ART therapy
was 2,813,892 years between the years 2000 and 2010.15 Due to recent improvements in
availability and accessibility of combination ART medications, currently, HIV/AIDS
constitutes a chronic disease with decreasing incidence, increasing prevalence and 97%
decrease in progression to AIDS and death as of the year 2014.16
Many factors contribute to faster HIV disease progression, such as homelessness,
illegal commercial sex, drug abuse, alcohol addiction and criminalization of the disease
which contribute to barriers in access to effective ART and compliance with the
medications.17-21 Most of the PLWH live in marginalized neighborhoods with limited
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resources.22 Though the majority of the MASH cohort, from which our participants were
recruited, receive social security benefits and some forms of food assistance, many of
them experience poverty and some experience food insecurity.23 Food insecurity, poverty
and poor living conditions are associated with accelerated disease progression and poor
health outcomes, as reported in other studies.24,25 There is a large body of literature on
associations of alcohol,26 illicit drugs27 and tobacco use28 with a variety of health related
outcomes in this population. However, there are very few studies that relate caffeine
consumption to health related outcomes in HIV infected populations.
In a study done by Raboud et al.,29 CD4 cell counts were significantly lower in
consumers of moderate amounts of caffeine (<250 mg/day) compared to non-consumers
(0 mg/day). Another study done among clinically stable HIV positive individuals showed
that administration of caffeine (<250 mg/day) decreased CD4 cell counts by 54% and
CD8 cell counts by 55% compared to placebo (0 mg/d) .30 In contrast, an in-vitro study
showed that caffeine suppressed replication of infectious HIV-1 strains in cultures of
human peripheral mononuclear cells.31 This study demonstrated greater than 9-fold
reductions in HIV-1 p24 antigen values in samples treated with caffeine or caffeine
metabolites such as theobromine, paraxanthine or theophylline when compared to control
solutions.31 Similar findings were reported in another tissue culture study where caffeine
in concentrations of 10 µgm/liter significantly inhibited retroviral transduction of
dividing Human neuronal precursor (hNT-2) cells, thereby, blocking post integration
repair of HIV-1 viral strains and inhibiting viral replication cycles. 32 These effects have
been hypothesized to be related to a cellular target: the ataxia telangiectasia-mutated
Rad3-related (ATR) kinase.32
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Studies in HIV-seronegative populations have implicated caffeine use in a variety
of health problems. High caffeine intake (>400 mg/day) adversely affected the quality of
sleep and general well-being scores in healthy subjects,33,34 and precipitated anxiety
disorders in apparently healthy volunteers.35 High caffeine intake (480 mg/day),
adversely affected gabaminergic (inhibitory) neurotransmission, exacerbated mental
stress, and produced irreversible psychological derangements in apparently healthy
participants with anxiety disorders controlled through medications.36,37 Caffeine intake
(<250 mg/day) was also associated with nutritional losses such as cysteine-depletion and
decreased plasma levels of anti-oxidant trace elements such as zinc and selenium thereby
increasing susceptibility to oxidative damage of neuronal cells.38,39 Caffeine in doses of
300 mg/day was also associated with irregularities in blood pressure tracings and cardiac
function tests in susceptible populations.40,41
Excessive caffeine intakes were also associated with higher levels of
inflammation. In a cross-sectional survey conducted in 1514 men and 1528 women, men
who consumed more than 200 mg/day of caffeine had 50% higher interleukin 6 (IL-6),
30% higher C-reactive protein (CRP), 28% higher tumor necrosis factor- α (TNF-α) and
3% higher white blood cell (WBC) counts. Similarly women who consumed more than
200 mg/day of caffeine reported 54% higher IL-6, 38% higher CRP, 28% higher TNF-α
and 4% higher WBC counts.42
Caffeine (<250 mg/day) was associated with moderate weight loss in many
groups of healthy volunteers.43,44 This could be detrimental to HIV-infected patients
because higher body weight and fat-mass are associated with higher CD4 cell counts,
lower viral load and better health outcomes in participants receiving ART.45-47
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Since studies have found associations between excessive caffeine consumption
and many adverse effects in non-HIV infected populations, it is possible that some of
these effects may be more pronounced in HIV infected subjects, who are already
compromised in a variety of health related parameters. There are very few studies that
document the associations of caffeine and CD4 cells and HIV viral load. Existing studies
on the effects of caffeine on viral loads are in-vitro studies conducted in tissue cultures,
while the ones investigating CD4 counts have several shortcomings, including small
sample sizes and inadequate control for several variables associated with HIV disease
progression. Furthermore, some studies show adverse associations between caffeine and
immunological markers but potentially beneficial associations with virologic markers.
Therefore, a question remains on whether caffeine is beneficial or detrimental to PLWH.
The specific aim of this study was to investigate the immunological (CD4 cell counts)
and virologic (HIV viral load) measures of disease progression in association with
caffeine consumption in a group of PLWH on stable ART.
METHODS
Study Design and Setting
The present study recruited a convenience sample of 130 participants (65 consuming ≤
250 mg/day and 65 consuming > 250 mg/day of caffeine) from the MASH cohort, which
consisted of 803 HIV positive and 78 uninfected participants, followed for more than 10
years at the FIU research clinic in the Borinquen Health Care Center (BHCC). The
BHCC provides comprehensive range of health and social services to a culturally diverse
low income community. The recruitment for the present study took place from February
to July 2014. The present study included a baseline and 3-month follow-up visits, and
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participants received $5 as partial reimbursement for their time and efforts, for each of
the two visits. The initial screening included detailed explanation of the study as well as
obtaining informed voluntary written consent for participation. In order to obtain a study
sample of 128 participants as estimated in our sample size calculations, we screened a
total of 150 subjects, enrolled 130 participants and excluded 20 ineligible participants.
The present study also included secondary analysis of relevant variables collected for the
MASH cohort studies. Data collected during the baseline and 3-month visits were used
for the analyses of descriptive and inferential statistics. The inclusion and exclusion
criteria for the MASH cohort are presented in “Chapter 3: Methodology” and applicable
to our current study. The additional inclusion criteria for participants in the present study
were: enrollment in the MASH cohort; receiving ART; and willingness to participate in a
study with two visits, a baseline and one follow-up visit at 3 months. The exclusion
criteria were: cardiovascular abnormalities or implanted pacemakers; morbid medical
conditions such as uncontrolled hypertension, anemia, chronic inflammatory diseases or
mal-absorption syndromes. The Institutional Review Board at Florida International
University approved the study protocol and research procedures.
Measures
The questionnaires used in the present study were previously field tested and
validated in several large scale studies.48-51 However, we pre-tested these questionnaires
on 15 participants from the MASH cohort to ascertain their applicability and we
determined that revisions were not necessary for the questionnaires.
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Caffeine consumption questionnaire: We used the Modified Caffeine Consumption
Questionnaire (MCCQ) developed by Preston et al in the year 1998.52 This questionnaire
is easy to understand, compact, organized and reports adequate compliance, validity and
reliability.52 This questionnaire was field tested and validated in several large scale
studies and adequately reflected average daily caffeine consumption levels.48 It includes a
total of 21 sources of caffeine classified in to three groups, ‘Beverages’, ‘Over the
counter medications’ and ‘Prescription medications’. This questionnaire also included
‘Total caffeine consumption per day’ by adding these individual sources. Caffeine
consumption was analyzed both as a continuous variable and a categorical variable.
For both naturally occurring and artificially added caffeine sources, FDA
considers 400 mg/d to be generally safe and not associated with any dangerous side
effects.53,54 The World Health Organization (WHO) defines caffeine overuse as daily
consumption beyond 500 mg/d.55,56 Beyond this level caffeine produces visible adverse
effects collectively known as ‘caffeinism’. The World Health Organization (WHO) has
also cautioned that these adverse effects could be precipitated at much lower doses
depending on the physiological profiles of individuals as well as the genetic makeup of
the population.55,56 The International Classification of Diseases (ICD) manual considers
caffeine consumption above 250 mg/day to be associated with many mental and
behavioral disorders though it is inconclusive whether such effects would be uniformly
applicable in the general population.13 The Diagnostic and Statistical Manual of Mental
Disorders (DSM-5) considers consumption below 250 mg/day to be generally safe and
above this level to be associated with many adverse effects such as withdrawal, addiction,
irritability and craving.57 Summarizing these cutoffs, we concluded that caffeine
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consumption below 250 mg/day that is equivalent to 4 cups of coffee, irrespective of the
sources is generally safe and not associated with adverse effects. In this study, caffeine
categories included low (≤250 mg/day, within safe levels) and high (>250 mg/day,
beyond safe levels) based on these recommendations.
CD4 counts and viral load: The BHCC provides a variety of comprehensive health
services for HIV/AIDS patients which include quarterly check-up visits, laboratory
services, nutritional counseling and emergency services. Based on requests from their
primary health care physicians or their HIV/ STD consultant at BHCC, CD4 counts, viral
loads and other clinical variables are measured every six months for all PLWH. The
MASH cohort studies collected and documented these reports after appropriate medical
release forms were signed by the participants. The CD4 counts and viral loads were
analyzed as both continuous and categorical variables using clinically meaningful cutoff
points. In analyses where CD4 counts and viral load were considered as continuous
variables, they were transformed into CD4 square root and log 10 HIV viral load to ensure
normal distribution and better model fit criteria. In analysis where CD4 counts and HIV
viral loads were considered as categorical variables both variables were divided into three
groups with clinically meaningful cutoff points based on immunological and virologic
stratification of HIV disease progression by the World Health Organization (WHO).58,59
CD4 cell counts were stratified as >500 cells/μL , ≤500 and >200cells/μL , and < 200 μL
.58,59HIV viral load was stratified as undetectable HIV viral load <21; between 21 and
9,999 copies/mL, considered moderately controlled HIV viral load; and >10,000
copies/mL, considered uncontrolled viral load, based on the clinical cutoffs
recommended by the World Health Organization.50,51
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Control Variables
Demographic and socioeconomic information: Demographic and socioeconomic
information used in this study were collected by the MASH studies. Information used for
the current study included age, gender, ethnicity, education and income levels. A number
of health and lifestyle related factors such as tobacco use, alcohol consumption, and illicit
drug use were also gathered from the MASH data repository. All these variables were
adjusted in our analysis based on studies associating these variables with HIV disease
progression.26-28
Bio-impedance analysis (BIA): In the MASH cohort studies, after screening the
participants, height was recorded immediately using a stadiometer, calibrated according
to the instructions in user manual. Height was recorded to the nearest 0.5 inch after
removing shoes, socks and other footwear. Height was recorded only once to ensure that
it was uniform and there were no minor variations during every successive visit. Weight
was measured every visit to the nearest 0.1 lbs. using a standard weighing machine which
was calibrated and maintained throughout the study and the participants were requested
to remove their watches, shoes, mobile phones or other heavy materials. The data so
obtained along with age were entered into the bio-impedance machine (Biodynamics450)60 to obtain body cell mass, extracellular mass, lean body mass (LBM), fat mass,
body mass index (BMI) and intracellular and extracellular fluid levels. In addition we
also obtained the waist-to-hip ratio using a non-stretchable tape to measure the waist and
hip circumference at the narrowest levels of the waist and widest levels of the hip. While
estimating the effects of caffeine on immunological and virologic markers of HIV disease
progression, we adjusted for BMI and fat mass, based on studies associating these
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variables to better immunological and virologic profiles.45,61-63
ART medications: All participants enrolled in the study were on some form of ART.
Information about different types of antiretroviral medications prescribed by their
physicians was obtained during the MASH cohort visits. All analyses were adjusted for
these variables because all antiretroviral medications have profound effects on markers of
HIV disease progression.
Statistical Analysis
Field data were collected in paper based questionnaires and later entered into
RedCap database, imported into SPSS version 21 for Windows (Armonk, NY: IBM
Corp) and merged into a single dataset for analysis. Descriptive statistics were used to
understand the population characteristics and were expressed in terms of means, standard
deviations and percentages. The characteristics of the population were shown for all the
participants and separated based on low and high intakes of caffeine using the cutoff
points: >250 mg/day for high intake; and ≤250 mg/day for low or no intake. T-tests and
chi square tests were used to describe differences in demographics, health and lifestyle
characteristics and CD4 and viral load categories with respect to low and high levels of
caffeine consumption. Paired sample t-tests were used to measure differences in levels of
caffeine consumption between baseline and the follow-up visit for major sources, as well
as total levels of caffeine consumption. Linear regression was used to estimate the
strength of association between caffeine consumption and markers of HIV disease
progression, CD4 counts and viral load. Assumptions of linear regression were followed
prior to analyses. Linear mixed models (LMM) were used to determine over time changes
in the strength of these associations. For parameter estimation in LMM models,
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Restricted Maximum Likelihood (REML) was used. Multinomial logistic regressions
were used to determine the associations between high and low caffeine intake groups
with respect to different levels of disease progression (different categories of CD4 counts
and viral load). For liner and logistic regressions, as well as linear mixed model analysis,
we initially used crude models and subsequently adjusted for associated covariates
already described in Methodology. These covariates were also tested for significant
associations with the outcome variables using bivariate analysis before being
incorporated into the models. To increase the validity of the models, multicollinearity
among covariates was tested prior to the analyses. Adjusted models included non-missing
values for all independent variables included in the models. Statistical significance was
set at P<0.05 for all the analyses.
RESULTS
Demographic and Socio-economic Characteristics
A total of 130 participants were included in the study and 79 (60.8%) were men.
The mean age was 47.89 ±SD 6.37 years. Most of the participants were African
Americans (75.4%), Hispanics constituted 16.9%, Whites constituted 5.4% and other
races constituted 4.6 percent. About 24% of the participants had college education, while
45.4% were high school graduates and 30.8% had some form of primary education. All
participants had incomes under the level of poverty and the mean income was $495.91±
465.887. There were no significant differences in any socio-demographic variables
between low and high levels of caffeine consumption in both baseline and follow-up
visits (Table-1A, 1B).
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Health/lifestyle Characteristics
Sixty one percent of the participants reported smoking within the past six weeks
of their scheduled baseline visits, 57.9% reported alcohol use and 48.2% tested positive
for illicit drug use. Similarly, 63.2% reported smoking, 60.3% reported alcohol use and
65.8% tested positive for illicit drug use during the follow-up visit.
All participants were on ART during both the visits. Antiretroviral therapy took
many forms, 58.5% were on NRTI, 13.1% were on NNRTI and 47.7% were on PI in
several combinations, 26.2% of the participants were using a one-pill multi-drug
combination such as Atripla, Truvada and Combivir during the baseline visit. At the 3month visit, 63.8% were on NRTI, 13.8% were on NNRTI and 47.7% were on PI, and
25.4% were on a one-pill multi-drug combination during the follow-up visit. There were
no significant differences in the distribution of these variables between low and high
levels of caffeine consumption in both baseline and follow-up visits (Tables 2 and 3).
Caffeine Consumption
Total caffeine consumption was 337.63 ± 304.97 mg/day at baseline (Range: 01,498 mg/day), and 281.04 ± 260.85 mg/day (Range: 0-1,175 mg/day) at the 3-months
follow-up. Coffee constituted the largest source of caffeine and mean consumption levels
were 161.26± 194.95 mg/day at baseline, and 190.40 ± 205.03 mg/day at follow-up.
Caffeinated soft drinks constituted the second largest source of caffeine and mean
consumption levels were 63.23 ± 92.98 mg/day at baseline, and 29.66 ± 83.78 mg/day at
follow-up. There were no significant differences between baseline and follow-up visits
with respect to total caffeine consumption or caffeine from most of the sources. However,
there was significant decrease in consumption of caffeinated soft drinks (63.23 ± 92.98
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vs. 29.66 ± 83.78, P<0.00001), energy drinks (46.32 ± 134.42 vs. 9.61 ± 65.32, P=0.005)
and hot cocoa (1.03 ± 5.00 vs. 0.00 ± 0.00, P=0.020) from the baseline to the follow-up
visits (Table-4). For all other sources of caffeine in the questionnaire, except the ones
enlisted in Table 4, participants reported none to negligible levels of consumption at both
the visits.
Caffeine Consumption and Immunological And Virologic Markers of HIV Disease
Progression
Caffeine intake was significantly associated with CD4 cell count (β=1.532,
P=0.049) and log 10 viral load (β= -1.067, P=0.048) after adjusting for age, gender,
race/ethnicity, education, income, and time from diagnosis of HIV, drug use, smoking
status, alcohol use, different types of ART medications, BMI and total fat mass (Table-5).
Linear mixed model analysis for the effect of caffeine intake on changes in parameters of
HIV disease progression between the two study visits, showed higher CD4 cell count
(β=1.720, P=0.042) and lower log 10 HIV viral load (β= -1.389, P=0.033) with increasing
caffeine consumption, in a dose-response manner, after adjusting for the same covariates
(Table-6).
Multinomial logistic regression showed that the odds of having CD4 counts <
200 cells/mm3 were 69% higher in participants who consumed less than 250 mg of
caffeine per day when compared to participants who consumed greater than 250 mg, after
adjusting for the same covariates (OR=1.690, 95% CI: 1.123 -3.879, P=0.047). Similarly
the odds of having CD4 counts 200-499 cells/mm3 were 53% higher in participants who
consumed less than 250 mg of caffeine per day when compared to participants who
consumed greater than 250 mg, after adjusting for the same covariates (OR=1.537, 95%
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CI: 0.522 -5.136, P=0.198). The odds of presenting HIV viral loads greater than 10,000
copies of HIV viral RNA/mm3 were 93% higher in in participants who consumed less
than 250 mg of caffeine per day when compared to participants who consumed greater
than 250 mg after adjusting for covariates (OR=1.933, 95%CI: 1.254 -6.192, P=0.048).
However caffeine consumption did not affect the odds of presenting HIV viral loads 219,999 copies of HIV viral RNA/mm3 (OR=0.964, 95%CI: 0.317 -3.444, P=0.437). To
summarize, the participants who consumed less caffeine had lower CD4 and higher viral
loads. All the significant odds continued overtime and retained significant when
associations over the three month period were considered (Table 7, 8, 9 and 10).
DISCUSSION
The characteristics of our population were epidemiologically similar to those
described by others in Miami-Dade County.64,65 More than half of the participants were
consuming alcohol and smoking cigarettes, and 48.2% used illicit drugs confirmed by
urine toxicology, therefore, we adjusted for these variables in the analyses, to evaluate the
independent effect of caffeine. The apparent beneficial effects of high consumption of
caffeine on HIV disease progression was unexpected, although there is evidence from invitro studies on caffeine decreasing the replication of the HIV virus in tissue cultures.31,32
In our study, only after adjusting for other relevant variables affecting HIV disease
progression, caffeine consumption became significantly associated with both
immunological and virologic markers of disease progression. This suggests a complex
and moderate impact of caffeine on parameters of HIV disease progression. Our findings
need to be confirmed by larger studies, as they could be incidental findings. Furthermore,
there are very few studies that explore the relationship between caffeine and HIV disease
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progression, and there is lack of scientific consensus on this topic, probably due to the
general acceptance of caffeine as a safe consumer product.53
A study conducted by Raboud et al.29 among clinically stable HIV-infected
patients showed significant reductions in CD4 counts among caffeine consumers
compared to non-consumers, after adjusting for age, gender, medications, presence of
opportunistic infections (oral candidiasis) and potential measurement errors. However,
this study had several limitations and differences from our study. The study was
conducted before the advent of combined ART; caffeine consumption was considered a
categorical variable with subjects either reporting or not reporting caffeine consumption;
and the study had a small sample size of 30 participants, which limited its external
validity.29 Because of these shortcomings, this study could have missed the beneficial
effects of caffeine. Furthermore, the findings in our study could be more relevant because
of the larger sample size and adjustments for several covariates that have significant
confounding effects on immunological and virologic parameters.
Bishop et al.,30 conducted a study in clinically stable PLWH to establish the effects
of caffeine consumption and exercise on CD4 and CD8 cell counts. The participants were
asked to abstain from consumption of caffeine for 60 hours prior to the experiment. Half
of the subjects were administered 350 mg/day of caffeine, while the remaining subjects
were administered placebo. There was 54% decrease in circulating CD4 cell counts and
55% decrease in circulating CD8 cell counts post exercise in subjects administered
caffeine compared to the placebo group, after adjusting for factors such as age, gender,
BMI, lean body mass and fluid input and output levels.30 This study also reports that post
exercise plasma catecholamine levels were significantly higher in those administered

110

caffeine when compared to placebo.30 This study hypothesized that caffeine produced
alterations in lymphocyte subset trafficking as well as expression of CD69 molecules
which are important intermediate steps in generating and recruiting inflammatory cells.30
Through this process, caffeine decreased production and recruitment of inflammatory
cells to the targeted areas of inflammation which included decreased circulating CD4 and
CD8 cells.30 It is not clear whether these results were produced by caffeine itself or the
stress hormones such as catecholamines that are associated with exercise and caffeine
consumption.66-69
Our study found mostly beneficial effects of caffeine consumption. The
beneficial findings in our study are supported by two in-vitro studies. The first in-vitro
study showed that caffeine suppressed replication of infectious HIV-1 strains in cultures
of human peripheral mononuclear cells.31 Caffeine in 100 millimolar concentrations
exerted these effects by inhibiting the integration step of the HIV-1 viral replication
cycle. This study also showed that other methyl-xanthines such as theophylline,
theobromine, and paraxanthine, in 100 millimolar doses act through the same processes
to inhibit HIV-1 replication. They observed a 9-fold reduction in HIV-1 p24 antigen
values in samples treated with caffeine, theobromine, paraxanthine or theophylline when
compared to control solutions.31 The second in-vitro study found that caffeine in
concentrations of 10 µgm/liter significantly inhibited retroviral transduction of dividing
human Neuronal Precursor (hNT-2) cells thereby blocking post integration repair of HIV1 viral strains. These effects have been postulated to a cellular target- ‘the ataxia
telangiectasia-mutated and Rad3-related (ATR) kinase’.32 Caffeine inhibits viral DNA
repair at the DNA damage-activated checkpoints, thereby inhibiting viral replication
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cycle.32 Our study observed an inverse association between caffeine consumption and
viral load which might be ascribable to these mechanisms.
Nevertheless, we should also note that tissue culture studies and studies on human
beings are not comparable. Many confounders associated with the lifestyle, dietary and
other confounding factors could have influenced the findings in our study. Our sample
size was also very limited due to the feasibility and constraints of the study settings.
Large scale studies with controlled intake of nutrients and health and lifestyle factors and
adequate sample size should be planned in the future to ascertain the findings in our
study.
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Table 1A: Baseline Demographic Characteristics of PLWH by Caffeine Consumption
Levels
Variables

Age in years
(Mean±SD)
Gender, N (%)
Male
Female
Ethnicity, N (%)
White
Hispanic
Black
Other
Education in
years, N (%)
<12
12
>12
Income in dollars
per month

47.89 ± 6.37

Baseline
Low
High
caffeine
caffeine
intake
intake
(≤250
(>250
mg/d)
mg/d)
47.57±6.81 48.00±6.15

79 (60.8%)
51 (39.2%)

40 (61.5%)
25 (38.5%)

Total

P-value

0.706
0.857

39 (60.0%)
26 (40.0%)
0.057

7 (5.4%)
22 (16.9%)
98 (75.4%)
3 (2.3%)

3 (4.6%)
7 (10.8%)
55 (84.6%)
0 (0.0%)

4 (6.2%)
15 (23.1%)
43 (66.2%)
3 (4.6%)
0.202

40 (30.8%)
59 (45.4%)
31 (23.8%)
495.91 ±
465.887

24 (36.9%)
29 (44.6%)
12 (18.5%)
464.00 ±
419.667

16 (24.6%)
30 (46.2%)
19 (29.2%)
527.34 ±
508.637

0.442

Note: P-values corresponds to χ2 tests for categorical variables and t-test for continuous
variables
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Table 1B: Follow-up Demographic Characteristics of PLWH by Caffeine Consumption
Levels
Variables

Age in years
(Mean±SD)
Gender, N (%)
Male
Female
Ethnicity, N (%)
White
Hispanic
Black
Other
Education in
years, N (%)
<12
12
>12
Income in dollars
per month

47.89 ± 6.37

Follow-up
Low
High
caffeine
caffeine
intake
intake
(≤250
(>250
mg/d)
mg/d)
46.63±7.33 48.87±5.38

79 (60.8%)
51 (39.2%)

43 (68.3%)
20 (31.7%)

36 (53.7%)
31 (46.3%)

7 (5.4%)
22 (16.9%)
98 (75.4%)
3 (2.3%)

4 (6.3%)
9 (14.3%)
50 (79.4%)
0 (0.0%)

3(4.5%)
13 (19.4%)
48 (71.6%)
3 (4.6%)

Total

P-value

0.490
0.090

0.285

0.670
40 (30.8%)
59 (45.4%)
31 (23.8%)
495.91 ±
465.887

21 (33.3%)
29 (46.0%)
13 (20.6%)
498.80 ±
511.708

19 (28.4%)
30 (44.8%)
18 (26.9%)
492.89 ±
416.619

0.943

Note: P-values corresponds to χ2 tests for categorical variables and t-test for continuous
variables
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Table 2: Baseline Health and Lifestyle Characteristics of PLWH by Caffeine
Consumption Levels
Variables

Smoking
cigarettes

Total

Low caffeine
intake
(≤250 mg/d)

High caffeine
intake
(>250 mg/d)

0.582
80 (63.5%)
Yes 46 (36.5%)
No

39 (60.9%)
25 (39.1%)

41 (66.1%)
21 (33.9%)

Alcohol use

0.721
Yes 73 (57.9%)
No 53 (42.1%)

36 (56.3%)
28 (43.8%)

37 (59.7%)
25 (40.3%)

Yes 53 (48.2%)
No 57 (51.8%)

25 (43.9%)
32 (56.1%)

28 (52.8%)
25 (47.2%)

Yes 44 (33.8%)
No 86 (66.2%)

21 (32.3%)
44 (67.7%)

23 (35.4%)
42 (64.6%)

Drug use

0.445

Marijuana

0.853

Cocaine

0.706
Yes 41 (31.5%)
No 89 (68.5%)

19 (29.2%)
46 (70.8%)

22 (33.8%)
43 (66.2%)

Yes 10 (9.1%)
6 (10.5%)
No 100 (90.9%) 51 (89.5%)

4 (7.5%)
49 (92.5%)

34 (26.2%)
Yes 96 (73.8%)
No

12 (18.5%)
53 (81.5%)

Other Drugs

ART
Multicombination

P-value

0.744

0.072
22 (33.8%)
43 (66.2%)

NRTI

0.594
Yes 76 (58.5%)
No 54 (41.5%)

40 (61.5%)
25 (38.5%)

36 (55.4%)
29 (44.6%)

Yes 17 (13.1%) 10 (15.4%)
No 113 (86.9%) 55 (84.6%)

7 (10.8%)
58 (89.2%)

NNRTI

0.604

PI

0.380

Yes 62 (47.7%) 34 (52.3)
28 (43.1%)
No 68 (52.3%) 31 (47.7%)
37 (56.9%)
All variables reported as N (%)
Note: P-values correspond to χ2 tests for all variables
ART: Antiretroviral therapy.
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Table 3: Follow-up Health and Lifestyle Characteristics of PLWH by Caffeine
Consumption Levels
Variables

Total

Low caffeine
intake
(≤250 mg/d)

Smoking
cigarettes

High caffeine
intake
(>250 mg/d)

Pvalue
0.271

79 (63.2%) 41 (68.3%)
Yes 46 (36.8%) 19 (31.7%)
No
Alcohol use
Yes 76 (60.3%) 34 (56.7%)
No 50 (39.7%) 26 (43.3%)
Drug use
Yes 79 (65.8%) 45 (75.0%)
No 41 (34.2%) 15 (25.0%)
Marijuana
Yes 67 (55.8%) 38 (63.3%)
No 53 (44.2%) 22 (36.7%)
Cocaine
Yes 48 (40.0%) 29 (48.3%)
No 72 (60.0%) 31 (51.7%)
Other drugs
Yes 13 (10.9%) 6 (10.0%)
No 106 (89.1%) 54 (90.0%)
ART
Multicombination
33 (25.4%) 20 (31.7%)
Yes 97 (74.6%) 43 (68.3%)
No
NRTI
Yes 83 (63.8%) 40 (63.5%)
No 47 (36.2%) 23 (36.5%)
NNRTI
Yes 18 (13.8%) 9 (14.3%)
No 112 (86.2%) 54 (85.7%)
PI
Yes 62 (47.7%) 28 (44.4%)
No 68 (52.3%) 35 (55.6%)
All variables reported as N (%)
Note: P-values correspond to χ2 tests all variables.
ART: Antiretroviral therapy.

116

38 (58.5%)
27 (41.5%)
0.469
42 (63.6%)
24 (36.4%)
0.054
34 (56.7%)
26 (43.3%)
0.141
29 (48.3%)
31 (51.7%)
0.093
19 (31.7%)
41 (68.3%)
0.496
7 (11.9%)
52 (88.1%)
0.113
13 (19.4%)
54 (80.6%)
1.000
43 (64.2%)
24 (35.8%)
1.000
9 (13.4%)
58 (86.6%)
0.488
34 (50.7%)
33 (49.3%)

Table 4: Mean Caffeine Intake: Baseline and Follow-up Visit
Food source
Baseline
Follow-up
Coffee
161.26 ± 194.95
190.40 ± 205.03
De-Caffeinated
0.83 ± 9.21
0.03 ± 0.43
coffee
Expresso
14.40 ± 64.35
13.92 ± 57.82
Tea
34.70 ± 64.32
31.58 ± 59.36
Green tea
7.34 ± 62.93
4.20 ± 21.62
Energy drinks
46.32 ± 134.42
9.61 ± 65.32
Hot cocoa
1.03 ± 5.00
0.00 ± 0.00
Caffeinated soft
63.23 ± 92.98
29.66 ± 83.78
drinks
Chocolate candy
3.69 ± 13.81
2.00 ± 17.93
bars
Anacin
0.24 ± 2.80
0.00 ± 0.00
Appetite control
4.61 ± 39.10
0.00 ± 0.00
pills
Total
337.63 ± 304.97
281.04 ± 260.85
All variables reported as mean ± SD
Note: P-values correspond to t-tests for all variables
*Significant

P-value
0.206
0.329
0.942
0.640
0.594
0.005*
0.020*
<0.0001*
0.402
0.319
0.181
0.890

Table 5: Linear Regression of the Effect of Caffeine Consumption on Immunological
and Virologic Markers of Disease Progression
Disease
progression
variables

Unadjusted

Adjusted†

Beta
SE
P-value Beta
SE
P-value
CD4 square root
1.215
0.099
0.465
1.532
0.241
0.049*
Log 10 Viral load b -1.023 0.043
0.588
-1.067
0.081
0.048*
a
2
Model R = 0.135, F (17) = 15.313, P = .047.
b
Model R2 = 0.174, F (17) = 16.379, P = .047.
†
Model adjusted for age, income, race/ethnicity, time from diagnosis of HIV, drug use,
alcohol consumption, smoking status, BMI, total body fat percentage.
*Significant
a
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Table 6: Linear Mixed Model Analysis of Overtime Changes in the Effects of Caffeine
Consumption on Immunological and Virologic Markers of Disease Progression
Disease progression
variables

Unadjusted

Adjusted†

Beta
SE
P-value Beta
SE
P-value
CD4 square root a
0.900
0.3011 0.402
1.720
0.901
0.042*
b
Log 10 Viral load
-0.9774
0.8002 0.777
-1.389 0.786
0.033*
a
Model: -2 Restricted Log Likelihood = 1055.823; Akaike’s Information Criteria (AIC) =
1059.823; Schwarz’s Bayesian Criteria (BIC) = 1065.910.
b
Model: -2 Restricted Log Likelihood = 2597.274; Akaike’s Information Criteria (AIC) =
2601.274; Schwarz’s Bayesian Criteria (BIC) = 2607.36.
†
Model adjusted for age, income, race/ethnicity, time from diagnosis of HIV, drug use,
alcohol consumption, smoking status, BMI, total body fat percentage.
*Significant

Table 7: Baseline: CD4 count and Viral Load Categories by Levels of Caffeine
Consumption†
Variables

Total

Low caffeine
intake
(≤250 mg/d)

CD4 count

High caffeine
intake
(>250 mg/d)

P-value

0.811
≤199a 15 (13.0%)
8 (13.8%)
7 (12.3%)
200-499b 53 (46.1%)
25 (43.1%)
28 (49.1%)
c
≥500 47 (40.9%)
25 (43.1%)
22 (38.6%)
HIV viral load
0.971
c
≤21 32 (28.6%)
16 (28.6%)
16 (28.6%)
21-9999b 55 (49.1%)
27 (50.0%)
28 (50.0%)
a
≥10000 25 (22.3%)
13 (21.4%)
12 (21.4%)
All variables reported as N (%)
Note: P-values correspond to χ2 tests for all variables.
a
Inadequate control over disease progression
b
Moderate control over disease progression
c
Adequate control over disease progression
†World Health Organization. Who Case Definitions of HIV for Surveillance and Revised
Clinical Staging and Immunological Classification of HIV-Related Disease in Adults and
Children. 2007; http://www.who.int/hiv/pub/guidelines/WHO%20HIV%20Staging.pdf.
Accessed September 30, 2014.
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Table 8: Follow-up CD4 count and Viral Load Categories by Levels of Caffeine
Consumption†
Variables

Total

Low caffeine High caffeine
intake
intake
(≤250 mg/d) (>250 mg/d)

P-value

CD4 count43,44
0.024*
a
≤199 17 (15.5%) 6 (11.1%)
11 (19.6%)
200-499b 41 (37.3%) 27 (50.0%)
14 (25.0%)
c
≥500 52 (47.3%) 21 (38.9%)
31 (55.4%)
HIV viral
0.616
43,44
c
load
≤21
34 (31.5%) 18 (34.0%)
16 (29.1%)
21-9999b 50 (46.3%) 22 (41.5%)
28 (50.9%)
a
≥10000 24 (22.2%) 13 (24.5%)
11 (20.0%)
All variables reported as N (%)
Note: P-values correspond to χ2 tests for all variables.
a
Inadequate control over disease progression
b
Moderate control over disease progression
c
Adequate control over disease progression
*Significant
†World Health Organization. Who Case Definitions of HIV for Surveillance and Revised
Clinical Staging and Immunological Classification of HIV-Related Disease in Adults and
Children. 2007; http://www.who.int/hiv/pub/guidelines/WHO%20HIV%20Staging.pdf.
Accessed September 30, 2014.
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Table 9: Baseline Multinomial Logistic Regression of the Effect of Caffeine
Consumption Levels on CD4 and Viral Load Categorical Levels

OR

Caffeine
intake
High
Low

Adjusted†
95% CI

Unadjusted
95% CI

POR
Pvalue
value
CD4 count >500 versus ≤199 (High risk for disease progression)

Ref
Ref
Ref
Ref
0.994
(0.310 - 3.188)
0.992
1.690 (1.123 -3.879) 0.047*
CD4 count >500 versus 200-499 (Moderate risk for disease
progression)
High
Ref
Ref
Ref
Ref
Low
1.237
(0.579 - 2.795)
0.548
1.537 (0.522 -5.136) 0.198
HIV viral load ≤21 and 21-9999 (Moderate risk for disease
progression)
High
Ref
Ref
Ref
Ref
Low
0.874
(0.367 - 2.079)
0.761
0.964 (0.317 -3.444) 0.437
HIV viral load ≤21 and ≥10000 (High risk for disease progression)
High
Ref
Ref
Ref
Ref
Low
0.857
(0.332 - 2.214)
0.750
1.933 (1.254 -6.192) 0.048*
R2 = 0.213 (Cox and Snell), 0.219 (Nagelkerke). χ2 (36) = 47.638, P =0.029
†
Model adjusted for age, income, race/ethnicity, time from diagnosis of HIV, drug use,
alcohol consumption, smoking status, BMI, total body fat percentage.
*Significant
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Table 10: Overtime Multinomial Logistic Regression of the Effect of Caffeine
Consumption Levels on CD4 and Viral Load Categorical Levels
Caffein
e intake

OR

Adjusted†
95% CI

Unadjusted
95% CI

POR
Pvalue
value
CD4 count >500 versus ≤199 (High risk for disease progression)
High
Ref
Ref
Ref
Ref
Low
1.242
(0.398 - 3.878) 0.709 1.876 (1.216 - 8.763) 0.047*
CD4 count >500 versus 200-499 (Moderate risk for disease
progression)
High
Ref
Ref
Ref
Ref
Low
0.351
(0.150 - 1.822)
0.159 1.375 (0.094 - 2.500) 0.066
HIV viral load ≤21 and 21-9999 (Moderate risk for disease
progression)
High
Ref
Ref
Ref
Ref
Low
1.057
(0.772 - 4.470)
0.167 1.186 (0.288 - 4.878) 0.113
HIV viral load ≤21 and ≥10000 (High risk for disease progression)
High
Ref
Ref
Ref
Ref
Low
1.300
(0.274 - 5.674)
0.900 1.863 (1.217 - 7.894) 0.048*
R2 = 0.216 (Cox and Snell), 0.215 (Nagelkerke). χ2 (36) = 45.478, P=0.020
†
Model adjusted for age, income, race/ethnicity, time from diagnosis of HIV, drug use,
alcohol consumption, smoking status, BMI, total body fat percentage.
*Significant
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CHAPTER-V: CAFFEINE INTAKE AND ASSOCIATIONS WITH SLEEP
QUALITY AND GENERALIZED ANXIETY SCORES IN MIAMI ADULT
STUDIES ON HIV (MASH) COHORT—AN OBSERVATIONAL STUDY
ABSTRACT
Introduction: People living with HIV (PLWH) report deteriorated sleep quality,
increased periods of insomnia, post morning sleepiness, cognitive impairment, and
chronic fatigue. Caffeine consumption adversely affects sleep quality and anxiety
symptoms in many vulnerable populations. Although there are many studies on caffeine
consumption and sleep and anxiety symptoms in HIV non-infected populations,
inadequate information is available in PLWH.
Methods: We examined caffeine intake and sleep quality, insomnia levels, and anxiety
symptoms in a convenience sample of 130 clinically stable HIV positive participants (65
consuming ≤ 250 mg/day and 65 consuming > 250 mg/day of caffeine) recruited from the
Miami Adult Studies on HIV (MASH) cohort. This study included a baseline and a
follow-up visit at 3 month. After obtaining written informed consent, caffeine
consumption, sleep quality, insomnia levels and anxiety symptoms were determined
using Modified Caffeine Consumption Questionnaire (MCCQ), Pittsburg Insomnia
Rating Scale (PIRS), Pittsburg Sleep Quality Index (PSQI) and Generalized Anxiety
Disorder-7 (GAD-7) questionnaires. Information on demographics, anthropometries,
body composition measures, substance abuse and antiretroviral therapy (ART) were
collected from the MASH cohort database. T-tests and chi-square were used to describe
demographics and health and lifestyle characteristics. Linear regressions were used to
analyze baseline data for relationships between caffeine consumption, insomnia, sleep
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quality and anxiety symptoms. Linear Mixed Models were used to understand the effect
of caffeine consumption on these parameters over time.
Results: The mean age of the cohort was 47.89 ± 6.37 years, 60.8% were male
participants and 75.4% were African-Americans. All participants were on ART
throughout this study. Mean caffeine intake at baseline was 161.26 ± 194.95 mg/day (3-8
cups of coffee) (Range: 0 mg-1498 mg/day) and did not change significantly at 3-month
follow-up visit. Linear regressions showed significant associations between higher
caffeine consumption and higher global PIRS scores (β=1.776, P=0.046), higher global
PSQI scores (β=2.587, P=0.038) and higher GAD-7 scores (β=1.674, P=0.027) after
adjusting for associated covariates. Linear mixed model analysis showed that higher
caffeine consumption was associated with higher global PIRS scores (β=1.678, P=0.047),
higher global PSQI scores (β=2.594, P=0.006) and higher GAD-7 scores (β=0.937,
P=0.048), in a dose-response manner, after adjusting for covariates.
Conclusion: Higher caffeine consumption was associated with higher levels of insomnia,
poor sleep quality and higher levels of anxiety symptoms in PLWH. Although our
previous studies have suggested a benefit of higher caffeine consumption on markers of
HIV disease progression, in vulnerable patients, high doses of caffeine can aggravate
existing psychological conditions. Effective interventions to reduce caffeine intake in this
population need to be developed and tested in future large scale studies.
Keywords: Modified Caffeine Consumption Questionnaire (MCCQ), HIV infection,
Pittsburg Insomnia Rating Scale (PIRS), Pittsburg Sleep Quality Index (PSQI) and
Generalized Anxiety Disorder-7 (GAD-7)
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INTRODUCTION
According to the 2013 CDC estimates, about 1.2 million people were living with
HIV/AIDS (PLWH) in United States. In Miami-Dade County, there were 26,760
PLWH.1 PLWH report deteriorated sleep quality, increased periods of insomnia, post
morning sleepiness, cognitive impairments, and chronic fatigue.2-6 Sleep quality
measured by the Pittsburgh Sleep Quality Index (PSQI) was significantly lower in
PLWH, when compared to the general population, after adjusting for other co-morbidities
and over-the-counter sleep medications.4 In another study among clinically stable
PLWH, it was found that poor sleep quality and increased psychological distress scores
were associated with lower CD4 cell counts and higher HIV viral load after adjusting for
the effects of ART.7 In a study conducted to identify the correlates of sleep quality in
PLWH, using the “Symptom Experience Dimension” of the revised “UCSF Symptom
Management Conceptual Model”, the variables significantly affecting sleep quality were
trait and state anxiety scores, general well-being scores, length of time living with HIV
disease and diagnosis of clinical depression.5 The length of time living with HIV disease
strongly correlated with worst sleep quality measured by the Pittsburg Sleep Quality
Index (PSQI) questionnaire after adjusting for other predictor variables mentioned
above.5 Another study done among 146 clinically stable PLWH showed that stress levels
measured by State and Trait Anxiety (STA) Questionnaires were significantly associated
with deteriorated sleep quality, after adjusting for covariates such as age, sex, ART, other
medications, substance use and income.8 Similarly, better sleep quality, measured by the
PSQI and Pittsburg Insomnia Rating Scale (PIRS) was associated with better cognitive
performance on tasks of attention, frontal/executive functions, and psychomotor/motor
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speeds in PLWH, after adjusting for medications, alcohol consumption and drug use.6
Additionally this study reported that more than one third of the PLWH participants were
chronically and severely sleep deprived.6
In a study that investigated the effects of caffeine on cognitive and psychomotor
performance and sleep quality at night, in HIV non-infected participants, it was observed
that caffeine in doses of 250 mg/day, irrespective of sources, significantly decreased the
initial critical flicker fusion threshold (CFFT) scores which signifies higher levels of
neuronal excitability after adjusting for age, BMI, exercise, gender, body composition
measures and lifestyle factors.9 In a randomized double-blind study of 72 HIV noninfected participants with various forms of anxiety disorders, oral administration of 480
mg/day of caffeine provoked acute stress responses measured through State and Trait
Anxiety Questionnaires.10 General stress levels estimated by the State and Trait Anxiety
Questionnaires, were substantially higher in subjects administered 480 mg/day of
caffeine when compared to control solutions after adjusting for gender, age, educational
level, occupation and anxiolytic medications. Four hundred and eighty mg of caffeine
precipitated panic attacks in 60.7% all of the participants in the experimental arm of the
study. This study concluded that higher doses of caffeine (480 mg/day) precipitated
anxiety and panic attacks even in HIV non-infected volunteers.10
Caffeine intake also affected sleep quality as reported by a study conducted
among 88 HIV-positive participants.11 In this study, sleep quality was measured by the
Revised Pittsburg Sleep Quality Index (RPSQI) Questionnaire. Mean caffeine intake of
the sample was 476 mg/day or 2.4 times the US consumption average of 200 mg/day. It
was found that subjects having high levels of caffeine consumption (>400 mg/day)
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reported poor PSQI scores.11 Within one month, subjects who reduced their baseline
caffeine consumption by 90% or higher, showed significant improvements in PSQI
scores after adjusting for covariates such as sleep medications, other co-morbidities and
substance use.
In summary, the literature shows that caffeine consumption is associated with
compromised sleep quality, altered sleep patterns, increased periods of insomnia, and
increased stress and anxiety symptoms. All these parameters could produce adverse
effects on disease progression in PLWH.7 The specific aim of the current study was to
explore whether caffeine consumption affected sleep quality, insomnia levels and anxiety
symptoms in a convenience sample of 130 participants (65 consuming ≤ 250 mg/day and
65 consuming > 250 mg/day of caffeine) recruited from the Miami Adult Studies of HIV
(MASH) cohort. We also observed for the effects of sleep quality, insomnia and anxiety
symptoms on immunological and virologic markers of HIV disease progression.
METHODS
Study Design and Setting
The present study recruited a convenience sample of 130 participants (65 consuming ≤
250 mg/day and 65 consuming > 250 mg/day of caffeine) from the MASH cohort, which
consisted of 803 HIV positive and 78 uninfected participants, followed for more than 10
years at the FIU research clinic in the Borinquen Health Care Center (BHCC). The
BHCC provides comprehensive range of health and social services to a culturally diverse
low income community. The recruitment for the present study took place from February
to July 2014. The present study included a baseline and 3-month follow-up visits, and
participants received $5 as partial reimbursement for their time and efforts, for each of
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the two visits. The initial screening included detailed explanation of the study as well as
obtaining informed voluntary written consent for participation. In order to obtain a study
sample of 128 participants as estimated in our sample size calculations, we screened a
total of 150 subjects, enrolled 130 participants and excluded 20 ineligible participants.
The present study also included secondary analysis of relevant variables collected for the
MASH cohort studies. Data collected during the baseline and 3-month visits were used
for the analyses of descriptive and inferential statistics. The inclusion and exclusion
criteria for the MASH cohort are presented in “Chapter 3: Methodology” and applicable
to our current study. The additional inclusion criteria for participants in the present study
were: enrollment in the MASH cohort; receiving ART; and willingness to participate in a
study with two visits, a baseline and one follow-up visit at 3 months. The exclusion
criteria were: cardiovascular abnormalities or implanted pacemakers; morbid medical
conditions such as uncontrolled hypertension, anemia, chronic inflammatory diseases or
mal-absorption syndromes. The Institutional Review Board at Florida International
University approved the study protocol and research procedures.
Measures
The questionnaires used in the present study were previously field tested and validated in
several large scale studies.12-15 However, we pre-tested these questionnaires on 15
participants from the MASH cohort to ascertain their applicability and we determined
that revisions were not necessary for the questionnaires.
Caffeine consumption questionnaire: We used the Modified Caffeine Consumption
Questionnaire (MCCQ) developed by Preston et al. in the year 1998.16 This questionnaire
is easy to understand, compact, organized and reported adequate compliance, validity and
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reliability.16 This questionnaire was field tested and validated in many large scale studies
and adequately reflected average daily caffeine consumption levels.12 It includes a total
of 21 sources of caffeine classified in to three groups, ‘Beverages’, ‘Over the counter
medications’ and ‘Prescription medications’. This questionnaire also included ‘Total
caffeine consumption per day’ by adding these individual sources. Caffeine consumption
was analyzed both as a continuous variable and a categorical variable.
For both naturally occurring and artificially added caffeine sources, FDA
considers 400 mg/day (7 cups of Coffee) to be generally safe and not associated with any
dangerous side effects.17,18 The World Health Organization (WHO) defines caffeine
overuse as daily consumption beyond 500 mg/d.19,20 Beyond this level caffeine produces
visible adverse effects collectively known as ‘Caffeinism’. The World Health
Organization (WHO) has also cautioned that these adverse effects could be precipitated at
much lower doses depending on the physiological profiles of individuals as well as the
genetic makeup of the population. 19,20 The International Classification of Diseases (ICD)
manual considers caffeine consumption above 250 mg/day to be associated with many
mental and behavioral disorders though it is inconclusive whether such effects would be
uniformly applicable in the general population.13 The Diagnostic and Statistical Manual
of Mental Disorders (DSM-5) considers consumption below 250 mg/day to be generally
safe and above this level to be associated with many adverse effects such as withdrawal,
addiction, irritability and craving.21 Summarizing these cutoffs, we concluded that
caffeine consumption below 250 mg/day that is equivalent to 4 cups of coffee,
irrespective of the sources is generally safe and not associated with adverse effects. In
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this study, caffeine categories included low (≤250 mg/day, within safe levels) and high
(>250 mg/day, beyond safe levels) based on these recommendations.
The Pittsburg Insomnia Rating Scale (PIRS): The PIRS is a 66-item self-report
questionnaire that measures the subjective levels of insomnia experienced over the past
seven days.13 This questionnaire consists of four components: Distress Score; Sleep
Parameter Score; Quality of Life Score; and Total Insomnia Score. The ‘Distress Score’
equals the total of first 46 questions each rated on a 0-3 scale and higher scores indicate
increased levels of subjective distress symptoms experienced by the participants.
Similarly, the ‘Sleep Parameter Score’ totals questions 47 to 56, each rated on a 0-3 scale
and higher scores signify poor sleep quality. The ‘Quality of Life Sore’ sums questions
57 to 65, and higher scores signify poor quality of life. The ‘The Global PIRS Score’
sums all the 65 questions and higher scores represent increased subjective reports of
insomnia. The original study validating the questionnaire13 also recommends scores 0-50
as ‘No Insomnia’, scores 51-100 as ‘Moderate Insomnia’ and scores greater than 100 as
‘Severe Insomnia’.13 The PIRS questionnaire showed excellent internal consistency, testretest reliability and discriminative validity in a mixed sample of 456 normal adult
participants between 18 and 85 years in the original study. The original study also
reported a Cronbach's alpha coefficient of 0.88 indicating high internal consistency and
an intra-class correlation of 0.89 indicating good test-retest reliability.13 The original
study also reported a sensitivity of 83.4% and a specificity of 88.6% for the
questionnaire.13 In the present study the global PIRS scores were analyzed as both
continuous and categorical variables. The global PIRS score categories included: ≤50 (No
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Insomnia), 51-100 (Moderate Insomnia), and >100(Severe Insomnia) as recommended in
the original study.13
The Pittsburg Sleep Quality Index questionnaire (PSQI): The PSQI is a 19-item selfreport questionnaire that measures self-reported quality of sleep over the past 30 days.14
This questionnaire includes seven individual components: Sleep Duration; Sleep
Disturbance; Sleep Latency; Days Dysfunction due to Sleepiness; Sleep Efficiency;
Overall Sleep Quality; and Need Meds to Sleep. Each component is rated on a 0–3 scale,
with higher scores signifying worsening outcomes. ‘Sleep Duration’ is calculated using
question 4 and represents the total number hours slept per day. ‘Sleep Disturbance’ is
calculated by summarizing individual scores in questions 5b to 5j and represents various
factors like bad dreams, pain, breathing problems etc. that have impaired the quality of
sleep. ‘Sleep Latency’ represents the total time spent awake on bed trying to sleep each
day and is calculated using the questions 2 and 5 with necessary re-coding. ‘Days
Dysfunction due to Sleepiness’ is calculated from questions 8 and 9 and represents daily
problems related to sleep, such as having trouble staying awake or having enough
enthusiasm to get things done. ‘Sleep Efficiency’ is calculated from questions 1 and 3
and represents the ratio of actual number of hours of sleep, given the number of hours
spent in bed. ‘Overall Sleep Quality’ is calculated from question 6 and represents general
sleep quality over the past month. ‘Need Meds to Sleep’ is calculated from question 7
and represents use of sleep medications over the past month. These seven component
scores are added to obtain a global PSQI score which ranges from 0 to 21 and higher
scores represent worsening sleep quality. According to the original study a global PSQI
score of 5 or greater represents poor sleep quality.14 However other studies recommend
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scores 0-5 as good sleep quality, 6-10 as poor sleep quality and greater than 10 as worst
sleep quality.22,23 This questionnaire had good internal consistency, test-retest reliability,
and discriminative validity in the original study with a sample of 168 participants aged 19
to 83 years.14 The original study also reported a Cronbach's alpha coefficient of 0.83
indicating high internal consistency and an intra-class correlation of 0.85 indicating good
test-retest reliability.14,24 The original study also reported a sensitivity of 89.6% and a
specificity of 86.5% for the questionnaire.14,24 In the current study the global PSQI scores
were analyzed as both continuous and categorical variables. The global PSQI score
categories included: ≤5 (Good Sleep Quality), 6-10 (Poor Sleep Quality), and >10 (Worst
Sleep Quality).23,24
The Generalized Anxiety Disorder-7 (GAD-7) questionnaire: The GAD-7 is a 7-item
self-reported questionnaire for screening and evaluating the severity of generalized
anxiety symptoms over the past two weeks.15 Although primarily developed for
measuring generalized anxiety disorder, studies have also reported good sensitivity and
specificity for many other anxiety and panic disorders.25 There are seven questions about
anxiety symptoms each rated on a 0-3 scale representing the options ‘not at all’, ‘several
days’ , ‘more than half the days’ , and ‘nearly every day’. The total scores range from 0
to 21 and higher scores represent greater anxiety levels. GAD-7 had shown good internal
consistency, test-retest reliability, and discriminative validity in the original study of
2470 participants aged 19 to 95 years.15 The original study of this questionnaire reported
a Cronbach's alpha coefficient of 0.92 indicating very high internal consistency and an
intra-class correlation of 0.83 indicating good test-retest reliability.15 The original study
also reported a sensitivity of 89% and a specificity of 82% for the questionnaire.15 In the
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current study, the GAD-7 scores were analyzed as both continuous and categorical
variables. The GAD-7 score categories included: ≤5 (Minimal Anxiety), 6-10 (Mild
Anxiety), 11-15 (Moderate Anxiety) and >15 (Severe Anxiety), as recommended in the
original study.15
Immunological and virologic variables: CD4 counts, viral loads and other clinical
variables are determined for the participants’ healthcare visits by their primary health
care physicians. The MASH cohort studies collected and documented these reports after
appropriate medical release forms were signed by the participants. The MASH studies
also paid a compensation of $15 every six months to motivate participants towards timely
submission of medical records and lab reports, which included CD4 counts and viral
load. In the current chapter, CD4 counts and viral loads were analyzed as continuous
variables and transformed into CD4 square root and log 10 viral load to ensure normal
distribution and better model fit criteria.
Control Variables
Demographic and socioeconomic information: Demographic and socioeconomic
information used in this study were collected by the MASH studies. Information used for
the current study included age, gender, ethnicity, education and income levels. A number
of health and lifestyle related factors such as tobacco use, alcohol consumption and illicit
drug use were also gathered from the MASH data repository. These controlled variables
were selected based on studies associating them with sleep quality and anxiety
disorders.13-16,25-27
ART medications: We obtained information about types of the antiretroviral medications
prescribed and administered by their physicians during the MASH cohort visits. We
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adjusted the analyses for these variables because some of the antiretroviral medications
are associated with sleep and anxiety disorders.26-28
Statistical Analysis
Field data were collected in paper based questionnaires and later entered into RedCap
database, then imported into SPSS version 21 for Windows (Armonk, NY: IBM Corp)
and merged into a single dataset for analysis. Descriptive statistics were used to
understand the population characteristics and were expressed in terms of means, standard
deviations and percentages. The characteristics of the population were shown for all the
participants and separated based on low and high intakes of caffeine using the cutoff
points: >250 mg/day for high intake; and ≤250 mg/day for low or no intake as described
in the Methods section above.17,18,19,20 T-tests and chi square tests were used to describe
differences in demographics, health and lifestyle characteristics, and individual
components and global scores of PIRS, PSQI and GAD-7 questionnaires, with respect to
low and high levels of caffeine consumption. Paired sample t-tests were used to measure
differences in levels of caffeine consumption as well as the individual components and
global scores of PIRS, PSQI and GAD-7 questionnaires, between the baseline and 3month visits. Linear regression was used to estimate the strength of association between
caffeine consumption and the individual components and global scores of PIRS, PSQI
and GAD-7 questionnaires. Assumptions of linear regression were followed prior to
analyses. Linear mixed models (LMM) were used to determine the overtime changes in
the strength of these associations. For parameter estimation in LMM models restricted
maximum likelihood (REML) was used. Multinomial logistic regressions were used to
determine the associations between high and low caffeine intake groups with respect to
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different categories of global scores of PIRS, PSQI and GAD-7 questionnaires. Linear
Regression was also used to estimate the strength of association between global scores of
PIRS, PSQI and GAD-7 questionnaires and the markers of HIV disease progression
(CD4 counts and viral load). Linear Mixed Models were used to estimate the changes
over time in the strength of these associations. For Linear and Logistic Regressions and
Linear Mixed Model analysis, we initially used crude models and subsequently adjusted
for the covariates already described in the methodology. These covariates were also
tested for significant associations with the outcome variables using bivariate analysis
before being incorporated into the models. To increase the validity of the models,
multicollinearity among covariates was tested prior to the analyses. Adjusted models
included non-missing values for all independent variables included in the models.
Statistical significance was set at P<0.05 for all the analyses.
RESULTS
Demographic and Socio-economic Characteristics
A total of 130 participants were included in the study and 79 (60.8%) were men.
The mean age was 47.89 ± 6.37 years. Most of the participants were African Americans
(75.4%), Hispanics constituted 16.9%, Whites constituted 5.4% and other races
constituted 4.6 percent. About 24% of the participants had college education, while
45.4% were high school graduates and 30.8% has some form of primary education. All
participants had incomes under the level of poverty and the mean income was $495.91±
465.887. There were no significant differences in any socio-demographic variables
between low and high levels of caffeine consumption in both baseline and follow-up
visits (Table-1A, 1B).
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Health/lifestyle Characteristics
Sixty one percent of the participants reported smoking within the past six weeks
of their scheduled baseline visits, 57.9% reported alcohol use and 48.2% tested positive
for illicit drug use. Similarly, 63.2% reported smoking, 60.3% reported alcohol use and
65.8% tested positive for illicit drug use during the follow-up visit.
All participants were on ART during both visits. Antiretroviral therapy took many
forms, 58.5% were on NRTI, 13.1% were on NNRTI and 47.7% were on PI in several
combinations, 26.2% of the participants were using a one-pill multi-drug combination
such as Atripla, Truvada and Combivir during the baseline visit. At the 3-month visit,
63.8% were on NRTI, 13.8% were on NNRTI and 47.7% were on PI, and 25.4% were on
a one-pill multi-drug combination during the follow-up visit. There were no significant
differences in the distribution of these variables between low and high levels of caffeine
consumption in both baseline and follow-up visits (Tables 2 and 3).
Caffeine Consumption from Different Sources
Total caffeine consumption was 337.63 ± 304.97 mg/day at baseline (Range: 01,498 mg/day), and 281.04 ± 260.85 mg/day (Range: 0-1,175 mg/day) at the 3-months
follow-up. Coffee constituted the largest source of caffeine and mean consumption levels
were 161.26± 194.95 mg/day at baseline, and 190.40 ± 205.03 mg/day at follow-up.
Caffeinated soft drinks constituted the second largest source of caffeine and mean
consumption levels were 63.23 ± 92.98 mg/day at baseline, and 29.66 ± 83.78 mg/day at
follow-up. There were no significant differences between baseline and follow-up visits
with respect to total caffeine consumption or caffeine from most of the sources. However,
there was significant decrease in consumption of caffeinated soft drinks (63.23 ± 92.98
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vs. 29.66 ± 83.78, P<0.00001), energy drinks (46.32 ± 134.42 vs. 9.61 ± 65.32, P=0.005)
and hot cocoa (1.03 ± 5.00 vs. 0.00 ± 0.00, P=0.020) from the baseline to the follow-up
visits (Table-4). For all other sources of caffeine in the questionnaire, except the ones
enlisted in Table 4, participants reported none to negligible levels of consumption at both
the visits.
The Individual Components and Global PIRS, PSQI and GAD-7 Scores
Independent sample t-tests showed that most of the individual components and
global scores of PIRS, PSQI and GAD-7 questionnaires did not differ significantly
between the groups who consumed <250 mg of caffeine per day versus ≥ 250 mg/day, in
the baseline as well as 3-month follow-up visit. However, ‘Distress Score’ (31.44 ± 23.92
vs 72.33 ± 28.75, P=0.002), ‘The Global PIRS Scores’ (45.89 ± 133.13 vs 105.75 ±
41.12, P=0.002), ‘Days Dysfunction due to Sleepiness’ (0.60 ± 0.63 vs 1.89 ± 0.85,
P=0.002), and ‘Overall Sleep Quality Derangements’ (0.58 ± 0.63 vs 1.74 ± 0.85,
P=0.002), were significantly higher in those who consumed ≥ 250 mg/day when
compared to those who consumed <250 mg of caffeine per day (Tables 5, 6,8,9, 11,12).
Paired sample t-tests comparing the baseline and 3-month visits also showed that
most of the individual components and global scores of PIRS, PSQI and GAD-7
questionnaires did not differ significantly between the visits. ‘Sleep Disturbance’ (1.55 ±
0.74 vs 1.32 ± 0.83, P=0.019), ‘Sleep Latency’ (1.54 ± 1.05 vs 1.16 ± 0.89, P=0.001),
‘Sleep Efficiency’ (0.68 ± 0.96 vs 0.19 ± 0.53, P<0.001) and ‘Global PSQI’ (7.98 ± 5.59
vs 6.61 ± 4.87, P=0.031), however, were significantly higher during the baseline visit
when compared to follow-up visits (Tables 7, 9, 10, and 13).
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Relationship between Caffeine Intake and PIRS Variables
Caffeine consumption as a continuous variable was significantly associated with
Distress Score (β=1.506, P=0.048), Quality of Life Score (β=1.784, P=0.001), and global
PIRS Score (β=1.776, P=0.046), after adjusting for age, gender, race/ethnicity, education,
income, and time from diagnosis of HIV, drug use, smoking status, alcohol use, different
types of ART medications and use of sleep medications (Table 14). Linear Mixed Model
analysis for the effect of caffeine intake on changes in these scores, between the two
study visits, showed significantly increased Distress Score (β=1.347, P=0.036), Quality
of Life Sore (β=1.767, P=0.006) and Global PIRS Score (β=1.678, P=0.047), with
increasing caffeine consumption, in a dose-response manner, after adjusting for the same
covariates (Table 15). Multinomial logistic regressions showed that the odds of having
moderate insomnia were 9 times higher in participants consuming > 250 mg of caffeine
per day, when compared to participants consuming ≤250 mg per day, after adjusting for
the same covariates (OR=9.321, 95%CI: 3.324 -21.402, P=0.018). Similarly, the odds of
having severe insomnia were 17 times higher in participants consuming > 250 mg of
caffeine per day, when compared to participants consuming ≤250 mg per day, after
adjusting for the same covariates (OR=17.9558, 95%CI: 10.153 -94.512, P=0.003).
These odds also increased in significance, when changes over the three month period
were considered (Table 16 and 17).
Relationship between Caffeine Intake and PSQI Variables
Caffeine intake as a continuous variable was significantly associated with Sleep
Duration (β=1.199, P=0.049), Days Dysfunction due to Sleepiness (β=1.250, P=0.043),
Overall Sleep Quality (β=2.248, P=0.001), and Global PSQI scores (β=2.587, P=0.038),
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after adjusting for covariates such as age, gender, race/ethnicity, education, income, and
time from diagnosis of HIV, drug use, smoking status, alcohol use and different types of
ART medications (Table 18). Linear Mixed Model analysis for the effect of caffeine
intake on changes in these scores, between the two study visits, showed significantly
worse domains of ”Sleep Duration” (β=1.345, P=0.042), “Sleep Disturbance” (β=1,505,
P=0.032), “Sleep Latency” (β=1.323, P=0.023), “Days Dysfunction Due to Sleepiness”
(β=1.353, P=0.036), “Sleep Efficiency” (β=1.212, P=0.025), “Need Meds to Sleep”
(β=1.494, P=0.049) and “Global PSQI Scores” (β=2.594, P=0.0006), with increasing
caffeine consumption, in a dose-response manner, after adjusting for the same covariates
(Table 19).
Multinomial logistic regressions showed that the odds of having poor sleep
quality was 18 times higher in participants consuming >250 mg of caffeine per day when
compared to participants consuming ≤250 mg per day after adjusting for the same
covariates (OR=18.659, 95%CI: 8.016 -165.741, P=0.013). Similarly the odds of having
extremely low sleep quality was 19 times higher in participants consuming >250 mg of
caffeine per day when compared to participants consuming ≤250 mg per day after
adjusting for the same covariates (OR= 19.060, 95%CI: 16.906 -186.786, P=0.008).
When changes over the three month period were considered, the odd ratios for these
variables became more significant (Table 20 and 21).
Relationship between Caffeine Intake and GAD-7 Variables
Caffeine intake as a continuous variable was significantly associated with GAD-7
Score (β=1.674, p=0.027), after adjusting for covariates such as age, gender,
race/ethnicity, education, income, and time from diagnosis of HIV, drug use, smoking
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status, alcohol use, different types of ART medications and use of sleep medications
(Table 22). Linear mixed model analysis for the effect of caffeine intake on changes in
GAD-7 scores, between the two study visits, showed significantly increased scores
(β=0.937, P=0.048) with increasing caffeine consumption, in a dose-response manner,
after adjusting for the same covariates (Table 23). Multinomial logistic regressions
showed that the odds of having mild anxiety was 5 times higher in participants
consuming >250 mg of caffeine per day, when compared to participants consuming ≤250
mg per day after adjusting for the same covariates. (OR=5.107, 95%CI: 1.568 -33.499,
P=0.027). Similarly the odds of having moderate anxiety was 6 times greater (OR=
6.091, 95%CI: 2.333 -35.841, P=0.002) and the odds of having severe anxiety was 17
times greater (OR= 17.185, 95%CI: 5.185 -88.185, P=0.001) in participants consuming
>250 mg of caffeine per day, when compared to participants consuming ≤250 mg per day
after adjusting for the same covariates. These odds also increased in significance, when
changes over the three month period were considered (Tables 24 and 25).
Relationship between Global PIRS, Global PSQI, GAD-7 and Immunological and
Virologic Markers of Disease Progression
Linear regression showed that global PIRS scores were significantly associated
with lower CD4 cell counts (β=-1.202, P=0.015) after adjusting for time from diagnosis
of HIV, drug use, smoking status, alcohol use and different types of ART medications.
Similarly global PSQI scores (β=-1.149, P=0.036) and GAD-7 scores (β=-1.122,
P=0.031) were significantly associated with lower CD4 cell counts after adjusting for the
same covariates (Table 26).
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Linear regression showed that global PIRS scores was significantly associated
with higher HIV viral load (β=1.949, P=0.045) after adjusting for time from diagnosis of
HIV, drug use, smoking status, alcohol use and different types of ART medications.
Similarly global PSQI scores (β=1.988, P=0.031) and GAD-7 scores (β=1.269, P=0.029)
were significantly associated with higher HIV viral load after adjusting for the same
covariates (Table 26). However, linear mixed model analysis showed that these
associations diminished and lost insignificance overtime (Table 27).
DISCUSSION
The characteristics of our population were epidemiologically similar to those
described by others in Miami-Dade County.29,30 More than half of the participants were
consuming alcohol and smoking cigarettes, and 48.2% had a positive urine toxicology
result for illicit drugs.
The relationship between caffeine consumption and sleep quality, insomnia and
anxiety scores, were also expected, as caffeine consumption has been associated with
poor sleep quality and worsening anxiety symptoms in other studies on non-HIV infected
participants.31-34 There are also studies stating that HIV infected patients have
deteriorated sleep quality, increased periods of insomnia, post morning sleepiness,
cognitive impairments, increased anxiety symptoms and tiredness.2-6,35-38 However,
studies associating caffeine consumption to these adverse effects are rare in HIV positive
populations. Currently, only one study on HIV positive patients reports adverse effects of
caffeine consumption on sleep quality and general wellbeing.11 This study, however, was
limited due to its small sample size (N=88) and very high mean caffeine consumption
levels (476 mg/day), which was about 2.4 times the average consumption in United
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States. Though many studies have associated caffeine intake with impaired sleep quality
in HIV non-infected populations,4,5,39-43 our study is the among the few that investigated
the association between high caffeine consumption and sleep quality and anxiety
symptoms in a population of clinically stable PLWH.
We found that caffeine intake adversely affected many parameters of sleep and
anxiety measured by PIRS, PSQI and GAD-7 questionnaires, adjusting for income, years
since diagnosis of HIV, substance abuse and ART. Our analyses were adjusted by these
variables because the literature reported their associations with poor sleep quality.44-47
Our findings suggest that the adverse effects of caffeine on sleep and anxiety levels were
mild but compounded by medication side effects, cocaine and amphetamine use, which
have stronger effects on sleep disturbances and anxiety.
We also found that worsening sleep and anxiety scores measured through PIRS,
PSQI and GAD-7 questionnaires were associated with lower CD4 counts and higher HIV
viral load after adjusting for the covariates associated with HIV disease progression.48-50
Similar findings are also reported in another study in PLWH, where poor sleep quality
and worsening psychological distress scores were associated with lower CD4 cell counts
and higher HIV viral loads.7 Nevertheless, comparability with our study is limited,
because this study used a sample of PLWH beginning to show symptoms of AIDS,
whereas, our participants were clinically stable HIV positive participants receiving ART.
The deleterious effects of poor sleep quality and higher psychological distress scores on
HIV disease progression, would have been more prominent in PLWH who were
beginning to show symptoms of AIDS, compared to our stable HIV positive participants
receiving ART, because recovery of the immune function and controlled viral loads are
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only attained with ART.51 Our study findings are unique because we explored the adverse
effects of sleep loss and anxiety symptoms in the absence of advanced HIV disease
progression.
In spite of the findings in this study, we have to acknowledge some of its
limitations. The current study enrolled a convenience sample of 130 PLWH, thus the
results may not be generalizable. Participating in the baseline could also have influenced
the outcomes in the follow-up visit, as the participants could have been affected by an
“Interpersonal Expectancy Bias,” 52 by which they would have responded what they
believed the investigators wanted to hear or the investigators would have recorded what
they wanted to report.
Furthermore, the survey instruments used in the study do not measure the
outcomes within the same time frame. PIRS measured insomnia levels over the past one
month, GAD-7 measured anxiety symptoms over the past two weeks, PSQI measured
sleep quality over the past week and MCCQ measured caffeine consumption over the
past 24 hours. Furthermore these instruments are self-reported measures and susceptible
to memory and recall biases.
Large scale studies should be done with controlled dietary and lifestyle factors, as
well as controlled study settings, to overcome the limitations of our study. Though, our
findings showed that caffeine intake adversely affected sleep quality and anxiety
symptoms, and, in turn, adversely affected HIV disease progression, these findings
should be confirmed by such large scale studies.
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Table 1A: Baseline Demographic Characteristics of PLWH by Caffeine Consumption
Levels

Age in years
(Mean±SD)
Gender, N (%)

47.89 ± 6.37

Baseline
Low
High
caffeine
caffeine
intake
intake
(≤250
(>250
mg/d)
mg/d)
47.57±6.81 48.00±6.15

Male
Female
Ethnicity, N (%)
White
Hispanic
Black
Other
Education in years,
N (%)
<12
12
>12
Income in dollars
per month

79 (60.8%)
51 (39.2%)

40 (61.5%) 39 (60.0%)
25 (38.5%) 26 (40.0%)

Variables

Total

P-value

0.706
0.857

0.057
7 (5.4%)
22 (16.9%)
98 (75.4%)
3 (2.3%)

3 (4.6%)
7 (10.8%)
55 (84.6%)
0 (0.0%)

4 (6.2%)
15 (23.1%)
43 (66.2%)
3 (4.6%)
0.202

40 (30.8%)
59 (45.4%)
31 (23.8%)
495.91 ±
465.887

24 (36.9%)
29 (44.6%)
12 (18.5%)
464.00 ±
419.667

16 (24.6%)
30 (46.2%)
19 (29.2%)
527.34 ±
508.637

0.442

Note: P-values corresponds to χ2 tests for categorical variables and t-test for continuous
variables

151

Table 1B: Follow-up Demographic Characteristics of PLWH by Caffeine Consumption
Levels

Age in years
(Mean±SD)
Gender, N (%)

47.89 ± 6.37

Follow-up
Low
High
caffeine
caffeine
intake
intake
(≤250
(>250
mg/d)
mg/d)
46.63±7.33 48.87±5.38

Male
Female
Ethnicity, N (%)
White
Hispanic
Black
Other
Education in years,
N (%)
<12
12
>12
Income in dollars
per month

79 (60.8%)
51 (39.2%)

43 (68.3%)
20 (31.7%)

Variables

Total

P-value

0.490
0.090

36 (53.7%)
31 (46.3%)
0.285

7 (5.4%)
22 (16.9%)
98 (75.4%)
3 (2.3%)

4 (6.3%)
9 (14.3%)
50 (79.4%)
0 (0.0%)

3(4.5%)
13 (19.4%)
48 (71.6%)
3 (4.6%)
0.670

40 (30.8%)
59 (45.4%)
31 (23.8%)
495.91 ±
465.887

21 (33.3%)
29 (46.0%)
13 (20.6%)
498.80 ±
511.708

19 (28.4%)
30 (44.8%)
18 (26.9%)
492.89 ±
416.619

0.943

Note: P-values corresponds to χ2 tests for categorical variables and t-test for continuous
variables
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Table 2: Baseline Health and Lifestyle Characteristics of PLWH by Caffeine
Consumption Levels
Variables

Smoking
cigarettes

Total

Low caffeine
intake
(≤250 mg/d)

High caffeine
intake
(>250 mg/d)

Pvalue
0.582

80 (63.5%)
Yes 46 (36.5%)
No

39 (60.9%)
25 (39.1%)

41 (66.1%)
21 (33.9%)

Alcohol use

0.721
Yes 73 (57.9%)
No 53 (42.1%)

36 (56.3%)
28 (43.8%)

37 (59.7%)
25 (40.3%)

Yes 53 (48.2%)
No 57 (51.8%)

25 (43.9%)
32 (56.1%)

28 (52.8%)
25 (47.2%)

Yes 44 (33.8%)
No 86 (66.2%)

21 (32.3%)
44 (67.7%)

23 (35.4%)
42 (64.6%)

Drug use

0.445

Marijuana

0.853

Cocaine

0.706
Yes 41 (31.5%)
No 89 (68.5%)

19 (29.2%)
46 (70.8%)

22 (33.8%)
43 (66.2%)

Yes 10 (9.1%)
No 100 (90.9%)

6 (10.5%)
51 (89.5%)

4 (7.5%)
49 (92.5%)

Other Drugs

0.744

ART
Multi-combination
Yes 34 (26.2%)
22 (33.8%)
No 96 (73.8%)
43 (66.2%)
NRTI
Yes 76 (58.5%)
40 (61.5%)
No 54 (41.5%)
25 (38.5%)
NNRTI
Yes 17 (13.1%)
10 (15.4%)
No 113 (86.9%) 55 (84.6%)
PI
Yes 62 (47.7%)
34 (52.3)
No 68 (52.3%)
31 (47.7%)
All variables reported as N (%)
Note: P-values correspond to χ2 tests for all variables
ART: Antiretroviral therapy.
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0.072
12 (18.5%)
53 (81.5%)
0.594
36 (55.4%)
29 (44.6%)
0.604
7 (10.8%)
58 (89.2%)
0.380
28 (43.1%)
37 (56.9%)

Table 3: Follow-up Health and Lifestyle Characteristics of PLWH by Caffeine
Consumption Levels
Variables

Smoking
cigarettes

Total

Low caffeine
intake
(≤250 mg/d)

High caffeine
intake
(>250 mg/d)

0.271
79 (63.2%)
Yes 46 (36.8%)
No

41 (68.3%)
19 (31.7%)

38 (58.5%)
27 (41.5%)

Alcohol use

0.469
Yes 76 (60.3%)
No 50 (39.7%)

34 (56.7%)
26 (43.3%)

42 (63.6%)
24 (36.4%)

Yes 79 (65.8%)
No 41 (34.2%)

45 (75.0%)
15 (25.0%)

34 (56.7%)
26 (43.3%)

Drug use

0.054

Marijuana

0.141
Yes 67 (55.8%)
No 53 (44.2%)

38 (63.3%)
22 (36.7%)

29 (48.3%)
31 (51.7%)

Yes 48 (40.0%)
No 72 (60.0%)

29 (48.3%)
31 (51.7%)

19 (31.7%)
41 (68.3%)

Yes 13 (10.9%)
No 106 (89.1%)

6 (10.0%)
54 (90.0%)

7 (11.9%)
52 (88.1%)

33 (25.4%)
Yes 97 (74.6%)
No

20 (31.7%)
43 (68.3%)

13 (19.4%)
54 (80.6%)

Yes 83 (63.8%)
No 47 (36.2%)

40 (63.5%)
23 (36.5%)

43 (64.2%)
24 (35.8%)

Yes 18 (13.8%)
No 112 (86.2%)

9 (14.3%)
54 (85.7%)

9 (13.4%)
58 (86.6%)

Cocaine

0.093

Other drugs

ART
Multicombination

Pvalue

0.496

0.113

NRTI

1.000

NNRTI

1.000

PI

0.488
Yes 62 (47.7%)
No 68 (52.3%)

28 (44.4%)
35 (55.6%)

All variables reported as N (%)
Note: P-values correspond to χ2 tests all variables.
ART: Antiretroviral therapy.
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34 (50.7%)
33 (49.3%)

Table 4: Mean Caffeine Intake: Baseline and Follow-up Visit
Food source
Coffee
De-Caffeinated coffee
Expresso
Tea
Green tea
Energy drinks
Hot cocoa
Caffeinated soft drinks
Chocolate candy bars
Anacin
Appetite control pills

Baseline
161.26 ± 194.95
0.83 ± 9.21
14.40 ± 64.35
34.70 ± 64.32
7.34 ± 62.93
46.32 ± 134.42
1.03 ± 5.00
63.23 ± 92.98
3.69 ± 13.81
0.24 ± 2.80
4.61 ± 39.10

Follow-up
190.40 ± 205.03
0.03 ± 0.43
13.92 ± 57.82
31.58 ± 59.36
4.20 ± 21.62
9.61 ± 65.32
0.00 ± 0.00
29.66 ± 83.78
2.00 ± 17.93
0.00 ± 0.00
0.00 ± 0.00

P-value
0.206
0.329
0.942
0.640
0.594
0.005*
0.020*
<0.0001*
0.402
0.319
0.181

Total

337.63 ± 304.97

281.04 ± 260.85

0.890

All variables reported as mean ± SD
Note: P-values correspond to t-tests for all variables
*Significant

Table 5: Baseline PIRS Variables by Caffeine Consumption Levels
Variables

Low caffeine
intake
(≤250 mg/d)
Distress Score
31.44 ± 23.92
Sleep Parameter Score
7.56 ± 5.38
Quality of Life Score
6.87 ± 5.41
The Global PIRS Score
45.89 ± 133.13
All variables reported as mean ± SD
Note: P-values correspond to t-tests for all variables
*Significant

155

High caffeine
intake
(>250 mg/d)
72.33 ± 28.75
17.96 ± 7.28
15.44 ± 6.43
105.75 ± 41.12

P-value

0.002*
0.035*
0.588
0.002*

Table 6: Follow-Up PIRS Variables by Caffeine Consumption Levels
Variables

Low caffeine
intake
(≤250 mg/d)
24.77 ± 20.98
3.53 ± 5.81
4.50 ± 5.30
32.82 ± 30.10

High caffeine
intake
(>250 mg/d)
85.70 ± 22.52
20.34 ± 6.14
17.85 ± 4.46
128.89 ± 31.24

Distress Score
Sleep Parameter Score
Quality of Life Score
The Global PIRS
Score
All variables reported as mean ± SD
Note: P-values correspond to t-tests for all variables

P-value

0.543
0.022*
0.001*
0.449

Table 7: Mean Scores of PIRS Variables: Baseline and Follow-Up Visit
Variables
BL
PIRS SCORES
Distress Score
51.89 ± 33.39
Sleep Parameter Score
12.76 ± 8.24
Quality of Life Sore
11.16 ± 7.32
The Global PIRS Score
75.82 ± 47.81
All variables reported as mean ± SD
Note: P-values correspond to t-tests for all variables

FU
56.17 ± 37.48
12.20 ± 10.32
11.38 ± 8.27
79.76 ± 54.97

P-value
0.331
0.622
0.817
0.537

Table 8: Baseline PSQI Variables by Caffeine Consumption Levels
Variables

Low caffeine
intake
(≤250 mg/d)
0.03 ± 0.17
1.08 ± 0.32
0.72 ± 0.62
0.60 ± 0.63

Sleep Duration
Sleep Disturbance
Sleep Latency
Days Dysfunction due to
Sleepiness
Sleep Efficiency
0.22 ± 0.57
Overall Sleep Quality
0.58 ± 0.63
Need Meds to Sleep
0.52 ± 0.61
Global PSQI
3.75 ± 2.55
All variables reported as mean ± SD
Note: P-values correspond to t-tests for all variables
*Significant
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High caffeine
intake
(>250 mg/d)
1.14 ± 0.98
2.03 ± 0.74
2.35 ± 0.69
1.89 ± 0.85

P-value

1.15 ± 1.04
1.74 ± 0.85
1.89 ± 0.86
12.20 ± 4.51

0.568
0.002*
0.588
0.039*

0.068
0.039*
0.059
0.002*

Table 9: Follow-Up PSQI Variables by Caffeine Consumption Levels
Variables

Sleep Duration
Sleep Disturbance
Sleep Latency
Days Dysfunction due to
Sleepiness
Sleep Efficiency
Overall Sleep Quality
Need Meds to Sleep
Global PSQI

Low
caffeine
intake
(≤250 mg/d)
0.19 ± 0.56
0.68 ± 0.66
0.57 ± 0.79
0.41 ± 0.75

High
caffeine
intake
(>250 mg/d)
0.76 ± 0.87
1.93 ± 0.43
1.72 ± 0.57
1.99 ± 0.53

P-value

0.046*
0.532
0.579
0.002*

0.10 ± 0.46
0.29 ± 0.60
0.38 ± 0.65
2.62 ± 3.35

0.28 ± 0.57
1.94 ± 0.54
1.75 ± 0.53
10.36 ± 2.53

0.041*
0.002*
0.598
0.001*

All variables reported as mean ± SD
Note: P-values correspond to t-tests for all variables
*Significant
Table 10: Mean Scores of PSQI Variables: Baseline and Follow-Up Visit
Variables
BL
FU
PSQI SCORES
Sleep Duration
0.58 ± 0.89
0.48 ± 0.79
Sleep Disturbance
1.55 ± 0.74
1.32 ± 0.83
Sleep Latency
1.54 ± 1.05
1.16 ± 0.89
Days Dysfunction due to
1.25 ± 0.98
1.22 ± 1.02
Sleepiness
Sleep Efficiency
0.68 ± 0.96
0.19 ± 0.53
Overall Sleep Quality
1.16 ± 0.94
1.14 ± 1.01
Need Meds to Sleep
1.21 ± 1.01
1.08 ± 0.90
Global PSQI
7.98 ± 5.59
6.61 ± 4.87
All variables reported as mean ± SD
Note: P-values correspond to t-tests for all variables
*Significant

P-value
0.292
0.019*
0.001*
0.852
<0.0001*
0.851
0.299
0.031*

Table 11: Baseline GAD-7 Scores by Caffeine Consumption Levels
Variables

Low caffeine intake
High caffeine intake
(≤250 mg/d)
(>250 mg/d)
GAD-7 scores 4.42 ± 3,441
12.78 ± 5.014
All variables reported as mean ± SD
Note: P-values correspond to t-tests for all variables
*Significant
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P-value
0.024*

Table 12: Follow-Up GAD-7 Scores by Caffeine Consumption Levels
Variables

Low caffeine
High caffeine
intake
intake
(≤250 mg/d)
(>250 mg/d)
GAD-7 scores
3.41 ± 1.272
14.03 ± 0.361
All variables reported as mean ± SD
Note: P-values correspond to t-tests for all variables
*Significant

P-value

0.043*

Table 13: Mean GAD-7 Scores: Baseline and Follow-Up Visit
Variables
BL
FU
GAD-7 Score
8.60 ± 5.999
8.88 ± 6.450
All variables reported as mean ± SD
Note: P-values correspond to t-tests for all variables

P-value
0.711

Table 14: Linear Regression of the Effect of Caffeine Consumption on
PIRS Variables
PIRS Varables
Beta
1.088
1.022

Unadjusted
SE
P-value
1.006
0.239
1.001
0.599

Beta
1.506
1.890

Adjusted†
SE
P-value
1.103
0.048*
1.096
0.586

Distress Score
Sleep Parameter
Score
Quality of Life
1.018
1.001
0.002*
1.784
1.226
0.001*
Score
The Global PIRS
1.128
1.057
0.048*
1.776
1.120
0.046*
a
Score
a
Model R2 = 0.213, F (16) = 28.367, P= 0.042.
†
Model adjusted for age, income, race ethnicity, time from diagnosis of HIV, drug,
tobacco and alcohol use, sleep medications and types of ART medication.
*Significant
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Table 15: Linear Mixed Model (LMM) Analysis of Overtime Changes in PIRS Variables
due to Caffeine Consumption
PIRS variables
Beta
1.095
1.256

Unadjusted
SE
P-value
1.004
0.045*
1.127
0.587

Beta
1.347
1.304

Adjusted†
SE
P-value
1.200
0.036*
1.183
0.045*

Distress Score
Sleep Parameter
Score
Quality of Life
1.202
1.114
0.046
1.767
1.168
0.006*
Score
The Global PIRS
1.141
1.070
0.035*
1.678
1.010
0.047*
Score a
a
Model: -2 Restricted Log Likelihood = 1952.149; Akaike’s Information Criteria (AIC) =
1956.149; Schwarz’s Bayesian Criteria (BIC) = 1962.725.
†
Model adjusted for age, income, race ethnicity, time from diagnosis of HIV, drug,
tobacco and alcohol use, sleep medications and types of ART medication.
*Significant

Table 16: Baseline Multinomial Logistic Regression of the Effect of Caffeine
Consumption Levels on Global PIRS Score Categories

Caffeine
intake

OR

Adjusted†
95% CI

Unadjusted
95% CI

POR
Pvalue
value
PIRS ≤50 (No Insomnia) versus PIRS 51-100 (Moderate Insomnia)
Low
Ref
Ref
Ref
Ref
High 4.395 (0.436 –25.689) 0.190
9.321 (3.324-21.402)
0.018*
PIRS ≤50 (No Insomnia) versus PIRS >100 (Severe Insomnia)
Low
Ref
Ref
Ref
Ref
High 9.314 (0.928 –35.245) 0.095 17.958 (10.153 – 94.512) 0.003*
R2 = 0.176 (Cox and Snell), 0.188 (Nagelkerke). χ2 (32) = 42.679, P=0.031
†
Model adjusted for age, income, race ethnicity, time from diagnosis of HIV, drug,
tobacco and alcohol use, sleep medications and types of ART medication.
*Significant
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Table 17: Over Time Multinomial Logistic Regression of the Effect of Caffeine
Consumption Levels on Global PIRS Score Categories

Caffeine
intake

OR

Adjusted†
95% CI

Unadjusted
95% CI

POR
Pvalue
value
PIRS ≤50 (No Insomnia) versus PIRS 51-100 (Moderate Insomnia)
Low
Ref
Ref
Ref
Ref
High 3.469 (0.369-13.535)
0.130 15.550 (4.982 -96.042) 0.019*
PIRS ≤50 (No Insomnia) versus PIRS >100 (Severe Insomnia)
Low
Ref
Ref
Ref
Ref
High 9.667 (0.965-963.457) 0.110 23.988 (8.245 – 5.652)
0.013*
2
2
R = 0.170 (Cox and Snell), 0.181 (Nagelkerke). χ (30) = 37.654, P=0.034
†
Model adjusted for age, income, race ethnicity, time from diagnosis of HIV, drug,
tobacco and alcohol use, sleep medications and types of ART medication.
*Significant

Table 18: Linear Regression of the Effect of Caffeine Consumption on PSQI Variables
PSQI Variables

Unadjusted
SE
P-value
1.220
0.568
1.124
0.564
1.188
0.786
1.173
0.239

Adjusted†
SE
P-value
1.228
0.049*
1.380
0.540
1.015
0.548
1.193
0.043*

Beta
Beta
Sleep Duration
1.194
1.199
Sleep Disturbance 1.201
1.932
Sleep Latency
1.271
1.258
Days Dysfunction 1.259
1.250
due to Sleepiness
Sleep Efficiency
2.157
2.430
0.568
2.195
1.263
0.049*
Overall Sleep
2.239
2.175
0.002*
2.248
2.182
0.001*
Quality
Need Meds to
1.268
1.176
0.987
1.274
1.197
0.589
Sleep
Global PSQI a
2.159
1.812
0.048*
2.587
1.058
0.038*
a
Model R2 = 0.191, F (15) = 26.491, P= 0.034.
†
Model adjusted for age, income, race ethnicity, time from diagnosis of HIV, drug,
tobacco and alcohol use, sleep medications and types of ART medication.
*Significant
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Table 19: Linear Mixed Model (LMM) Analysis of Overtime Changes in PSQI Variables
due to Caffeine Consumption
PSQI variables
Beta
1.162
1.216
1.245
1.263

Unadjusted
SE
P-value
1.054
0.450
1.112
0.570
1.154
0.568
1.146
0.460

Beta
1.345
1.505
1.323
1.353

Adjusted†
SE
P-value
1.134
0.042*
1.122
0.032*
1.170
0.023*
1.161
0.036*

Sleep Duration
Sleep Disturbance
Sleep Latency
Days Dysfunction
due to Sleepiness
Sleep Efficiency
1.104
1.016
0.450
1.212
1.178
0.025*
Overall Sleep
1.256
1.143
0.570
1.575
1.152
0.058
Quality
Need Meds to
1.258
1.136
0.470
1.494
1.147
0.049*
Sleep
Global PSQI a
2.150
1.067
0.048*
2.594
1.190
0.006*
a
Model: -2 Restricted Log Likelihood = 1074.021; Akaike’s Information Criteria (AIC) =
1078.021; Schwarz’s Bayesian Criteria (BIC) = 1084.608.
†
Model adjusted for age, income, race ethnicity, time from diagnosis of HIV, drug,
tobacco and alcohol use, sleep medications and types of ART medication.
*Significant
Table 20: Baseline Multinomial Logistic Regression of the Effect of Caffeine
Consumption Levels on Global PSQI Score Categories

Caffeine
intake

OR

Unadjusted
95% CI

P-value

OR

Adjusted†
95% CI

Pvalue

PSQI ≤5 (Good Sleep Quality) versus PSQI 6-10 (Poor Sleep Quality)
Low
Ref
Ref
Ref
Ref
High 2.585 (0.625 - 93.988) 0.058
18.659 (8.016 -165.741)
0.013*
PSQI ≤5 (Good Sleep Quality) versus PSQI >10 (Worst Sleep Quality)
Low
Ref
Ref
Ref
Ref
High 3.899 (1.609 -193.863) 0.047* 19.060 (16.906-186.786) 0.008*
R2 = 0.218 (Cox and Snell), 0.218 (Nagelkerke). χ2 (28) = 44.688, P =0.038
†
Model adjusted for age, income, race ethnicity, time from diagnosis of HIV, drug,
tobacco and alcohol use, sleep medications and types of ART medication.
*Significant
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Table 21: Over Time Multinomial Logistic Regression of the Effect of Caffeine
Consumption Levels on Global PSQI Score Categories

Caffeine
intake

OR

Adjusted†
95% CI

Unadjusted
95% CI

POR
Pvalue
value
PSQI ≤5 (Good Sleep Quality) versus PSQI 6-10 (Poor Sleep Quality)
Low
Ref
Ref
Ref
Ref
High 2.994 (0.382 – 7.067) 0.509 33.577 (24.695 -82.962) 0.039*
PSQI ≤5 (Good Sleep Quality) versus PSQI >10 (Worst Sleep Quality)
Low
Ref
Ref
Ref
Ref
High 3.470 (0.627 - 2.939)
0.870 65.201 (49.882-96.662) 0.015*
R2 = 0.165 (Cox and Snell), 0.174 (Nagelkerke). χ2 (30) = 29.596, P =0.042
†
Model adjusted for age, income, race ethnicity, time from diagnosis of HIV, drug,
tobacco and alcohol use, sleep medications and types of ART medication.
*Significant
Table 22: Linear Regression of the Effect of Caffeine Consumption on GAD-7 Scores
Generalized
Anxiety

Unadjusted

Adjusted†

Beta
SE
P-value Beta
SE
P-value
GAD-7 Score a
0.963
1.375
0.674
1.647
0.917
0.027*
a
2
Model R = 0.182, F (17) = 22.279, P = 0.039.
†
Model adjusted for age, income, time from diagnosis of HIV, drug use, alcohol
consumption, smoking status and types of ART medications.
*Significant
Table 23: Linear Mixed Model (LMM) Analysis of Over Time Changes in GAD-7
Scores due to Caffeine Consumption
Generalized
Anxiety

Adjusted†

Unadjusted

Beta
SE
P-value Beta
SE
P-value
GAD-7 Score a 0.917
0.848
0.569
0.937
0.218
0.048*
a
Model: -2 Restricted Log Likelihood = 1096.531; Akaike’s Information Criteria (AIC) =
1100.531; Schwarz’s Bayesian Criteria (BIC) = 1107.087.
†
Model adjusted for age, income, time from diagnosis of HIV, drug use, alcohol
consumption, smoking status and types of ART medications.
*Significant
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Table 24: Baseline Multinomial Logistic Regression of the Effect of Caffeine
Consumption Levels on GAD-7 Score Categories

Caffeine
intake

OR

Adjusted†
95% CI

Unadjusted
95% CI

POR
Pvalue
value
GAD-7 Scores ≤5 (Minimal Anxiety) versus GAD-7 Scores 6-10 (Mild
Anxiety)
Low
Ref
Ref
Ref
Ref
High 1.150 (0.387 – 7.009) 0.482
5.107 (1.568 -33.499)
0.027*
GAD-7 Scores ≤5 (Minimal Anxiety) versus GAD-7 Scores 11-15
(Moderate Anxiety)
Low
Ref
Ref
Ref
Ref
High 4.714 (0.578 – 8.734) 0.160
6.091
(2.333 – 35.841) 0.002*
GAD-7 Scores ≤5 (Minimal Anxiety) versus GAD-7 Scores 15-20
(Severe Anxiety)
Low
Ref
Ref
Ref
Ref
High 5.904 (0.714 – 9.150) 0.080 17.185 (5.185 -88.185)
0.001*
R2 = 0.167 (Cox and Snell), 0.172 (Nagelkerke). χ2 (48) = 42.416, P =0.035
†
Model adjusted for age, income, time from diagnosis of HIV, drug use, alcohol
consumption, smoking status and types of ART medications.
*Significant
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Table 25: Over Time Multinomial Logistic Regression of the Effect of Caffeine
Consumption Levels on GAD-7 Score Categories

Caffeine
intake

Unadjusted
95% CI

OR

Pvalue

OR

Adjusted†
95% CI

P -value

GAD-7 ≤5 Scores (Minimal Anxiety) versus GAD-7 Scores 6-10 (Mild
Anxiety)
Low
Ref
Ref
Ref
Ref
High 1.160 (0.387 –17.009)
0.482 12.107 (1.568-33.499)
0.037*
GAD-7 Scores ≤5 (Minimal Anxiety) versus GAD-7 Scores 10-15
(Moderate Anxiety)
Low
Ref
Ref
Ref
Ref
High 2.714 (0.578 –28.734)
0.316 22.911 (6.333-53.841)
0.033*
GAD-7 Scores ≤5 (Minimal Anxiety) versus GAD-7 Scores 15-20
(Severe Anxiety)
Low
Ref
Ref
Ref
Ref
High 3.222 (0.906 –29.063)
0.179 32.185 (7.185-87.185)
0.002*
2
2
R = 0.173 (Cox and Snell), 0.180 (Nagelkerke). χ (42) = 46.202, P =0.043
†
Model adjusted for age, income, time from diagnosis of HIV, drug use, alcohol
consumption, smoking status and types of ART medications.
*Significant
Table 26: Linear Regression Analysis of the Effect of Global PIRS, Global PSQI and
GAD-7 Scores on Immunological and Virologic Markers of Disease Progression

Beta

Unadjusted
SE
P-value

a

Beta

Adjusted†
SE
P-value

Global PIRS
CD4 square root -0.913 0.128
0.316
-1.202 0.649
0.015*
Log 10 Viral load 1.659
0.735
0.698
1.949
0.933
0.045*
b
Global PSQI
CD4 square root -0.782 0.110
0.479
-1.149 0.931
0.036*
Log 10 Viral load 1.176
0.924
0.741
1.988
0.828
0.031*
GAD-7 c
CD4 square root -0.476 0.239
0.643
-1.122 0.964
0.031*
Log 10 Viral load 1.508
1.219
0.417
1.269
0.425
0.029*
a
2
Model R = 0.187, F (14) = 32.390, P = 0.041.
b
Model R2 = 0.188, F (14) = 28.833, P =0.046.
c
Model R2 = 0.220, F (14) = 20.862, P = 0.014.
†
Model adjusted for time from diagnosis of HIV, drug use, smoking status, alcohol use
and different types of ART medications. *Significant

164

Table 27: Linear Mixed Model Analysis of Over Time Changes in Immunological and
Virologic Markers of Disease Progression due to Global PIRS, Global PSQI and GAD-7
Scores
Unadjusted
SE
P-value

Adjusted†
SE
P-value

Beta
Beta
Global PIRS a
CD4 square root
-0.643 0.126
0.817
-0.923 0.680
0.732
Log 10 Viral load
0.848
0.714
0.732
1.213
0.615
0.890
b
Global PSQI
CD4 square root
-0.537 0.638
0.401
-1.081 0.722
0.260
Log 10 Viral load
0.918
0.814
0.201
1.013
0.716
0.429
c
GAD-7
CD4 square root
-0.366 0.152
0.900
-1.011 0.583
0.838
Log 10 Viral load
0.960
0.811
0.608
0.984
0.213
0.880
a
Model: -2 Restricted Log Likelihood = 1146.722; Akaike’s Information Criteria (AIC) =
1150.722; Schwarz’s Bayesian Criteria (BIC) = 1157.005.
b
Model: -2 Restricted Log Likelihood = 1140.831; Akaike’s Information Criteria (AIC)
=1144.831; Schwarz’s Bayesian Criteria (BIC) = 1151.115.
c
Model: -2 Restricted Log Likelihood = 1142.502; Akaike’s Information Criteria (AIC) =
1146.502; Schwarz’s Bayesian Criteria (BIC) = 1152.785.
†
Model adjusted for time from diagnosis of HIV, drug use, smoking status, alcohol use
and different types of ART medications.
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CHAPTER-VI: CAFFEINE INTAKE AND ITS ASSOCIATION WITH
NUTRITIONAL PARAMETERS IN MIAMI ADULT STUDIES OF HIV (MASH)
COHORT—AN OBSERVATIONAL STUDY
ABSTRACT
Introduction: In a number of studies, people living with HIV (PLWH) have reported
inadequate dietary intakes and compromised body compositions measures even when
they were on ART. Additionally, weight-loss and reduced body fat reserves were
associated with accelerated HIV-disease progression. Although the literature abounds on
studies on caffeine consumption and its relationship with changes in bodyweight and
body composition in healthy populations, similar studies in PLWH are few.
Methods: We examined the impact of high caffeine consumption on dietary intake and
body composition measures in a convenience sample of 130 HIV+ participants (65
consuming ≤ 250 mg/day and 65 consuming > 250 mg/day of caffeine) recruited from the
Miami Adult Studies on HIV (MASH) cohort. This study included a baseline and a 3month follow-up visits. After obtaining written informed consent, caffeine consumption
was estimated using Modified Caffeine Consumption Questionnaire (MCCQ).
Information on demographics, anthropometries, body composition measures, substance
use, 24-hour dietary recall, Food Security Scores and antiretroviral therapy (ART) were
obtained from the MASH cohort database. T-tests and chi-square were used to describe
demographics and health and lifestyle characteristics. Linear regressions were used to
analyze baseline data for the effects of caffeine intake on the outcome variables. Linear
Mixed Models were used to estimate the effect of caffeine consumption on these
parameters over time.
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Results: The mean age of the cohort was 47.89 ± 6.37 years, 60.8% were males and
75.4% were African-Americans. All participants were on antiretroviral treatment (ART)
throughout the study. Mean caffeine intake at the baseline was 161.26 ± 194.95 mg/day
(3-8 cups of coffee) (Range: 0 mg-1498 mg/day) and did not change significantly at the
3-month visit. Fat (93.43 ± 48.484 vs 170.94 ± 44.585, P=0.048), carbohydrate (259.15
± 132.242 vs 341.83 ± 133.437, P=0.048) and protein (85.24 ± 40.866 vs 94.82 ± 54.556,
P=0.046) intakes were significantly lower in participants consuming > 250 mg of
caffeine/day, compared to those who consumed ≤ 250 mg of caffeine/day. Higher
caffeine consumption was also associated with lower fat mass (β=-0.994, P=0.042),
lower caloric intakes (β=-1.643, P=0.042) and lower fat consumption (β=-1.902,
P=0.044), in conjunction with the use of other anorexic agents such as cocaine use and
amphetamine after adjusting for HIV viral load and ART medications.
Conclusion: Higher caffeine consumption was associated with lower dietary intakes of
macronutrients and lower fat reserves. These associations also became weaker or
disappeared when adjusting for, or excluding, the use of other anorexic and stimulant
drugs such as cocaine and methamphetamine, suggesting that caffeine may worsen the
action of these drugs. Future large scale studies are needed to understand the level of
caffeine’s influences on these health and nutritional outcomes.
Keywords: Modified Caffeine Consumption Questionnaire (MCCQ), HIV infection,
Body Mass Index (BMI), Lean Body Mass (LBM).
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INTRODUCTION
With significant improvements in availability and accessibility of combination
ART, HIV is currently a chronic disease with decreasing incidence, increasing prevalence
and 97% decrease in progression to AIDS and death, thereby increasing the number of
people living with HIV (PLWH).1 According to CDC’s estimates in 2013, there were
about 1.2 million PLWH in the US2 and 26,760 of them were living in Miami.3
Most of the PLWH in Miami live in marginalized neighborhoods with limited
resources.4 Many socioeconomic factors such as homelessness, illegal commercial sex,
drug abuse, alcohol addiction, extreme tobacco use and criminalization act as barriers for
access to nutritious foods and supplements and compliance with ART.5-10 Though the
majority of the MASH cohort, from which our participants were recruited, received social
security benefits and some forms of food assistance, many experience food insecurity.10
Food insecurity and decreased food intake are associated with uncontrolled HIV viral
load and increased mortality even in participants on ART.11,12 Similarly weight loss and
lower BMI are associated with faster disease progression as measured by lower CD4 cell
counts and uncontrolled HIV viral load even in PLWH on ART.13-15
Caffeine shows anorexic, lipolytic and thermogenic effects due to its inhibitory
action on cAMP degradation pathway, as well as increased cAMP generation via
stimulation of beta-adrenergic receptors.16 In a double blind placebo controlled study on
healthy volunteers, caffeine intake (100, 200 and 400 mg/day) produced a positive and
dose-dependent increase in resting energy expenditures (REE), (r = 0.86; P< 0.001), after
controlling for plasma lactate levels and plasma triglyceride levels.17 In another double
blind placebo controlled study on the supplement Meltdown®, containing caffeine (400
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mg/pill), participants who were administered the supplement once per day, recorded
higher Area Under the Curve (AUC) for serum norepinephrine levels (NE), glycerol, free
fatty acids (FFA), and basal metabolic rate (BMR) compared to placebo, indicating
increased Resting Energy Expenditures (REE).18 Similar effects were reported in another
study where 450 mg/day of caffeine produced higher AUC for resting oxygen uptake
(VO2), which is also a measure of REE.19 Caffeine at a dose of 700 mg/day also
produced 2-fold increase in lipid turnover (P < 0.005), increased thermic effect (P <
0.001), and 2.3 times increased oxidative free fatty acid (FFA) disposal (P < 0.01)
compared to placebo pills, indicating increased REE and lipid breakdown.16
Caffeine consumption (250 mg/day) was also associated with lower plasma
levels of antioxidant trace elements such as Zinc And Selenium after controlling for
dietary intakes, age, physical activity and substance use.20 This relationship also showed
a dose-response pattern, with lower caffeine consumption associated with decreased
depletion of antioxidant trace elements.20
In summary, the literature supports that caffeine acted as an anorexic agent,
increased energy expenditure, precipitated weight loss, and depleted antioxidant
nutrients. Such effects could be detrimental to PLWH, because many of them already
experience food scarcity and insecurity.10 Our study evaluated the effects of caffeine
consumption on nutrient intake, body composition and nutritional indicators in a group of
PLWH who were recruited from the MASH cohort. This study also examined the
relationship between food security scores and caffeine consumption levels. In addition,
this study also examined the net effects of body composition measures and macronutrient
intakes on markers of HIV disease progression (CD4 counts and viral load).
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METHODS
Study Design and Setting
The present study recruited a convenience sample of 130 participants (65 consuming ≤
250 mg/day and 65 consuming > 250 mg/day of caffeine) from the MASH cohort, which
consisted of 803 HIV positive and 78 uninfected participants, followed for more than 10
years at the FIU research clinic in the Borinquen Health Care Center (BHCC). The
BHCC provides comprehensive range of health and social services to a culturally diverse
low income community. The recruitment for the present study took place from February
to July 2014. The present study included a baseline and a 3-month follow-up visit, and
participants received $5 as partial reimbursement for their time and efforts, for each of
the two visits. The initial screening included detailed explanation of the study as well as
obtaining informed voluntary written consent for participation. In order to obtain a study
sample of 128 participants as estimated in our sample size calculations, we screened a
total of 150 subjects, enrolled 130 participants and excluded 20 ineligible participants.
The present study also included secondary analysis of relevant variables collected for the
MASH cohort studies. Data collected during the baseline and 3-month visits were used
for the analyses of descriptive and inferential statistics. The inclusion and exclusion
criteria for the MASH cohort are presented in “Chapter 3: Methodology” and applicable
to our current study. The additional inclusion criteria for participants in the present study
were: enrollment in the MASH cohort; receiving ART; and willingness to participate in a
study with two visits, a baseline and one follow-up visit at 3 months. The exclusion
criteria were: cardiovascular abnormalities or implanted pacemakers; morbid medical
conditions such as uncontrolled hypertension, anemia, chronic inflammatory diseases or
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mal-absorption syndromes. The Institutional Review Board at Florida International
University approved the study protocol and research procedures.
Survey Instruments, Outcome Measures and Variables
The questionnaires used in the present study were previously field tested and validated in
several large scale studies.21-24 However, we pre-tested these questionnaires on 15
participants from the MASH cohort to ascertain their applicability and we determined
that revisions were not necessary for the questionnaires.
Caffeine consumption questionnaire: We used the Modified Caffeine Consumption
Questionnaire (MCCQ) developed by Preston et al in the year 1998.25 This questionnaire
is easy to understand, compact, organized and reports adequate compliance, validity and
reliability.25 This questionnaire was field tested and validated in several large scale
studies and adequately reflected average daily caffeine consumption levels.21 It includes a
total of 21 sources of caffeine classified in to three groups, ‘Beverages’, ‘Over the
counter medications’ and ‘Prescription medications’. This questionnaire also included
‘Total caffeine consumption per day’ by adding these individual sources. Caffeine
consumption was analyzed both as a continuous variable and a categorical variable.
For both naturally occurring and artificially added caffeine sources, FDA
considers 400 mg/day (6-7 cups of coffee) to be generally safe and not associated with
any dangerous side effects.26,27 The World Health Organization (WHO) defines caffeine
overuse as daily consumption beyond 500 mg/d.28,29 Beyond this level caffeine produces
visible adverse effects collectively known as ‘caffeinism’. The World Health
Organization (WHO) has also cautioned that these adverse effects could be precipitated at
much lower doses depending on the physiological profiles of individuals as well as the
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genetic makeup of the population.28,29 The International Classification of Diseases (ICD)
manual considers caffeine consumption above 250 mg/day to be associated with many
mental and behavioral disorders though it is inconclusive whether such effects would be
uniformly applicable in the general population.13 The Diagnostic and Statistical Manual
of Mental Disorders (DSM-5) considers consumption below 250 mg/day to be generally
safe and above this level to be associated with many adverse effects such as withdrawal,
addiction, irritability and craving.30 Summarizing these cutoffs, we concluded that
caffeine consumption below 250 mg/day that is equivalent to 4 cups of coffee,
irrespective of the sources is generally safe and not associated with adverse effects. In
this study, caffeine categories included low (≤250 mg/day, within safe levels) and high
(>250 mg/day, beyond safe levels) based on these recommendations.
Nutritional Status Assessment
Dietary intakes: All research personnel in the MASH cohort studies were trained to
obtain 24-hour dietary recalls, which were used to estimate daily dietary and nutrient
consumption by the participants. During each MASH cohort study visit, participants were
queried about foods and beverages consumed on the day prior to the visit. All details
including cooking methods, amount consumed, additional ingredients and seasonings and
food brands were recorded to ensure comprehensiveness of the obtained information. We
also used props like food models and measuring cups to ensure accuracy of the amounts
and volumes consumed and to provide cues for better recall of consumed foods. We used
Nutribase Professional Software Version 9 (Cybersoft Inc, 2011), into which all the
collected information were entered to obtain a detailed estimation of kilocalories,
macronutrients and micronutrients consumed by the participants. Adequacy of nutrient
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intakes were determined using the Daily Values (DV), developed by the FDA by
combining two sets of reference values, the Daily Reference Values (DRV) and the
Reference Daily Intakes (RDI), to include a comprehensive list of all essential nutrients,
including the nutrients for which Recommended Dietary Allowances (RDA) are not
established.31
Body composition measures: In the MASH cohort studies, after screening the
participants, height was recorded immediately using a stadiometer, calibrated according
to the instructions in the user’s manual. Height was recorded to the nearest 0.5 inch after
removing shoes, socks and other footwear. Height was recorded only once to ensure that
it was uniform and there were no minor variations during every successive visit. Weight
was measured every visit to the nearest 0.1 lbs. using a standard weighing machine which
was calibrated and maintained throughout the study. Participants were requested to
remove their watches, shoes, mobile phones or other heavy materials possessed by them.
The data so obtained, along with age, were entered into the bio-impedance machine
(Biodynamics-450)32 to obtain several body composition measures, including body cell
mass, extracellular mass, lean body mass (LBM), fat mass, body mass index (BMI) and
intracellular and extracellular fluid levels. In addition, we also obtained the waist-to-hip
ratio using a non-stretchable tape to measure the waist and hip circumferences at the
narrowest levels of the waist and widest levels of the hip.
Biochemical indicators: Nutritional biomarkers which included serum albumin,
hemoglobin and hematocrit were obtained at the semiannual MASH visits . In addition,
participants provided their most recent laboratory reports from their regular treatment
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visits. The MASH cohort studies also collected other relevant laboratory and clinical data
after the participants signed a medical release form.
Immunological and virologic variables: CD4 counts, viral loads and other clinical
variables were obtained from participants’ medical charts and collected by the MASH
cohort study after appropriate medical release by the participants. In the current research,
CD4 counts and viral loads were analyzed as continuous variables and transformed into
CD4 square root and log 10 viral load to ensure normal distribution and better model fit
criteria.
Control Variables
Demographic and socioeconomic information: Demographic variables used for the
current study included age, gender, race/ethnicity, education and income levels. A
number of health and lifestyle related factors such as tobacco use, alcohol consumption,
and illicit drug use were also obtained from the MASH data repository. All these
variables were controlled in our analysis based on studies associating these variables with
adverse health and nutritional outcomes in HIV.33-46
ART medications: We obtained information about types of the antiretroviral medications
prescribed by their physicians during the MASH cohort visits. We controlled for these
variables because some of the antiretroviral medications were associated with altered
nutrition and body composition measures.47-49
Statistical Analysis
Field data were collected in paper based questionnaires and later entered into RedCap
database, imported into SPSS version 21 for Windows (Armonk, NY: IBM Corp), and
merged into a single dataset for analysis. Descriptive statistics used to understand the

179

characteristics of the cohort were expressed in terms of means, standard deviations and
percentages and were separated based on low and high intakes of caffeine using the
cutoff points: > 250 mg/day for high intake; and ≤ 250 mg/day for low or no intake. Ttests and chi square tests were used to compare the differences in demographics, health
and lifestyle characteristics, nutrient intakes and percentages of participants who were not
meeting the Daily Values (DV) for the nutrients, between the low and high caffeine
groups. Paired sample t-tests were used to understand the changes in caffeine and nutrient
intakes between the baseline and 3-month visits. Linear regression analyses were used to
estimate the strength of the association of caffeine intake as a continuous variable with
body composition measures; nutritional status indicators, dietary intakes and food
security scores. Assumptions of linear regression were followed prior to analyses. Linear
mixed models (LMM) were used to determine the changes in these associations over
time. For parameter estimation in LMM models, Restricted Maximum Likelihood
(REML) was used. Multinomial logistic regressions were used to determine the strength
of associations between different categories of caffeine intake (low and high) and
different categories of food insecurity measured through FSQ scores. Linear Regression
was also used to estimate the strength of association between body composition, dietary
intakes and food security scores and the markers of HIV disease progression (CD4 counts
and viral load). Linear Mixed Models were used to estimate the changes over time in the
strength of these associations. For both liner and logistic regressions, as well as liner
mixed model analysis, we initially used crude models and subsequently adjusted for
covariates such as age, gender, race/ethnicity, grades of schooling, income, time from
diagnosis of HIV, drug use, alcohol use, smoking and different types of antiretroviral
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medications, based on studies associating these risk factors with adverse health and
nutritional outcomes in HIV.33-49 These covariates were also tested for significant
associations with the outcome variables using bivariate analysis before being
incorporated into the models. To increase the validity of the models, mutlicollinearity
among covariates was tested prior to the analyses. Adjusted models included non-missing
values for all independent variables included in the models. Statistical significance was
set at P < 0.05 for all the analyses.
RESULTS
Demographic and Socio-economic Characteristics
A total of 130 participants were included in the study and 79 (60.8%) were men.
The mean age of the sample was 47.89 ± 6.37 years. Most of the participants were
African Americans (75.4%), Hispanics constituted 16.9%, Whites constituted 5.4% and
other races were 4.6 percent. Less than one fourth (23.8%) of the participants had college
education, while 45.4% were high school graduates and 30.8% has some form of primary
education. All participants had incomes under the level of poverty and the mean income
was $495.91± 465.887. There were no significant differences in any socio-demographic
variables between low and high levels of caffeine consumption in both baseline and
follow-up visits (Table-1A, 1B).
Health/lifestyle Characteristics
Sixty one percent of the participants reported smoking within the past six weeks
of their scheduled baseline visits, 57.9% reported alcohol use and 48.2% tested positive
for illicit drug use. Similarly, 63.2% reported smoking, 60.3% reported alcohol use and
65.8% tested positive for illicit drug use during the follow-up visit.
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All participants were on ART during the entire duration of the study.
Antiretroviral therapy took many forms, 58.5% were on NRTI, 13.1% were on NNRTI
and 47.7% were on PI in several combinations, 26.2% of the participants were using a
one-pill multi-drug combination such as Atripla, Truvada and Combivir during the
baseline visit. At the 3-month visit, 63.8% were on NRTI, 13.8% were on NNRTI and
47.7% were on PI, and 25.4% were on a one-pill multi-drug combination. There were no
significant differences in the distribution of these variables between low and high levels
of caffeine consumption in both baseline and follow-up visits, or in the distribution of
these variables between baseline and follow-up visits (Tables 2 and 3).
Caffeine Consumption from Different Sources
The mean total caffeine consumption from all sources was 337.63 ± 304.97 mg/day
(Range: 0-1,498 mg/day) at baseline, and 281.04 ± 260.85 mg/day (Range: 0-1,175
mg/day) at follow-up. Coffee constituted the largest source of caffeine and mean
consumption levels were 161.26 ± 194.95 mg/day at baseline, and 190.40 ± 205.03
mg/day at follow-up. Caffeinated soft drinks constituted the second largest source of
caffeine and mean consumption levels were 63.23 ± 92.98 mg/day at baseline, and 29.66
± 83.78 mg/day at follow-up. There were no significant differences between baseline and
follow-up visits with respect to total caffeine consumption or caffeine from most of the
sources. However, there was significant decrease in consumption of caffeinated soft
drinks (63.23 ± 92.98 vs. 29.66 ± 83.78, P<0.00001), energy drinks (46.32 ± 134.42 vs.
9.61 ± 65.32, P=0.005) and hot cocoa (1.03 ± 5.00 vs. 0.00 ± 0.00, P=0.020) from the
baseline to the follow-up visits (Table 4). For all other sources of caffeine in the
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questionnaire, except the ones enlisted in Table 4, participants reported none to negligible
levels of consumption at both the visits.
Dietary Intakes by Caffeine Consumption Status
During the baseline visit, total fat (93.43 ± 48.484 vs 170.94 ± 44.585, P=0.048),
carbohydrate (259.15 ± 132.242 vs 341.83 ± 133.437, P=0.048) and protein intakes
(85.24 ± 40.866 vs 94.82 ± 54.556, P=0.046) were significantly lower in participants
consuming > 250 mg of caffeine per day, compared to participants consuming ≤ 250 mg
of caffeine per day (Table 5). Similarly intakes of Sodium, Chloride, Potassium, Calcium,
Magnesium, Phosphorus, Vitamin C, Thiamine, Riboflavin, Niacin, Vitamin B 6 , Vitamin
B 12 , Iron, Zinc and Selenium were also significantly lower in high caffeine consumers
compared to low caffeine consumers (Table 5). During the follow-up visits, total calories
(1858.27 ± 932.055 vs 2100.52 ± 1127.868, P=0.017), carbohydrate (151.32 ± 116.795
vs 255.27 ± 152.914, P=0.042), protein (43.48 ± 37.841 vs 86.49 ± 42.173, P=0.017) and
fat intake (77.52 ± 56.469 vs 183.72 ± 68.771, P=0.026) were significantly lower in high
caffeine consumers compared to low caffeine consumers (Table 6). Total intakes of
Cholesterol, Sodium, Potassium, Thiamine, Riboflavin, Niacin, and Vitamin B 6 were also
significantly lower in high caffeine group compared to low caffeine group (Table 6).
However, there were no significant differences in any nutrient intakes between baseline
and follow-up visit (Table 7). During the baseline visit, nutrient intakes were below Daily
Values (DV), for many micronutrients (Table 8). All participants reported nutrient
intakes below DV for chromium, molybdenum, and chloride. More than 90% of the
participants reported consumption below DV for Potassium, Vitamin D, Vitamin E,
Vitamin K, Pantothenic Acid, Iodine, Copper, and Manganese. For many of the
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remaining nutrients, 50.0% to 87.7% of the participants reported consumption below DV
(Table 8). For total fat, Saturated Fat, Sodium, and protein, less than 50% of participants
reported consumption below DV (Table 8). For most of the nutrients, there were no
significant differences between low and high caffeine consumers with respect to the
proportion of participants failing to meet the DV, except Sodium (24.6% vs 10.8%,
P=0.039). Similar trends were observed in follow-up visit (Table 9). More than 99% of
the participants reported consumption below DV for Chromium, Molybdenum and
Chloride. Similar to baseline findings, only for total fat, saturated fat, Sodium, and
protein, less than 50% of participants reported consumption below DV. For many
nutrients there were no significant differences between low and high caffeine consumers
with respect to proportion of participants failing to meet the DV, except for total fat
(38.1% vs 56.7%, P=0.034) which was higher in participants consuming ≤ 250 mg of
caffeine per day.
Relationship between Caffeine Consumption and Body Composition Measures and
Biochemical Indicators
Mean BMI for this cohort was 26.81 ± 7.82 kg/m2 and mean waist to hip ratio was 0.93.
Higher caffeine consumption was associated with lower fat mass (β=-0.994, P=0.042)
after adjusting for time from diagnosis of HIV, drug use, smoking status, alcohol use and
different types of ART medications (Table 10). Linear mixed model analysis showed that
this relationship increased overtime (β=-1.987, P=0.035), after adjusting for the same
covariates (Table 11). Though BMI was not significantly different between low and high
caffeine consuming participants, when caffeine was combined with cocaine and
amphetamine to form a composite measure of total anorectic agents, we found that BMI
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(27.70 ± 7.332 vs 25.51 ± 6.461, P=0.046) was significantly lower and HIV viral load
(3.23 ± 1.465 vs 2.09 ± 1.137, P=0.000) was significantly higher in those who consumed
high caffeine, and reported cocaine and amphetamine use. Similarly linear regression
analysis also showed that the effect of cocaine on BMI (β=-2.502, P=0.013) decreased
upon adjusting for caffeine (β=-2.352, P=0.046), thus justifying that caffeine
compounded the weight loss effects of other powerful anorectic agents such as cocaine.
Relationship between Dietary Intakes and Caffeine Consumption
Higher caffeine intake was significantly associated with lower total caloric intake (β=1.643, P=0.042) and lower calories from fat (β=-1.902, P=0.044), after adjusting for time
from diagnosis of HIV, drug use, smoking status, alcohol use and different types of ART
medications (Table 12). Linear Mixed Models for the effects of caffeine on macronutrient
consumption over time showed no associations (Table 13).
Relationship between Body Composition and Macronutrient Intake and CD4 Count
and Viral Load
No associations were found between body composition measures or macronutrient
intakes and CD4 counts and HIV viral load (Table 14, 16). Linear mixed models for the
effects of body composition measures and macronutrient intakes on CD4 counts and viral
load over time, also showed no associations (Table 15, 17).
DISCUSSION
During the baseline and follow-up visits, PLWH reported inadequate intakes for
many nutrients, such as, total energy, carbohydrate, protein, fat, and many electrolytes,
vitamins and minerals. All participants had incomes below the poverty level and more
than half of them were consuming alcohol, smoking cigarettes, and had positive urine
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toxicology result for illicit drugs. Poverty, substance abuse and dependence could have
adversely influenced their dietary intake and food purchasing potential, which is
supported by previous reports.50 A study done among 459 men and 212 women, living
with HIV, found that food insecurity was associated with poverty and substance use. One
in four participants in this study reported alcohol and tobacco purchase with resources
allocated for food.50
In our study, caffeine consumption was associated with decreased dietary intakes
for several nutrients and decreased fat mass. Caffeine also contributed to the weight loss
effects of other powerful anorectic agents such as cocaine and amphetamine. These
adverse associations of caffeine were superimposed on the already inadequate diet
recorded for most participants. Adverse effects of caffeine on energy deficits and weight
loss were observed in many non-HIV infected populations.51-54 In a long-term follow-up
study of eighteen years, conducted in 1333 males and 4085 females with type-2 diabetes,
there was a strong association between caffeine consumption (> 4 cups/day which is
approximately >240 mg caffeine/day) and weight loss after controlling for age, baseline
body weight, insulin and anti-diabetic drugs, physical activity and lifestyle factors.51
Further analysis of the same study found a dose–response relationship between caffeine
intake and weight loss.51 In a systematic review of twenty studies on the protective
effects of caffeine in diabetes, twelve studies reported weight loss due to caffeine
consumption.52 This review also stated an estimated 100 kcal/day increased energy
deficits due to habitual consumption of 7 cups of coffee (400 mg caffeine/day).52 Eight
of these twenty studies also reported a dose-response relationship between caffeine intake
and weight loss.52
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Our study also reported that total fat mass was adversely affected by caffeine
consumption. Probable mechanisms include increased basal energy expenditures (BEE)
and the thermogenic effects of caffeine.54 Similar mechanisms were reported in a study
done in young healthy women, where, caffeine increased BEE, even in the presence of
genetic abnormalities predisposing to decreased BEE. The Arg allele in the beta-3
adrenergic receptor gene (beta-3-AR) is a marker for obesity-related traits, and mutations
in this gene leads to decreased BEE.54 In a group of women showing beta-3-AR
Trp64Arg abnormalities, and consequently decreased BEE, an average early morning
dose of 250 mg/day of caffeine, produced significant increase in BEE, measured by
indirect open-circuit calorimeter at four intervals during the day, after controlling for age,
physical activity, height, blood pressure, dietary intakes of fat, proteins, carbohydrates,
cholesterol, fiber, BMI and lifestyle factors.54 This study showed that caffeine,
independent of genetic predispositions to gain weight, increased resting energy
expenditure leading to significant fat loss.54
Our study did not find any association between body composition measures, CD4
cell count and HIV viral load. However, higher total fat mass and higher BMI have been
associated with better immunological and virologic profiles. Such beneficial effects were
reported by Jones et al.,13 in a study among 871 HIV positive women followed for three
years. Cross sectional analysis, survival analysis and longitudinal analysis revealed that,
all five HIV disease severity outcomes such as CD4 cell count and viral load; time to ﬁrst
occurrence of CD4 cell count ≤200 cells/mm3; ﬁrst occurrence of CD4 cell count ≤100
cells/mm3; ﬁrst occurrence of other infection/malignancy; and HIV-related deaths, were
significantly delayed in women in the obese group (BMI≥35 kg/m2), after controlling for
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ART status, baseline BMI, baseline CD4 cell counts, attrition due to death and
progression to AIDS, age and lifestyle factors.13 A longitudinal study conducted among
125 HIV-1 seropositive drug users on ART showed that non-obese individuals reported
25% decline in CD4 cell counts, compared to 18% decline in obese patients (P<0.004),
over a period of 18 months.55 This study also showed that BMI was inversely associated
with time towards progression to AIDS and death, after controlling for covariates such as
ART and drug use. This study states that HIV infection constitutes a chronic hypermetabolic state with increased demands on existing fat reserves, which if not replenished,
would aggravate the process of wasting.55 Many other studies have also reported that
resting metabolic rate (RMR) was significantly higher in HIV positive patients compared
to healthy controls, leading to energy deficits and wasting.56-58 The importance of
preserving healthy BMI in PLWH is adequately emphasized in a review by Langford et
al.,59 which summarized that BMI <20.3 kg/m2 in men and <18.5 kg/m2 in women were
strong indicators of mortality due to HIV, in many racially diverse populations. This
review also stated that BMI values 17–18 kg/m2 and < 16 kg/m2 increased the risk for
progression to AIDS by twice and 5 times, respectively, and that BMI <18.5 kg/m2 was as
useful as clinical staging and serological and immunological markers for decisions about
ART initiations.59 All these studies justify the need to prevent weight loss; especially loss
of fat mass in HIV positive patients. Therefore, high caffeine intake, a known anorectic,
should be prevented in PLWH reporting decreased BMI, fat mass and signs of wasting.
Our study also found that caffeine consumption was associated with lower intakes
of several micronutrients such as Vitamin C, Thiamin, Riboflavin, Niacin, Vitamin B 6 ,
Vitamin B 12 , Iron, Zinc and Selenium. This is consistent with previous findings reported
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in a study of 225 HIV positive participants, where caffeine at a level of 115 mg/day was
associated with decreased plasma levels of Zinc, after controlling for age, gender, CD4
count, viral load and ART.20 Though the mechanisms for such findings are unclear,
decreased dietary intakes could have precipitated such events, as supported by our study.
Future large studies should investigate such effects to understand the bio-chemical
mechanisms for such micronutrient depletions. Similar to what we observed in our study,
a study by Laurie et al.,60 on 264 HIV positive and 127 un-infected participants, reported
significantly lower intakes of Vitamin C and Vitamin E, in HIV positive participants,
when compared to un-infected participants, after controlling for several dietary,
behavioral and lifestyle factors. Furthermore, deficiencies of micronutrients such as Zinc
and Selenium have been independently associated with accelerated HIV disease
progression and mortality risks,61,62 and caffeine intake is one more factor that could
affect this relationship.
In spite of the findings in this study, we have to acknowledge some of its
limitations. The current study enrolled a consecutive convenient sample of 130 HIV
positive participants and the generalizability is weak. Participating in the baseline could
also have influenced the outcomes in the follow-up visit, as the participants could have
been affected by an “Interpersonal Expectancy Bias,” 63 by which they would have
responded what they believed the investigators wanted to hear or the investigators would
have recorded what they wanted to report. In addition, the 24-hour dietary recall used for
assessing nutrient consumption is a self-reported parameter and subject to memory and
recall biases.
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Large scale studies should be conducted with controlled dietary and lifestyle
factors, as well as controlled study settings, to overcome the limitations of our study.
Though, our findings showed that caffeine intake adversely affected dietary intakes of
several nutrients and body composition measures and, in turn, adversely affected HIV
disease progression, these findings should be confirmed by such large scale studies.
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Table 1A: Baseline Demographic Characteristics of PLWH by Caffeine Consumption
Levels

Variables

Total

Baseline
Low
High
caffeine
caffeine
intake
intake
(≤250
(>250
mg/d)
mg/d)
47.57±6.81 48.00±6.15

Age in years
(Mean±SD)
Gender, N (%)

47.89 ± 6.37

Male
Female
Ethnicity, N (%)
White
Hispanic
Black
Other
Education in years,
N (%)
<12
12
>12
Income in dollars
per month

79 (60.8%)
51 (39.2%)

40 (61.5%)
25 (38.5%)

39 (60.0%)
26 (40.0%)

7 (5.4%)
22 (16.9%)
98 (75.4%)
3 (2.3%)

3 (4.6%)
7 (10.8%)
55 (84.6%)
0 (0.0%)

4 (6.2%)
15 (23.1%)
43 (66.2%)
3 (4.6%)

P-value

0.706
0.857

0.057

0.202
40 (30.8%)
59 (45.4%)
31 (23.8%)
495.91 ±
465.887

24 (36.9%)
29 (44.6%)
12 (18.5%)
464.00 ±
419.667

16 (24.6%)
30 (46.2%)
19 (29.2%)
527.34 ±
508.637

0.442

Note: P-values corresponds to χ2 tests for categorical variables and t-test for continuous
variables
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Table 1B: Follow-up Demographic Characteristics of PLWH by Caffeine Consumption
Levels
Variables

Total

Follow-up
Low
High
caffeine
caffeine
intake
intake
(≤250
(>250
mg/d)
mg/d)
46.63±7.33 48.87±5.38

Age in years
(Mean±SD)
Gender, N (%)

47.89 ± 6.37

Male
Female
Ethnicity, N (%)
White
Hispanic
Black
Other
Education in years,
N (%)
<12
12
>12
Income in dollars
per month

79 (60.8%)
51 (39.2%)

43 (68.3%)
20 (31.7%)

36 (53.7%)
31 (46.3%)

7 (5.4%)
22 (16.9%)
98 (75.4%)
3 (2.3%)

4 (6.3%)
9 (14.3%)
50 (79.4%)
0 (0.0%)

3(4.5%)
13 (19.4%)
48 (71.6%)
3 (4.6%)

P-value

0.490
0.090

0.285

0.670
40 (30.8%)
59 (45.4%)
31 (23.8%)
495.91 ±
465.887

21 (33.3%)
29 (46.0%)
13 (20.6%)
498.80 ±
511.708

19 (28.4%)
30 (44.8%)
18 (26.9%)
492.89 ±
416.619

0.943

Note: P-values corresponds to χ2 tests for categorical variables and t-test for continuous
variables

192

Table 2: Baseline Health and Lifestyle Characteristics of PLWH by Caffeine
Consumption Levels
Variables

Smoking cigarettes
Yes
No
Alcohol use
Yes
No
Drug use
Yes
No
Marijuana
Yes
No
Cocaine
Yes
No
Other Drugs
Yes
No
ART
Multi-combination
Yes
No
NRTI
Yes
No
NNRTI
Yes
No

Total

Low caffeine
intake
(≤250 mg/d)

High caffeine
intake
(>250 mg/d)

Pvalue
0.582

80 (63.5%) 39 (60.9%)
46 (36.5%) 25 (39.1%)

41 (66.1%)
21 (33.9%)
0.721

73 (57.9%) 36 (56.3%)
53 (42.1%) 28 (43.8%)

37 (59.7%)
25 (40.3%)

53 (48.2%) 25 (43.9%)
57 (51.8%) 32 (56.1%)

28 (52.8%)
25 (47.2%)

44 (33.8%) 21 (32.3%)
86 (66.2%) 44 (67.7%)

23 (35.4%)
42 (64.6%)

0.445

0.853

0.706
41 (31.5%) 19 (29.2%)
89 (68.5%) 46 (70.8%)

22 (33.8%)
43 (66.2%)

10 (9.1%)
100
(90.9%)

4 (7.5%)
49 (92.5%)

0.744
6 (10.5%)
51 (89.5%)

0.072
34 (26.2%) 22 (33.8%)
96 (73.8%) 43 (66.2%)

12 (18.5%)
53 (81.5%)
0.594

76 (58.5%) 40 (61.5%)
54 (41.5%) 25 (38.5%)

36 (55.4%)
29 (44.6%)

17 (13.1%) 10 (15.4%)
113
55 (84.6%)
(86.9%)

7 (10.8%)
58 (89.2%)

Yes 62 (47.7%) 34 (52.3)
No 68 (52.3%) 31 (47.7%)
All variables reported as N (%)
Note: P-values correspond to χ2 tests for all variables
ART: Antiretroviral therapy.

28 (43.1%)
37 (56.9%)

0.604

PI

0.380
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Table 3: Follow-up Health and Lifestyle Characteristics of PLWH by Caffeine
Consumption Levels
Variables

Smoking
cigarettes

Total

Low caffeine
intake
(≤250 mg/d)

High caffeine
intake
(>250 mg/d)

Pvalue
0.271

79 (63.2%) 41 (68.3%)
Yes 46 (36.8%) 19 (31.7%)
No

38 (58.5%)
27 (41.5%)

Yes 76 (60.3%) 34 (56.7%)
No 50 (39.7%) 26 (43.3%)

42 (63.6%)
24 (36.4%)

Alcohol use

0.469

Drug use

0.054
Yes 79 (65.8%) 45 (75.0%)
No 41 (34.2%) 15 (25.0%)

34 (56.7%)
26 (43.3%)

Yes 67 (55.8%) 38 (63.3%)
No 53 (44.2%) 22 (36.7%)

29 (48.3%)
31 (51.7%)

Marijuana

0.141

Cocaine

0.093
Yes 48 (40.0%) 29 (48.3%)
No 72 (60.0%) 31 (51.7%)

19 (31.7%)
41 (68.3%)

Other drugs

0.496
Yes 13 (10.9%) 6 (10.0%)
No 106
54 (90.0%)
(89.1%)

ART
Multi-combination
Yes
No
NRTI
Yes
No
NNRTI
Yes
No

7 (11.9%)
52 (88.1%)

0.113
33 (25.4%) 20 (31.7%)
97 (74.6%) 43 (68.3%)

13 (19.4%)
54 (80.6%)
1.000

83 (63.8%) 40 (63.5%)
47 (36.2%) 23 (36.5%)

43 (64.2%)
24 (35.8%)

18 (13.8%) 9 (14.3%)
112
54 (85.7%)
(86.2%)

9 (13.4%)
58 (86.6%)

1.000

PI

0.488

Yes 62 (47.7%) 28 (44.4%)
No 68 (52.3%) 35 (55.6%)
All variables reported as N (%)
Note: P-values correspond to χ2 tests all variables.
ART: Antiretroviral therapy.
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34 (50.7%)
33 (49.3%)

Table 4: Mean Caffeine Intake: Baseline and Follow-up Visit
Food source
Coffee
De-Caffeinated coffee
Expresso
Tea
Green tea
Energy drinks
Hot cocoa
Caffeinated soft drinks
Chocolate candy bars
Anacin
Appetite control pills

Baseline
161.26 ± 194.95
0.83 ± 9.21
14.40 ± 64.35
34.70 ± 64.32
7.34 ± 62.93
46.32 ± 134.42
1.03 ± 5.00
63.23 ± 92.98
3.69 ± 13.81
0.24 ± 2.80
4.61 ± 39.10

Follow-up
190.40 ± 205.03
0.03 ± 0.43
13.92 ± 57.82
31.58 ± 59.36
4.20 ± 21.62
9.61 ± 65.32
0.00 ± 0.00
29.66 ± 83.78
2.00 ± 17.93
0.00 ± 0.00
0.00 ± 0.00

Total
337.63 ± 304.97
281.04 ± 260.85
All variables reported as mean ± SD
Note: P-values correspond to t-tests for all variables
*Significant
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P-value
0.206
0.329
0.942
0.640
0.594
0.005*
0.020*
<0.0001*
0.402
0.319
0.181
0.890

Table 5: Baseline: Mean Nutrient Intakes by Levels of Caffeine Consumption
Nutrient

Caffeine intake

P-valuea

Low
High
Total Calorie
1911.84 ± 1045.674
2038.36 ± 945.830
0.791
Total
341.83 ± 133.437
259.15 ± 132.242
0.048*
Carbohydrate
Protein
94.82 ± 54.556
85.24 ± 40.866
0.046*
Total Fat
170.94 ± 44.585
93.43 ± 48.484
0.048*
Saturated Fat
23.02 ± 15.899
24.51 ± 16.667
0.602
Cholesterol
359.27 ± 286.033
374.97 ± 304.754
0.762
Dietary Fiber
12.18 ± 9.783
13.06 ± 9.346
0.599
Sodium
3932.89 ± 2666.521
3177.54 ± 1756.021
0.016*
Chloride
8.93 ± 4.000
5.23 ± 4.172
0.032*
Potassium
1751.09 ± 1245.598
1437.63 ± 999.103
0.018*
Calcium
999.60 ± 466.681
651.53 ± 448.444
0.049*
Magnesium
177.62 ± 38.055
144.61 ± 84.679
0.010*
Phosphorus
856.29 ± 549.057
760.73 ± 491.577
0.030*
Vitamin A†
6259.44 ± 10687.908
5503.70 ± 10197.283
0.475
†
Vitamin C
110.38 ± 141.475
61.68 ± 71.914
0.029*
†
Vitamin D
77.13 ± 92.950
75.54 ± 93.053
0.659
Vitamin E†
1.12 ± 5.307
1.53 ± 4.980
0.266
†
Vitamin K
23.67 ± 29.992
30.22 ± 69.443
0.631
Thiamin
2.33 ± 1.762
1.08 ± 0.714
0.028*
Riboflavin
2.47 ± 1.037
1.29 ± 1.286
0.037*
Niacin
26.95 ± 13.737
17.14 ± 13.124
0.044*
Vitamin B6
1.44 ± 1.168
1.01 ± 0.904
0.022*
Folate
268.90 ± 226.207
258.16 ± 207.074
0.778
Vitamin B12
13.91 ± 4.189
5.75 ± 2.452
0.046*
Pantothenic
3.57 ± 2.192
3.57 ± 2.985
0.994
Acid
Iodine†
4.39 ± 7.979
4.74 ± 33.746
0.994
Iron
34.46 ± 9.319
25.80 ± 11.356
0.046*
Zinc
9.13 ± 1.774
4.64 ± 1.753
0.027*
Selenium
76.61 ± 5.797
45.27 ± 5.837
0.029*
†
Copper
0.77 ± 0.688
1.19 ± 4.261
0.426
Manganese
1.42 ± 1.419
1.59 ± 1.343
0.487
Chromium†
1.11 ± 6.354
0.41 ± 2.603
0.975
†
Molybdenum
0.65 ± 3.705
0.31 ± 2.481
0.555
All variables reported as mean ± SD
a
P-values correspond to t- tests for all variables
†
Mann-Whitney U test was used for comparison because the variables were not normally
distributed.
*Significant
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Table 6: Follow-up: Mean Nutrient Intakes by Levels of Caffeine Consumption
Nutrient

Caffeine intake

P-valuea

Low
High
Total Calorie
2100.52 ± 1127.868
1858.27 ± 932.055
0.017*
Total
255.27 ± 152.914
151.32 ± 116.795
0.042*
Carbohydrate
Protein
86.49 ± 42.173
43.48 ± 37.841
0.017*
Total Fat
183.72 ± 68.771
77.52 ± 56.469
0.026*
Saturated Fat†
30.45 ± 35.212
44.84 ± 178.663
0.121
Cholesterol
419.85 ± 347.931
300.71 ± 227.419
0.024*
Dietary Fiber†
13.45 ± 18.933
13.06 ± 7.673
0.163
Sodium
3911.67 ± 1857.343
3239.20 ± 2049.984
0.018*
Chloride†
42.54 ± 212.929
15.22 ± 70.847
0.638
Potassium
1482.16 ± 1264.208
666.63 ± 598.147
0.036*
Calcium
689.22 ± 480.232
705.43 ± 37.815
0.857
Magnesium
165.88 ± 109.738
169.48 ± 122.184
0.897
Phosphorus
818.62 ± 587.809
771.74 ± 508.395
0.627
Vitamin A†
5285.28 ± 13851.995
5153.94 ± 12370.864
0.334
†
Vitamin C
65.42 ± 91.662
79.52 ± 84.668
0.150
†
Vitamin D
96.57 ± 107.881
75.12 ± 91.308
0.293
Vitamin E†
4.58 ± 19.808
2.00 ± 8.892
0.241
†
Vitamin K
24.76 ± 36.634
31.95 ± 56.458
0.993
Thiamin
2.16 ± 1.055
1.05 ± 0.681
0.044*
Riboflavin
12.54 ± 1.755
8.24 ± 2.521
0.036*
Niacin
18.69 ± 5.191
5.61 ± 1.769
0.034*
Vitamin B6
2.34 ± 1.446
1.38 ± 0.875
0.048*
†
Folate
288.24 ± 297.962
286.71 ± 178.391
0.180
Vitamin B12†
6.84 ± 30.140
4.04 ± 9.221
0.672
Pantothenic acid
3.99 ± 3.748
3.27 ± 1.868
0.176
Iodine†
6.06 ± 25.970
2.27 ± 11.227
0.402
Iron
17.31 ± 7.898
14.67 ± 8.972
0.285
Zinc
9.61 ± 3.021
7.91 ± 5.847
0.244
Selenium
71.57 ± 52.860
69.47 ± 59.698
0.833
†
Copper
1.63 ± 6.081
20.54 ± 161.78
0.958
Manganese†
1.97 ± 5.313
23.98 ± 184.300
0.212
†
Chromium
3.51 ± 14.574
11.52 ± 83.442
0.668
Molybdenum†
3.48 ± 13.972
1.18 ± 5.810
0.392
All variables reported as mean ± SD
a
P-values correspond to t- tests for all variables
†
Mann-Whitney U test was used for comparison because the variables were not normally
distributed
*Significant
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Table 7: Differences in Mean Nutrient Intake between Baseline and Follow-Up Visit
Nutrient
BL
FU
Total Calorie
1981.84 ± 1024.674
2098.84 ± 1032.674
Total Carbohydrate
250.49 ± 132.610
253.23 ± 134.986
Protein
84.72 ± 48.069
84.95 ± 39.887
Total Fat
72.18 ± 46.411
80.52 ± 62.563
Saturated Fat
23.77 ± 16.242
37.87 ± 13.305
Cholesterol
367.12 ± 94.499
358.45 ± 97.012
Dietary Fiber
12.62 ± 9.540
13.25 ± 4.228
Sodium
3105.22 ± 2250.051
3274.32 ± 1951.772
Chloride
120.62 ± 29.820
128.46 ± 56.673
Potassium
1594.36 ± 1135.664
1577.23 ± 1134.212
Calcium
625.57 ± 456.621
697.58 ± 408.816
Magnesium
161.11 ± 115.273
167.73 ± 117.936
Phosphorus
808.51 ± 521.298
794.46 ± 546.676
Vitamin A
5881.57 ± 1411.824
5217.59 ± 1058.457
Vitamin C
86.03 ± 14.427
72.69 ± 18.067
Vitamin D
76.34 ± 42.644
85.52 ± 49.874
Vitamin E
1.32 ± 0.130
3.25 ± 1.189
Vitamin K
26.95 ± 5.381
28.46 ± 4.842
Thiamin
1.21 ± 0.345
1.11 ± 0.880
Riboflavin
1.38 ± 0.167
4.99 ± 1.299
Niacin
18.04 ± 13.413
27.41 ± 11.594
Vitamin B6
1.22 ± 0.062
1.36 ± 0.182
Folate
263.53 ± 216.077
287.45 ± 242.801
Vitamin B12
4.83 ± 1.192
5.40 ± 1.957
Pantothenic acid
3.57 ± 2.608
3.62 ± 2.944
Iodine
3.07 ± 2.483
4.11 ± 1.805
Iron
15.13 ± 10.369
15.95 ± 10.032
Zinc
8.88 ± 2.737
8.73 ± 2.154
Selenium
75.94 ± 56.600
70.49 ± 56.280
Copper
9.98 ± 3.048
11.38 ± 6.183
Manganese
1.50 ± 0.379
3.31 ± 2.339
Chromium
8.76 ± 4.849
7.64 ± 3.667
Molybdenum
6.48 ± 3.145
12.29 ± 8.603
All variables reported as mean ± SD.
Note: P-values correspond to t- tests for all variables
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Pvalue
0.838
0.835
0.962
0.143
0.214
0.788
0.671
0.401
0.058
0.889
0.183
0.674
0.810
0.656
0.247
0.419
0.168
0.808
0.462
0.320
0.296
0.298
0.371
0.811
0.880
0.707
0.588
0.868
0.360
0.309
0.311
0.200
0.060

Table 8: Baseline, PLWH with Nutrient Intakes below Daily Values (DV) by Levels of
Caffeine Consumption
Nutrient

Total

Caffeine intake
Low
High
36 (55.4%)
34 (52.3%)
45 (69.2%)
47 (72.3%)
18 (28.1%)
11 (17.2%)
33 (50.8%)
28 (43.8%)
32 (50.8%)
26 (41.9%)
36 (55.4%)
35 (53.8%)
56 (86.2%)
58 (89.2%)
16 (24.6%)
7 (10.8%)
65 (100%)
65 (100%)
57 (87.7%)
62 (95.4%)
54 (83.1%)
52 (80.0%)
62 (95.4%)
64 (98.5%)
43 (66.2%)
50 (76.9%)
45 (69.2%)
50 (76.9%)
31 (47.7%)
42 (64.6%)
64 (98.5%)
63 (96.9%)
63 (96.9%)
64 (98.5%)
59 (90.8%)
60 (92.3%)
46 (70.8%)
50 (76.9%)
41 (63.1%)
47 (74.6%)
39 (60.9%)
42 (64.6%)
47 (72.3%)
55 (84.6%)
53 (81.5%)
53 (81.5%)
52 (81.3%)
56 (87.5%)
64 (98.5%)
63 (98.4%)
65 (100%)
64 (98.5%)
46 (70.8%)
41 (65.1%)
51 (81.0%)
55 (84.6%)
33 (50.8%)
33 (50.8%)
63 (96.9%)
63 (96.9%)
47 (72.3%)
39 (60.0%)
65 (100%)
65(100%)
65 (100%)
65 (100%)

P-value

Total Calorie
70 (53.8%)
0.860
Total Carbohydrate
92 (70.8%)
0.700
Protein
29 (22.7%)
0.139
Total Fat
61 (47.3%)
0.425
Saturated Fat
58 (46.4%)
0.321
Cholesterol
71 (54.6%)
0.860
Dietary Fiber
114 (87.7%)
0.593
Sodium
23 (17.7%)
0.039*
Chloride†
130 (100%)
N/A
Potassium
119 (91.5%)
0.115
Calcium
106 (81.5%)
0.651
Magnesium
126 (96.9%)
0.310
Phosphorus
93 (71.5%)
0.174
Vitamin A
95 (73.1%)
0.323
Vitamin C
73 (56.2%)
0.052
Vitamin D
127 (97.7%)
0.559
Vitamin E
127 (97.7%)
0.599
Vitamin K
119 (91.5%)
0.753
Thiamin
96 (73.8%)
0.425
Riboflavin
88 (68.8%)
0.160
Niacin
81 (62.8%)
0.666
Vitamin B6
102 (78.5%)
0.088
Folate
106 (81.5%)
1.000
Vitamin B12
108 (84.4%)
0.330
Pantothenic acid
127 (98.4%)
0.991
Iodine
129 (00.2%)
0.315
Iron
87 (68.0%)
0.490
Zinc
106 (82.8%)
0.583
Selenium
66(50.8%)
1.000
Copper
126 (96.9%)
1.000
Manganese
86 (66.2%)
0.138
†
Chromium
130 (100%)
N/A
†
Molybdenum
130 (100%)
N/A
All variables reported as N (%)
Note: P-values correspond to χ2 tests for all variables
†
Pearson’s Chi-Square test could not be done because all participants reported
consumption below Daily Values (DV) for the nutrient.
*Significant
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Table 9: Follow-Up, PLWH with Nutrient Intakes below Daily Values (DV) by Levels of
Caffeine Consumption
Nutrient

Total

Caffeine intake
Low
High
33 (52.4%)
39 (59.1%)
24 (38.1%)
38 (56.7%)
25 (39.7%)
31 (46.3%)
31 (49.2%)
41 (61.2%)
6 (9.5%)
8 (11.9%)
57 (90.5%)
64 (95.5%)
43 (68.3%)
52 (77.6%)

P-value

Total Calorie
72 (55.8%)
0.481
Total Fat
62 (47.7%)
0.034*
Saturated Fat
56 (43.1%)
0.449
Cholesterol
72 (55.4%)
0.169
Sodium
14 (10.8%)
0.657
Potassium
121 (93.1%)
0.257
Total
95 (73.1%)
0.229
Carbohydrate
Dietary Fiber
119 (92.2%) 58 (92.1%)
61 (92.4%)
0.939
Protein
19 (14.7%)
11 (17.5%)
8 (12.1%)
0.392
Vitamin A
102 (78.5%) 52 (82.5%)
50 (74.6%)
0.273
Vitamin C
76 (58.9%)
39 (62.9%)
37 (55.2%)
0.376
Calcium
100 (76.9%) 48 (76.2%)
52 (77.6%)
0.848
Iron
87 (66.9%)
40 (63.5%)
47 (70.1%)
0.420
Vitamin D
129 (99.2%) 62 (98.4%)
67 (100%)
0.301
Vitamin E
124 (95.4%) 60 (95.2%)
64 (95.5%)
0.938
Vitamin K
119 (91.5%) 60 (95.2%)
59 (88.1%)
0.142
Thiamin
100 (78.1%) 49 (79.0%)
51 (77.3%)
0.810
Riboflavin
91 (71.7%)
43 (70.5%)
48 (72.7%)
0.780
Niacin
78 (61.9%)
39 (65.0%)
39 (59.1%)
0.495
Vitamin B6
95 (73.1%)
49 (77.8%)
46 (68.7%)
0.241
Folate
104 (80%)
52 (82.5%)
52 (77.6%)
0.483
Vitamin B12
109 (84.5%) 55 (87.3%)
54 (81.8%)
0.390
Pantothenic acid
126 (97.7%) 59 (95.2%)
67 (100%)
0.068
Phosphorus
91 (70.0%)
43 (68.3%)
48 (71.6%)
0.674
Iodine
129 (99.2%) 62 (98.4%)
67 (100%)
0.301
Magnesium
123 (94.6%) 59 (93.7%)
64 (95.5%)
0.637
Zinc
109 (83.8%) 51 (81.0%)
58 (86.6%)
0.385
Selenium
75 (57.7%)
35 (55.6%)
40 (59.7%)
0.633
Copper
116 (89.2%) 54 (85.7%)
62 (92.5%)
0.210
Manganese
81 (62.3%)
43 (68.3%)
38 (56.7%)
0.175
Chromium
129 (99.2%)
63 (100%)
66 (98.5%)
0.330
Molybdenum
129 (99.2%) 62 (98.4%)
67 (100%)
0.301
†
Chloride
130 (100%)
63 (100%)
67 (100%)
N/A
All variables reported as N (%)
Note: P-values correspond to χ2 tests for all variables
†
Pearson’s Chi-Square test could not be done because all participants reported
consumption below recommended daily values for the nutrient.
*Significance

200

Table 10: Linear Regression of the Effect of Caffeine Consumption on Body
Composition Measures and Nutritional Indicators
Body
Composition
Variables

Unadjusted

Adjusted†

β
SE
P-value
β
SE
P-value
Waist/Hip ratio -2.200 1.042
0.920
-2.345
1.190
0.573
BMI lbs/in2
-0.001 0.002
0.648
-0.002
0.002
0.064
LBM lbs
-0.001 0.007
0.885
0.002
0.007
0.761
b
Fat mass lbs
-0.449 0.774
0.058
-0.994
0.737
0.042*
Hemoglobin g/dl 0.027
0.007
0.706
-0.029
0.008
0.503
Hematocrit %
0.001
0.002
0.708
-0.001
0.001
0.667
Albumin g/dl
0.001
0.001
0.361
0.004
0.001
0.604
a
2
Model R = 0.187, F (16) = 25.075, P = .039.
b
Model R2 = 0.155, F (16) = 24.292, P = .034.
†
Model adjusted for age, gender, income, time from diagnosis of HIV, drug use, alcohol
consumption, smoking status and types of ART medications.
*Significant
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Table 11: Linear Mixed Model (LMM) Analysis of Over Time Changes in Body
Composition Measures and Nutritional Indicators due to Caffeine Consumption
Body
Composition
Variables

Adjusted†

Unadjusted
β
0.268

SE
0.875

P-value
0.113

β
0.389

SE
0.987

P-value
0.095

Waist/Hip
ratio
BMI lbs/in2b
-1.310 0.870
0.647
0.987
0.910
0.532
LBM lbs
-0.477 0.332
0.815
-0.363
0.377
0.338
Fat mass lbs
-0.001 0.003
0.958
-1.987
0.910
0.035*
Hemoglobin
-0.003 0.004
0.425
0.002
0.002
0.265
g/dl
Hematocrit % 0.0007 0.001
0.463
0.0004
0.0006
0.532
Albumin g/dl 0.0002 0.0003
0.571
0.00020
0.0004
0.533
a
Model: -2 Restricted Log Likelihood = 1832.170; Akaike’s Information Criteria (AIC) =
1836.170; Schwarz’s Bayesian Criteria (BIC) = 1842.716.
b
Model: -2 Restricted Log Likelihood = 1252.041; Akaike’s Information Criteria (AIC) =
1256.014; Schwarz’s Bayesian Criteria (BIC) = 1262.539.
†
Model adjusted for age, gender, income, time from diagnosis of HIV, drug use, alcohol
consumption, smoking status and types of ART medications.
*Significant
Table 12: Linear Regression of the Effect of Caffeine Consumption on Macronutrient
Consumption
Macronutrient
Intake

β

Unadjusted
SE

Pvalue
0.644
0.247
0.692
0.647

β

Adjusted†
SE
P-value

Total Kcala
-1.071
1.208
-1.643 1.491
0.042*
Kcal from Protein -0.065
0.056
-0.078 0.072
0.277
Kcal from Carbs
0.604
0.152
-0.972 0.178
0.956
Kcal from Fatsb
-1.043
0.121
-1.902 0.155
0.044*
a
Model R2 = 0.213, F (16) = 35.707, P= 0.038.
b
Model R2 = 0.185, F (16) = 30.681, P= .0.008.
c
Model R2 = 0.185, F (16) = 16.300, P= 0.022.
†
Model adjusted for age, gender, income, time from diagnosis of HIV, drug use, alcohol
consumption, smoking status and types of ART medications.
*Significant
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Table 13: Linear Mixed Model (LMM) Analysis of Over Time Changes in Macronutrient
Consumption due to Caffeine Consumption
Food Intake and
Unadjusted
Adjusted†
Food Security
β
SE
Pβ
SE
PVariables
value
value
Total Kcal
-0.933 0.821
0.257
-0.402
0.942
0.670
Kcal from Protein
0.013
0.049
0.784
0.039
0.058
0.506
Kcal from Carbs
-0.099 0.108
0.361
-0.079
0.116
0.497
Kcal from Fats
-0.895 0.991
0.367
-0.317
0.118
0.789
a
Model: -2 Restricted Log Likelihood = 1761.542; Akaike’s Information Criteria (AIC) =
1765.542; Schwarz’s Bayesian Criteria (BIC) = 1772.088.
†
Model adjusted for age, gender, income, time from diagnosis of HIV, drug use, alcohol
consumption, smoking status and types of ART medications.
*Significant

Table 14: Linear Regression of the Effect of Body Composition Measures and
Macronutrient Intake on CD4 Cell Count
Adjusted†

Body
Composition, and
Macronutrient
consumption

Unadjusted
β

SE

Pvalue

β

SE

Pvalue

BMI lbs/in2a
Fat mass lbsb
Total Kcal
Kcal from Protein

1.225
1.653
1.209
-1.658

1.010
1.226
0.147
1.344

0.643
0.085
0.158
0.058

1.568
2.028
0.137
-0.005

1.149
1.034
0.169
0.004

0.325
0.404
0.422
0.202

Kcal from Carbs
Kcal from Fats

-1.103
1.267

1.012
1.001

0.391
0.485

-0.001
1.185

0.001
1.016

0.485
0.262

a

Model R2 = 0.159, F (14) = 23.773, P= .047.
Model R2 = 0.174, F (14) = 16.379, P = .042.
†
Model adjusted for time from diagnosis of HIV, Cocaine and Methamphetamine use,
HIV viral load.

b
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Table 15: Linear Regression of the Effect of Body Composition Measures and
Macronutrient Intake on HIV Viral Load
Body Composition,
and Macronutrient
consumption
BMI lbs/in2a
Fat mass lbsb
Total Kcal
Kcal from Protein
Kcal from Carbs
Kcal from Fats

β
0.151
0.592
0.219
-0.786
-0.915
0.930

Unadjusted
SE
Pvalue
0.076 0.068
0.176 0.052
0.097 0.625
0.153 0.609
0.757 0.347
0.765 0.226

Adjusted†
SE
P-value

β
0.972
0.936
0.901
-0.987
-0.934
0.965

0.486
0.223
0.710
0.155
0.857
0.794

0.567
0.056
0.624
0.994
0.517
0.827

a

Model: -2 Restricted Log Likelihood = 1129.609; Akaike’s Information Criteria (AIC) =
1133.609; Schwarz’s Bayesian Criteria (BIC) = 1139.868.
b
Model: -2 Restricted Log Likelihood = 1136.666; Akaike’s Information Criteria (AIC) =
1140.666; Schwarz’s Bayesian Criteria (BIC) = 1146.937.
†
Model adjusted for time from diagnosis of HIV, Cocaine and Methamphetamine use,
HIV viral load.

Table 16: . Linear Mixed Model (LMM) Analysis of Over Time Changes in CD4 Cell
Counts due to changes in Body Composition Measures and Macronutrient intakes
Body Composition,
and Macronutrient
consumption

Adjusted†

Unadjusted
β

SE

Pvalue
0.142
0.248
0.858
0.956
0.764
0.939

β

SE

Pvalue
0.430
0.347
0.389
0.344
0.257
0.390

BMI lbs/in2c
-0.048 0.023
-0.033
0.031
Fat mass lbsd
-0.010 0.005
-0.053
0.007
Total Kcal
0.988
0.346
1.032
0.360
Kcal from Protein
0.420
0.075
0.800
0.084
Kcal from Carbs
0.780
0.258
0.835
0.308
Kcal from Fats
-0.924 0.032
-0.930
0.035
c
Model R2 = 0.189, F (14) = 19.612, P = .036.
d
Model R2 = 0.182, F (14) = 18.560, P = .048.
†
Model adjusted for time from diagnosis of HIV, Cocaine and Methamphetamine use and
CD4 cell counts.
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Table 17: . Linear Mixed Model (LMM) Analysis of Over Time Changes in HIV Viral
Load due to changes in Body Composition Measures and Macronutrient intakes
Body Composition,
and
Macronutrient
consumption
BMI lbs/in2c
LBM lbs
Fat mass lbsd
Total Kcal
Kcal from Protein
Kcal from Carbs
Kcal from Fats

β
-0.463
-0.304
-0.810
-0.158
-0.214
0.218
0.974

Unadjusted
SE
P-value
0.026
0.380
0.472
0.121
0.134
0.137
0.547

0.324
0.793
0.456
0.253
0.740
0.155
0.622

c

β
-0.013
-0.532
-0.724
-0.586
-0.189
0.515
-0.834

Adjusted†
SE
P-value
0.018
0.483
0.485
0.123
0.035
0.192
0.851

0.322
0.261
0.314
0.845
0.922
0.421
0.851

Model: -2 Restricted Log Likelihood = 1605.359; Akaike’s Information Criteria (AIC) =
1609.359; Schwarz’s Bayesian Criteria (BIC) = 1615.595.
d
Model: -2 Restricted Log Likelihood = 1609.316; Akaike’s Information Criteria (AIC) =
1613.316; Schwarz’s Bayesian Criteria (BIC) = 1619.564.
†
Model adjusted for time from diagnosis of HIV, Cocaine and Methamphetamine use and
CD4 cell counts.
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CHAPTER-VII: SUMMARY AND CONCLUSIONS
The present study characterized a consecutive convenience sample of 130
PLWH (65 consuming ≤ 250 mg/day and 65 consuming > 250 mg/day of
caffeine), recruited from the MASH cohort, and investigated for the effects of
caffeine consumption on parameters of HIV disease progression crosssectionally
and over time. Additionally, this study examined the effects of caffeine
consumption on behavioral and nutritional parameters. The behavioral outcomes
evaluated included sleep quality, insomnia levels and generalized anxiety
symptoms. The nutritional parameters examined were nutrient intake,
anthropometrics and body composition measures. Finally, this study explored the
net combined impact of the behavioral and nutritional variables on HIV disease
progression both crosssectionally and over time.
The mean caffeine consumption for our cohort was 338 mg/day during the
baseline visit and 281 mg/day during the 3-month follow-up visit, and was higher
than US average of 200 mg/day during both the visits. 1-3 Caffeine intake from
coffee was also higher than the US average of 135 mg/day during both visits. The
Diagnostic and Statistical Manual of Mental Disorders (DSM-5) considers
consumption below 250 mg/day to be generally safe and not associated with any
adverse effect.4 Considering this recommendation, it is concerning that our cohort
reported a higher than safe, mean levels of caffeine consumption during both the
study visits.
The majority of the demographic findings of the current study were
epidemiologically similar to those described by others in Miami-Dade County.5,6
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Most of the participants were African Americans (75.4%). All participants had
incomes under the level of poverty and the mean income was $495.91± 465.887
per month. More than half of the participants in our cohort were consuming
alcohol and smoking cigarettes, and slightly less than half had a positive urine
toxicology result for illicit drugs. Our results suggested that higher caffeine was
associated with higher CD4 cell counts and lower viral load cross-sectionally,
adjusting for co-variates such as age, gender, education, income, time from
diagnosis of HIV, substance use, different types of ART medications, BMI and
total fat mass. Higher caffeine consumption was also associated with higher CD4
cell counts and better control over viral loads, when observed over time after 3months, adjusting for the same covariates. Higher caffeine consumption was also
associated with lower sleep quality, higher insomnia levels and higher generalized
anxiety symptoms, both crosssectionally and over time, adjusting for the
covariates. Approximately half of all participants reported inadequate dietary
intakes for many micronutrients during both the visits, independent of the effects
of caffeine. Higher caffeine intake was additionally associated with lower dietary
intakes of many nutrients and lower fat mass. Our results were paradoxical
because higher caffeine intakes were associated with improvements in parameters
of disease progression, but indirectly also precipitated adverse outcomes, since
higher caffeine intakes were associated with worsening behavioral and nutrition
measures. High caffeine intakes seemed to improve the recuperation of CD4 cells
and facilitated control over HIV viral load, whereas, caffeine also precipitated
many adverse outcomes associated with HIV disease progression such as

213

worsening sleep quality, increased insomnia and generalized anxiety levels, and
compromised dietary intakes and body composition measures and consequently
worsening HIV disease progression. These paradoxical and inconsistent findings
open new hypotheses for future large scale studies to shed light on other
behavioral and bio-chemical mechanisms responsible for these findings.
The majority of the adverse effects of caffeine became apparent, only after
controlling for covariates associated with HIV disease progression, suggesting a
mild but complex effects of caffeine on the adverse outcomes observed in this
study. Caffeine can only be implicated in mediating and moderating the adverse
and beneficial effects of other co-variates (with higher β coefficients) such as
cocaine and methamphetamine use and antiretroviral medications which have
greater effects on HIV disease progression parameters.
Our study reported decrease in mean caffeine consumption from 338
mg/day during baseline visit, to 281 mg/day during follow-up visit, though not
statistically significant. Caffeine intakes from caffeinated soft drinks and energy
drinks also decreased significantly, from 63 mg/day to 30 mg/day and 46 mg/day
to 10 mg/day, respectively, from the baseline to the 3-month follow-up visit. Over
three months, the effects of behavioral outcomes such as poor sleep quality,
insomnia, and generalized anxiety symptoms, on CD4 counts and viral load
diminished and lost statistical significance, thereby indicating decreasing effects
of these behavioral outcomes on HIV disease progression. These observations
could have been incidental findings or due to self-motivated changes in dietary
and lifestyle factors, and better compliance to medications, ascribable to the
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stimulant effect of caffeine, the free nutritional advice and counselling provided
during the visits, which would have facilitated better immune recuperation and
decreased disease progression. There is a possibility that such changes could also
be due to the ‘Hawthorn Effect’, where participants improved their behaviors in
response to the awareness of being observed by our study.7 These findings
suggest other approaches for improving the health and nutritional outcomes in
PLWH. In addition to restricted consumption of anorectic agents such as caffeine,
improved nutritional advice, dietary counseling and lifestyle-modifications could
be associated with alleviating some of the adverse outcomes reported in our study.
Since almost half of the participants reported illicit drugs use and more
than half of the participants reported alcohol use and smoking, the combined
effects of these substances could far outweigh the adverse effects of caffeine,
because many studies have associated substance use with adverse health and
nutritional consequences in HIV.8-11 Alcohol, drug and smoking cessation
interventions should accompany nutritional and dietary counseling initiatives in
order to achieve better immunologic and virologic profiles and thereby adequate
control over disease progression in this vulnerable population of PLWH.
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CHAPTER VIII: STRENGTHS AND LIMITATIONS
The greatest strength of our study is filling the gap in the literature on the
health effects of caffeine in PLWH, by examining the relationship of caffeine
consumption with parameters of disease progression, and with behavioral and
nutritional outcomes in this vulnerable population. For the first time, we identified
paradoxical findings in the relationship of caffeine intake with HIV disease
progression.
The current study followed a quasi-experimental design and gathered data
from a baseline and 3-month follow-up visit, and two MASH cohort study visits.
Because of the prospective observational characteristic of this study, changes in
associations over time could be measured and a number of causal associations
could be determined, controlling for the pertinent covariates. This greatly
contributed to the strengths of the study, because, not only cross-sectional
associations but also the causal effects with dose-response relationships were
reported for many outcome variables. Large scale experimental and interventional
studies planned in the future could benefit from our understandings on the effects
of caffeine on the outcome variables researched in our study.
Our study recorded one hundred percent response rates to all components
and questionnaires for both the study visits, thereby eliminating non-response and
attrition biases. All the questionnaires used in the current study were field tested
and validated in large scale studies.1-5 Our participants were recruited from the
MASH cohort and comprehensive protocols were already developed and
instituted for the MASH studies, thereby greatly facilitating precise data
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collecting procedures for the current study. All the data were collected and quality
assured by trained dietitians, nutritionists and registered nurses with substantial
experience in health-science research. Moreover, there were no adverse events or
compromised participant compliance with the visits, during the entire duration of
the current study. All these factors added to the validity and reliability of the data
gathered during the study.
In spite of the planned research design and implementation, there were
some limitations. The current study enrolled a consecutive convenient sample of
130 HIV positive participants from the MASH cohort, attending their treatment
visits at BHCC. This sample of frequent health care utilizers would have been
different form the population of PLWH in the United States. As this was not a
random sample from the total population of PLWH, our findings are not
generalizable, thus limiting the external validity of our study. In addition, many
un-accounted confounders beyond the ones controlled in the current study and
gathered in the MASH cohort studies, could have affected our results, thereby
limiting the internal validity of our findings. Experimental designs such as
randomized controlled trials, which have complete control over the study
variables, a comparable control arm, and high internal validity, should be planned
in the future to overcome these limitations and ascertain the findings of our study.
In the current study, there were two time points when the data was
gathered, and carryover effects from the initial baseline visit could have affected
the outcomes during the follow-up visit. Since these participants were followed
for a long time (2002 - 2014) for MASH cohort study visits, some carry-over
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effects from the MASH cohort studies could have also affected the findings in our
study. Biases such as the Pygmalion effect and the Golem effect,6 by which
participants tend to improve or moderate their responses to the outcome measures,
after learning about the expectations of the research and the research personnel,
could have affected our study. Biases such as the Hawthorne effect,7 by which,
participants could have modified their health and nutritional outcomes, because of
being monitored by the studies, could have also affected our study findings. In
addition, the participants could have been affected by an Interpersonal
Expectancy Bias,8 by which, they would have responded what they believed the
investigators wanted to hear, or the investigators would have recorded what they
wanted to report. Such biases get adequately balanced and controlled in
randomized control studies, due to the presence of a comparable control arm, and
should be planned in the future to retest and establish the findings of our study.
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CHAPTER IX: FUTURE RESEARCH
Our study findings will serve as a preface for further investigations on the
paradoxical effects of caffeine consumption in PLWH. Organizations such as
United States Food and Drug Administration (USFDA) and Food and Agriculture
Department (FAO), can plan and accomplish future large scale studies on the
effects of caffeine consumption in PLWH and regulate caffeine consumption in
this population of PLWH.
Though caffeine and its health effects have been widely researched in
several vulnerable populations such as students, business personnel, athletes,
night shift workers, military personnel, geriatric population, frequent travelers and
college and university professionals,1 similar studies are lacking in PLWH. Large
scale studies should be planned in the future with greater sample size, better
sample selection methods, other pertinent outcomes, and longer study durations
for confirming and explaining the findings of our study.
We had primarily focused on HIV disease progression, sleep and
generalized anxiety, and nutritional and body composition outcomes but did not
consider other potential domains such neuro-hormonal changes, nerve conduction
velocities, loco-motor stimulatory effects, simple reaction time, choice reaction
time, state and trait anxiety, Critical Flicker Fusion Threshold (CFFT) and muscle
sympathetic activity scores which are sleep and stress related variables affected
by caffeine consumption.2-7 These are open areas for research because they are
extensions of our study findings, where caffeine produced sleep loss and
heightened anxiety states. Though dependence, tolerance and withdrawal effects
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of caffeine have been researched in healthy populations,8-11 similar studies are
non-existent in PLWH and are open areas for future research.
There are very few studies on the effect of caffeine consumption on
parameters of disease progression and hence there is no scientific consensus on
this topic. Our study included CD4 counts and viral loads as markers of disease
progression and found conflicting evidences of caffeine being both beneficial and
detrimental to these variables. Several other markers such as time to ﬁrst
occurrence of CD4 cell count ≤100 cells/mm3; ﬁrst occurrence of other
infection/malignancy; and HIV-related deaths,12 could not be considered due to
the short duration of the study. These additional parameters could have aided a
better understanding about the effects of caffeine on HIV disease progression and
should be considered by future large scale studies. Other behavioral markers such
as the effect of caffeine consumption on mood, physical activity, routine physical
functioning and performance, should also be considered in future studies.
Future bio-chemical investigations are also critical to explain the dose
response relationship between increased caffeine consumption and increased CD4
cells and more controlled viral load observed in the current study. Caffeine has
been associated with changes in plasma levels of hormones such as norepinephrine, epinephrine, prostaglandins, cortisol, testosterone, and insulin, and
cytokines such as interleukins-6, interleukin-8, interleukin-18, 8-isoprostane,
interferons, tumor necrosis factors, E-selectins, Hypoxia-Inducible Factor-1α, and
Vascular Endothelial Growth Factor in many studies.13-22 To fully understand the
relationship of caffeine with parameters of disease progression, behavioral and
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nutritional factors and their inter-relationships, these biomarkers should be
measured and controlled, because they could explain the detrimental and
beneficial outcomes observed in our study. Future large scale studies with
sufficient resources should be planned to answer the questions raised by the
paradoxical outcomes of our study. Additionally caffeine consumption should be
considered for both the beneficial and the adverse effects in PLWH, in order to
derive recommendations on safe levels of consumption for this population.
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